


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update June 22 - June 28, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 26 2020

955 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[Drug shown to reduce coronavirus death risk could run out, experts warn \(Science\)](#)

[Winning by a nose: the dogs being trained to detect signs of Covid-19 \(Guardian\)](#)

[Lessons on Coronavirus Testing From the Adult Film Industry \(NYT\)](#)
[CRISPR pinpoints host genes that aid viral invasion \(Nature\)](#)
[A striking share of infected people never show classic symptoms \(Nature\)](#)
[How Brazilian scientists became ensnared in chloroquine politics \(Science\)](#)
[Covid-19 vaccine may not work for at-risk older people, say scientists \(Guardian\)](#)
[America Is Too Broken to Fight the Coronavirus \(NYT\)](#)
[E.U. May Bar American Travelers as It Reopens Borders \(NYT\)](#)
[Austrian Ski Resort Has Record Rate of Coronavirus Antibodies, Study Finds \(NYT\)](#)
[Mounting clues suggest the coronavirus might trigger diabetes \(Nature\)](#)
[How Germany tackled the pandemic, and Britain failed \(Guardian\)](#)
[How the Virus Won \(NYT\)](#)
[I'm a viral immunologist. Here's what antibody tests for Covid-19 tell us \(Guardian\)](#)
[Ensuring Uptake of Vaccines against SARS-CoV-2 \(NEJM\)](#)
[How the Coronavirus Short-Circuits the Immune System \(NYT\)](#)
[Can Covid Damage the Brain? \(NYT\)](#)
[America Is Facing 5 Epic Crises All at Once \(NYT\)](#)
[Risk of death in UK care homes 13 times higher than in Germany \(Guardian\)](#)
[Actual Coronavirus Infections Vastly Undercounted, C.D.C. Data Shows \(NYT\)](#)
['They Want to Kill Me': Many Covid Patients Have Terrifying Delirium \(NYT\)](#)
[How the World Missed Covid-19's Silent Spread \(NYT\)](#)

KeyArticles

Schlüsselartikel

- 1. Diabetes increases the mortality of patients with COVID-19: a meta-analysis.** [Acta Diabetol](#) 2020; Wu ZH, Tang Y, Cheng Q.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32583078>
- 2. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.** [Faseb j](#) 2020; Sorokin AV, Karathanasis SK, Yang ZH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32588493> **Development of Point-of-Care Biosensors for COVID-19.** [Front Chem](#) 2020; 8:517Choi JR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32574316>
- 3. Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.** [Med Clin \(Barc\)](#) 2020; Soraya GV, Ulhaq ZS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32586670>
- 4. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.** [Cell Metab.](#) 2020; Zhang XJ, Qin JJ, Cheng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592657>
- 5. Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside.** [Front Cell Dev Biol](#) 2020; 8:476Yu J, Chai P, Ge S, Fan X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582719>

6. **An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19).** Account Res 2020;1-7Yeo-Teh NSL, Tang BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573274>
 7. **COVID-19 and Heart: From Clinical Features to Pharmacological Implications.** J Clin Med 2020; 9Russo V, Bottino R, Carbone A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580344>
 8. **Cholesterol in Relation to COVID-19: Should We Care about It?** J Clin Med 2020; 9Radenkovic D, Chawla S, Pirro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570882>
 9. **Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis.** Front. Neurol. 2020; 11:565Pinzon RT, Wijaya VO, Buana RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574250>
 10. **The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.** Circ Res 2020; McFadyen JD, Stevens H, Peter K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586214>
 11. **Perspectives on the development of neutralizing antibodies against SARS-CoV-2.** Antib Ther 2020; 3:109-114Ho M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566896>
 12. **How to Fight an Infodemic: The Four Pillars of Infodemic Management.** J Med Internet Res 2020; 22:e21820Eysenbach G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589589>
 13. **Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?** Front. Immunol. 2020; 11:970Covian C, Retamal-Diaz A, Bueno SM, Kalergis AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574258>
 14. **Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients.** J Infect 2020; Cento V, Colagrossi L, Nava A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574567>
 15. **COVID-19-related strokes in adults below 55 years of age: a case series.** Neurol Sci 2020; Ashrafi F, Zali A, Ommi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583169>
-

Basic Science (39 articles)

1. **Re-analysis of SARS-CoV-2-infected host cell proteomics time-course data by impact pathway analysis and network analysis: a potential link with inflammatory response.** Aging (Albany NY) 2020; 12Bock JO, Ortea I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575076>

2. **COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.** *Ann. Hematol.* 2020; Marchetti M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583086>
3. **Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.** *Biol. Proced. Online* 2020; 22:11Zolfaghari Emameh R, Falak R, Bahreini E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572334>
4. **Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan.** *Biomed J* 2020; Huang SF, Huang YC, Chang FY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563697>
5. **Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.** *bioRxiv* 2020; Barnes CO, West AP, Jr., Huey-Tubman KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577645>
6. **A novel mathematics model of covid-19 with fractional derivative. Stability and numerical analysis.** *Chaos Solitons Fractals* 2020; 138:110006Alkhahtani BST, Alzaid SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565623>
7. **Novel fractional order SIDARTHE mathematical model of COVID-19 pandemic.** *Chaos Solitons Fractals* 2020; 138:110007Higazy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565624>
8. **Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.** *Clin Chem Lab Med* 2020; Alvarez JC, Moine P, Etting I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573468>
9. **COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.** *Comput. Biol. Med.* 2020; 121:103749Robson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568687>
10. **Methylation Pathways and SARS-CoV-2 Lung Infiltration and Cell Membrane-Virus Fusion Are Both Subject to Epigenetics.** *Front Cell Infect Microbiol* 2020; 10:290Pruimboom L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574283>
11. **The Zebrafish Disease and Drug Screening Model: A Strong Ally Against Covid-19.** *Front. Pharmacol.* 2020; 11:680Galindo-Villegas J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574234>
12. **Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19.** *Front. Pharmacol.* 2020; 11:870Narasaraju T, Tang BM, Herrmann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581816>
13. **An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?** *Front. Pharmacol.* 2020; 11:856Terrazzano G, Rubino V, Palatucci AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574238>
14. **Vesicular drug-delivery systems as theranostics in COVID-19.** *Future Med. Chem.* 2020; Satija S, Mehta M, Sharma M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589055>
15. **Comparative analysis of protein synthesis rate in COVID-19 with other human coronaviruses.** *Infect Genet Evol* 2020:104432Dasari CM, Bhukya R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592845>
16. **The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection.** *Int. Arch. Allergy Immunol.* 2020:1-6Kloc M, Ghobrial RM, Kubiak JZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564017>
17. **SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.** *J Biol Chem* 2020; Gupta R, Charron J, Stenger CL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587094>
18. **Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2).** *J Biol Chem* 2020; Kelly JA, Olson AN, Neupane K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571880>
19. **Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).** *J Biomol Struct Dyn* 2020:1-13Alamri MA, Tahir Ul Qamar M, Mirza MU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579061>
20. **Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.** *J Biomol Struct Dyn* 2020:1-10Amin SA, Ghosh K, Gayen S, Jha T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568618>
21. **Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.** *J Biomol Struct Dyn* 2020:1-12Chikhale RV, Gurav SS, Patil RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568012>
22. **Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.** *J Biomol Struct Dyn* 2020:1-8Costa AN, de Sa ERA, Bezerra RDS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567501>
23. **Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.** *J Biomol Struct Dyn* 2020:1-13Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568613>
24. **Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets.** *J Biomol Struct Dyn* 2020:1-13Nimgampalle M, Devanathan V, Saxena A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579059>
25. **Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.** *J Biomol Struct Dyn* 2020:1-12Selvaraj C, Dinesh DC, Panwar U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567979>
26. **Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.** *J Biomol Struct Dyn* 2020:1-16Yadav R, Imran M, Dhamija P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568013>
27. **Clinical pharmacology considerations for developing small molecule treatments for COVID-19.** *J. Clin. Pharmacol.* 2020; Brunson P, Saluja B, Sahajwalla C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579707>
28. **Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.** *J Med Virol* 2020; Baig AM, Khaleeq A, Hira S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573788>

29. **SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).** *J Med Virol* 2020; Ruan Z, Liu C, Guo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579254>
30. **Detection and analysis of clinical features of patients with different COVID-19 types.** *J Med Virol* 2020; Zhao Y, Zhou J, Pan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589755>
31. **Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.** *Med Hypotheses* 2020; 144:109976Balaji A, Bhuvaneshwari S, Kumar DN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563970>
32. **Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing.** *Mol. Cell. Proteomics* 2020; Zecha J, Lee CY, Bayer FP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591346>
33. **Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories.** *mSphere* 2020; 5Simmonds P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581081>
34. **Ocular Surface Expression of SARS-CoV-2 Receptors.** *Ocul Immunol Inflamm* 2020;1-4Leonardi A, Rosani U, Brun P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589459>
35. **[Can SARS-CoV-2 infect the eye?-An overview of the receptor status in ocular tissue].** *Ophthalmologe* 2020; Schnichels S, Rohrbach JM, Bayyoud T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583042>
36. **Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.** *PeerJ* 2020; 8:e9357Loganathan T, Ramachandran S, Shankaran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566414>
37. **Identifying phenotypes of COVID-19, defining their pathogenesis, and targeting treatments could improve outcomes.** *Respir. Physiol. Neurobiol.* 2020:103477Rajendram R, Kharal GA, Mahmood N, Kharal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592752>
38. **Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.** *Trends Pharmacol Sci* 2020; Luo W, Li YX, Jiang LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580895>
39. **The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.** *Virus Res.* 2020:198074Li JY, Liao CH, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589897>

Biomarkers - Genetics (65 articles)

1. **ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19.** *Aging (Albany NY)* 2020; 12Bousquet G, Falgarone G, Deutsch D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576712>
2. **Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019.** *Aging (Albany NY)* 2020; 12Sun JK, Zhang WH, Zou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589164>
3. **Review of Current Advances in Serologic Testing for COVID-19.** *Am J Clin Pathol* 2020; Espejo AP, Akgun Y, Al Mana AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583852>
4. **A 56-year-old man with RT-PCR negative nasopharyngeal swabs with Coronavirus Disease 2019 (COVID-19) Pneumonia.** *Ann. Agric. Environ. Med.* 2020; 27:317-318Dworzanska A, Tudrujek-Zdunek M, Mosiewicz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588614>
5. **Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.** *Ann Transl Med* 2020; 8:635Liu YP, Li GM, He J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566572>
6. **Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters.** *Ann Transl Med* 2020; 8:593Wang C, Deng R, Gou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566620>
7. **Laboratory characteristics of pregnant compared to non-pregnant women infected with SARS-CoV-2.** *Arch. Gynecol. Obstet.* 2020; Mohr-Sasson A, Chayo J, Bart Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572616>
8. **Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review.** *Arch Med Res* 2020; Vakili S, Savardashtaki A, Jamalnia S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571605>
9. **Laboratory considerations amidst the coronavirus disease 2019 outbreak: the Spedali Civili in Brescia experience.** *Bioanalysis* 2020; Garrafa E, Brugnoli D, Barbaro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573254>
10. **Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan.** *Biomed J* 2020; Huang SF, Huang YC, Chang FY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563697>
11. **Room-temperature-storable PCR Mixes for SARS-CoV-2 Detection.** *Clin. Biochem.* 2020; Xu J, Wang J, Zhong Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592724>
12. **SARS-CoV-2 RNA identification in nasopharyngeal swabs: issues in pre-analytics.** *Clin Chem Lab Med* 2020; Basso D, Aita A, Navaglia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573469>
13. **Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.** *Clin Chem Lab Med* 2020; 58:1100-1105Bonetti G, Manelli F, Patroni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573995>
14. **Impact of Heat-Inactivation on the detection of SARS-CoV-2 IgM and IgG Antibody by ELISA.** *Clin Chim Acta* 2020; Hu X, Zhang R, An T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569631>
15. **COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential.** *Clin Immunol* 2020:108516Jiang Y, Wei X, Guan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574709>
16. **Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** *Clin Infect Dis* 2020; Jamal AJ, Mozafarihashjin M, Coomes E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584972>
17. **A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients.** *Crit. Rev. Clin. Lab. Sci.* 2020:1-17Khartabil TAT, Russcher HH, van der Ven AA, de Rijke YBY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568604>

18. **An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.** *Curr. Protoc. Microbiol.* 2020; 58:e108Amanat F, White KM, Miorin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585083>
19. **Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19.** *Diabetes Metab Syndr* 2020; 14:929-931Mahajan K, Chand Negi P, Ganju N, Asotra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590335>
20. **Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19).** *Diagnosis (Berl)* 2020; Ciaccio M, Agnello L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589600>
21. **Efficacy of Serology Testing in Predicting Reinfection in Patients with SARS-CoV-2.** *Disaster Med Public Health Prep* 2020:1-7Chaturvedi R, Naidu R, Sheth S, Chakravarthy K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576315>
22. **Ethyl alcohol threshold test: a fast, reliable and affordable olfactory Assessment tool for COVID-19 patients.** *Eur Arch Otorhinolaryngol* 2020; Calvo-Henriquez C, Maldonado-Alvarado B, Chiesa-Estomba C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583183>
23. **LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins.** *Eur. J. Immunol.* 2020; Haljasmagi L, Remm A, Rumm AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584420>
24. **Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020.** *Euro Surveill* 2020; 25Muenchhoff M, Mairhofer H, Nitschko H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583765>
25. **Development of Point-of-Care Biosensors for COVID-19.** *Front Chem* 2020; 8:517Choi JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574316>
26. **Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study.** *Front Genet* 2020; 11:641Hemmat N, Derakhshani A, Bannazadeh Baghi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582303>
27. **Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes Involved in SARS-CoV-2 Infection and Human Quantitative Phenotypes.** *Front Genet* 2020; 11:613Lopera Maya EA, van der Graaf A, Lanting P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582302>
28. **Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:301Feng X, Li S, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582743>
29. **Early Detection and Assessment of Covid-19.** *Front Med (Lausanne)* 2020; 7:311Hashmi HAS, Asif HM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582748>
30. **Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context.** *Front Med (Lausanne)* 2020; 7:225Mertens P, De Vos N, Martiny D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574326>
31. **Identification of RT-PCR-Negative Asymptomatic COVID-19 Patients via Serological Testing.** *Front Public Health* 2020; 8:267Wu J, Liu X, Zhou D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582617>
32. **Rapid Direct Nucleic Acid Amplification Test without RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler.** *Genes (Basel)* 2020; 11Wee SK, Sivalingam SP, Yap EPH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570810>
33. **Utility of CT scan in patients with initial negative PCR for SARS-CoV2: a report of three cases.** *Infection* 2020; Bouiller K, Humbert S, Payet-Revest C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583171>
34. **Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs.** *Int J Mol Sci* 2020; 21Toptan T, Hoehl S, Westhaus S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575728>
35. **Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19.** *J Allergy Clin Immunol Pract* 2020; Chang, Zhao P, Zhang DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574840>
36. **Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study.** *J Allergy Clin Immunol Pract* 2020; Vultaggio A, Vivarelli E, Virgili G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565226>
37. **nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.** *J Biomol Struct Dyn* 2020:1-11Hamza M, Ali A, Khan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567487>
38. **Evaluation of rapid antigen test for detection of SARS-CoV-2 virus.** *J Clin Virol* 2020; 129:104500Mak GC, Cheng PK, Lau SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585619>
39. **Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).** *J Clin Virol* 2020; 129:104511Nicol T, Lefevre C, Serri O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593133>
40. **Insights into SARS-CoV-2, the Coronavirus Underlying COVID-19: Recent Genomic Data and the Development of Reverse Genetics Systems.** *J. Gen. Virol.* 2020; Silva S, Germano Mendes RP, Alves da Silva CT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579100>
41. **Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.** *J Hepatol* 2020; Fraga M, Moradpour D, Artru F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585161>
42. **RAPID SALIVARY TEST SUITABLE FOR A MASS SCREENING PROGRAM TO DETECT SARS-COV-2: A DIAGNOSTIC ACCURACY STUDY.** *J Infect* 2020; Azzi L, Baj A, Alberio T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579988>
43. **Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients.** *J Infect* 2020; Cento V, Colagrossi L, Nava A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574567>
44. **Diagnostic accuracy of the FebrIDx host response point-of-care test in patients hospitalised with suspected COVID-19.** *J Infect* 2020; Clark TW, Brendish NJ, Poole S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579983>
45. **Older age is associated with sustained detection of SARS-CoV-2 in nasopharyngeal swab samples.** *J Infect* 2020; Hattori T, Amishima M, Morinaga D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579989>
46. **Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus.** *J Infect* 2020; Skevaki C, Fragkou PC, Cheng C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579986>

47. **CD4+T, CD8+T counts and severe COVID-19: A meta-analysis.** *J Infect* 2020; Zhang H, Wu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569604>
48. **A case report of SARS-CoV-2 confirmed in saliva specimens up to 37 days after onset: Proposal of saliva specimens for COVID-19 diagnosis and virus monitoring.** *J Infect Chemother* 2020; Tajima Y, Suda Y, Yano K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571647>
49. **Elevated Serum Endothelial Cell Adhesion Molecules Expression in COVID-19 Patients.** *J Infect Dis* 2020; Tong M, Jiang Y, Xia D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582936>
50. **Should RT-PCR be considered a gold standard in the diagnosis of Covid-19?** *J Med Virol* 2020; Hernandez-Huerta MT, Mayoral LP, Navarro LMS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592498>
51. **Analysis of the diagnostic value of serum specific antibody testing for coronavirus disease 2019.** *J Med Virol* 2020; Yan M, Zheng Y, Sun Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592502>
52. **First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease.** *J Neurol* 2020; Domingues RB, Mendes-Correa MC, de Moura Leite FBV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564153>
53. **Saliva-based PCR tests for SARS-CoV-2 detection.** *J Oral Sci.* 2020; 62:350-351 Takeuchi Y, Furuchi M, Kamimoto A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581183>
54. **Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients.** *J Proteome Res.* 2020; Ihling C, Tanzler D, Hagemann S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568543>
55. **Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.** *Med Clin (Barc)* 2020; Soraya GV, Ulhaq ZS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586670>
56. **[Seroprevalence and SARS-CoV-2 testing in healthcare occupations].** *Ophthalmol* 2020; Ziemssen F, Bayyoud T, Bartz-Schmidt KU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588125>
57. **Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations.** *Pathogens* 2020; 9Slomka A, Kowalewski M, Zekanowska E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575786>
58. **Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers.** *Public Health* 2020; 185:88-90 Kumleben N, Bhopal R, Czymionka T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590234>
59. **Underestimation of COVID-19 cases in Japan: an analysis of RT-PCR testing for COVID-19 among 47 prefectures in Japan.** *QJM* 2020; Sawano T, Kotera Y, Ozaki A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573730>
60. **Identifying phenotypes of COVID-19, defining their pathogenesis, and targeting treatments could improve outcomes.** *Respir. Physiol. Neurobiol.* 2020:103477 Rajendram R, Kharal GA, Mahmood N, Kharal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592752>
61. **Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases.** *Sci China Life Sci* 2020; Huang W, Li C, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567003>
62. **Nanopore Targeted Sequencing for the Accurate and Comprehensive Detection of SARS-CoV-2 and Other Respiratory Viruses.** *Small* 2020:e2002169 Wang M, Fu A, Hu B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578378>
63. **Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.** *Trends Pharmacol Sci* 2020; Luo W, Li YX, Jiang LJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580895>
64. **Peripheral Blood Smear Findings in COVID-19.** *Turk J Haematol* 2020; Ahnach M, Ousti F, Nejari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586086>
65. **The Brighton collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines.** *Vaccine* 2020; Kim D, Robertson JS, Excler JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571717>

Children (23 articles)

1. **Clinical Characteristics and Blood Test Results in COVID-19 Patients.** *Ann. Clin. Lab. Sci.* 2020; 50:299-307 An XS, Li XY, Shang FT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581016>
2. **Efficacy of antibiotic agents in children with COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:619 Wang J, Tang Y, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566556>
3. **Clinical characteristics of children with COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:620 Wang Z, Zhou Q, Wang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566557>
4. **Coronavirus Disease 2019 (COVID-19) in Children: Vulnerable or Spared? A Systematic Review.** *Cureus* 2020; 12:e8207 Saleem H, Rahman J, Aslam N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577325>
5. **Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults.** *Eur. J. Immunol.* 2020; Moratto D, Giacomelli M, Chiarini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592406>
6. **Does Early Childhood Vaccination Protect Against COVID-19?** *Front Mol Biosci* 2020; 7:120 Sidiq KR, Sabir DK, Ali SM, Kodzius R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582766>
7. **Are They Just Two Children COVID-19 Cases Confused With Flu?** *Front Pediatr* 2020; 8:341 Zou B, Ma D, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582598>
8. **Pediatric ophthalmology, strabismus and neuro-ophthalmology practice in the COVID-19 era: All India Ophthalmological Society guidelines.** *Indian J Ophthalmol* 2020; 68:1300-1305 Saxena R, Singh D, Jethani J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587154>
9. **The effect of the Covid-19 Pandemic on pediatric urology.** *Int Braz J Urol* 2020; 46Tur AB, Prieto JC, Gomez-Fraile A, Corbetta JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568499>
10. **Herd Immunity and Vaccination of children for COVID19.** *Int J Infect Dis* 2020; Velavan TP, Pollard AJ, Kremsner PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585285>
11. **Reply to Challenges to paediatric services during COVID-19 Pandemic: a London, UK perspective.** *J Allergy Clin Immunol Pract* 2020; Bansal P, Bingemann TA, Greenhawt M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592788>
12. **Challenges to paediatric services during COVID-19 Pandemic: a London, UK perspective.** *J Allergy Clin Immunol Pract* 2020; Gritz A, Daniels R, Chodhari R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592788>

- term=32592787
13. **How the COVID-19 pandemic is affecting paediatric orthopaedics practice: a preliminary report.** *J. Child. Orthop.* 2020; 14:154-160 Peiro-Garcia A, Corominas L, Coelho A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582381>
 14. **COVID-19 Multisystem Inflammatory Syndrome in Three Teenagers with Confirmed SARS-CoV-2 Infection.** *J Med Virol* 2020; Ng KF, Kothari T, Bandi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568434>
 15. **Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience.** *J Med Virol* 2020; Riollano-Cruz M, Akkoyun E, Briceno-Brito E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584487>
 16. **Protecting children from iatrogenic harm during COVID19 pandemic.** *J. Paediatr. Child Health* 2020; Camporesi A, Diaz-Rubio F, Carroll CL, Gonzalez-Dambrasuskas S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568444>
 17. **SARS-CoV-2 Infection in Infants Less than 90 Days Old.** *J. Pediatr.* 2020; Mithal LB, Machut KZ, Muller WJ, Kociolek LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565095>
 18. **A Comparison Between Chinese Children Infected with COVID-19 and with SARS.** *J. Pediatr.* 2020; Xiong X, Chua GT, Chi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565097>
 19. **Anesthesia and potential aerosol generation during Magnetic Resonance Imaging in Children with COVID-19.** *Paediatr Anaesth* 2020; Drum E, McClung Pasqualino H, Subramanyam R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564492>
 20. **Human and novel coronavirus infections in children: a review.** *Paediatr Int Child Health* 2020:1-20 Rajapakse N, Dixit D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584199>
 21. **Mental health considerations for children & adolescents in COVID-19 Pandemic.** *Pak J Med Sci* 2020; 36:S67-s72 Imran N, Zeshan M, Pervaiz Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582317>
 22. **Clinical Characteristics of Acute Respiratory Syndrome with SARS-CoV-2 Infection in Children in South China.** *Pediatr Pulmonol* 2020; Zheng G, Wang B, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579293>
 23. **Suspected case of COVID-19-associated pancreatitis in a child.** *Radiol Case Rep* 2020; 15:1309-1312 Alloway BC, Yaeger SK, Mazzaccaro RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572339>

Clinical Features (37 articles)

1. **Clinical characteristics of older and younger patients infected with SARS-CoV-2.** *Agging (Albany NY)* 2020; 12 Zhou Z, Zhang M, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575073>
2. **Clinical Characteristics and Blood Test Results in COVID-19 Patients.** *Ann. Clin. Lab. Sci.* 2020; 50:299-307 An XS, Li XY, Shang FT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581016>
3. **Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.** *Ann. Clin. Lab. Sci.* 2020; 50:308-313 Brown RE, Wolf DA, Hunter RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581017>
4. **Investigation of COVID-19-related symptoms based on factor analysis.** *Ann Palliat Med* 2020; Luo Y, Wu J, Lu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576016>
5. **Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study.** *Ann Transl Med* 2020; 8:642 Hu W, Chen X, He B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566579>
6. **Clinical and CT findings of COVID-19: differences among three age groups.** *BMC Infect. Dis.* 2020; 20:434 Wang J, Zhu X, Xu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571228>
7. **Cutaneous manifestations in hospitalized patients diagnosed as COVID-19.** *Dermatol Ther* 2020; Askin O, Altunkalem RN, Altinisik DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579756>
8. **A case of erythema multiforme major in a patient with COVID 19: The role of corticosteroid treatment.** *Dermatol Ther* 2020:e13899 Demirbas A, Elmas OF, Atasoy M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589314>
9. **Clinical Characteristics and Outcome in Patients with Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State Associated with COVID-19: A Retrospective, Hospital-Based Observational Case Series.** *Diabetes Res Clin Pract* 2020:108279 Hoe Chan K, Thimmareddygar D, Ramahi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592843>
10. **Asymptomatic SARS-CoV-2 Infection in Nursing Homes, Barcelona, Spain, April 2020.** *Emerg Infect Dis* 2020; 26 Borrás-Bermejo B, Martínez-Gómez X, San Miguel MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574139>
11. **Clinical Course of Asymptomatic and Mildly Symptomatic Patients with Coronavirus Disease Admitted to Community Treatment Centers, South Korea.** *Emerg Infect Dis* 2020; 26 Lee YH, Hong CM, Kim DH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568662>
12. **Temperature screening has negligible value for control of COVID-19.** *Emerg. Med. Australas.* 2020; Mitra B, Luckhoff C, Mitchell RD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578926>
13. **Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications.** *Eur Urol Focus* 2020; Yang M, Chen S, Huang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563676>
14. **Official Data and Analytical Forecasts: Differences and Similarities Among Coronavirus Disease (COVID-19) Confirmed Cases and Deaths.** *Front Med (Lausanne)* 2020; 7:239 Ferraro OE, Puci MV, Montomoli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574330>
15. **Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series.** *Front Med (Lausanne)* 2020; 7:231 Tahvildari A, Arbabi M, Farsi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574328>
16. **Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.** *Front. Microbiol.* 2020; 11:1302 He Y, Wang J, Li F, Shi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582134>
17. **Are They Just Two Children COVID-19 Cases Confused With Flu?** *Front Pediatr* 2020; 8:341 Zou B, Ma D, Li Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582598>
18. **Clinical and Epidemiological Characteristics of COVID-19 Patients in Chongqing China.** *Front Public Health* 2020; 8:244 Yang A, Qiu Q, Kong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574309>

19. **In Reply: Challenges in interpreting the diagnostic performance of symptoms to predict COVID-19 status: the case of anosmia.** *Int Forum Allergy Rhinol* 2020; Roland LT, Loftus PA, Chang JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583946>
20. **Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China.** *Int J Epidemiol* 2020; Nie Y, Li J, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588051>
21. **Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19.** *J Allergy Clin Immunol Pract* 2020; Chang, Zhao P, Zhang DW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574840>
22. **Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea.** *J Clin Med* 2020; 9Choi MH, Ahn H, Ryu HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585855>
23. **Epidermolysis bullosa and the COVID-19 pandemic: challenges and recommendations.** *J Dermatolog Treat* 2020;1-6Vahidnezhad H, Moravvej H, Bahmanjahromi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589062>
24. **Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.** *J Eur Acad Dermatol Venereol* 2020; Matar S, Oules B, Sohler P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589293>
25. **Relapsing symmetric livedo reticularis in a patient with COVID-19 infection.** *J Eur Acad Dermatol Venereol* 2020; Verheyden M, Grosber M, Gutermuth J, Velkeniers B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588475>
26. **A case report of SARS-CoV-2 confirmed in saliva specimens up to 37 days after onset: Proposal of saliva specimens for COVID-19 diagnosis and virus monitoring.** *J Infect Chemother* 2020; Tajima Y, Suda Y, Yano K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571647>
27. **Clinical characteristics of the coronavirus disease 2019 (COVID-19) outbreak on a cruise ship.** *J Infect Chemother* 2020; Yoshimura Y, Sasaki H, Horiuchi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565152>
28. **The first few cases and fatalities of Corona Virus Disease 2019 (COVID-19) in the Eastern Mediterranean Region of the World Health Organization: A rapid review.** *J Infect Public Health* 2020; Abed Alah M, Abdeen S, Kehyayan V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586684>
29. **A 95-year-old patient with unexpected coronavirus disease 2019 masked by aspiration pneumonia: a case report.** *J Med Case Rep* 2020; 14:82Spannella F, Ristori L, Giulietti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576232>
30. **Detection and analysis of clinical features of patients with different COVID-19 types.** *J Med Virol* 2020; Zhao Y, Zhou J, Pan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589755>
31. **Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence.** *Laryngoscope Investig Otolaryngol* 2020; 5:354-359Gengler I, Wang JC, Speth MM, Sedaghat AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587887>
32. **Evaluation of organ function in patients with severe COVID-19 infections.** *Med Clin (Barc)* 2020; Zhu Y, Du Z, Zhu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586669>
33. **Ocular Manifestations of Hospitalized Patients with COVID-19 in Northeast of Iran.** *Ocul Immunol Inflamm* 2020;1-6Abrishami M, Tohidinezhad F, Daneshvar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569494>
34. **The clinical and demographical profile of Coronavirus illness: The tale of Tablighi Jamaat and Zaireen in Quarantine / Isolation center at Sukkur and Hyderabad.** *Pak J Med Sci* 2020; 36:S12-s16Ujjan ID, Devrajani BR, Ghanghro AA, Shah SZA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582307>
35. **Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations.** *Pathogens* 2020; 9Slomka A, Kowalewski M, Zekanowska E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575786>
36. **Clinical Characteristics of Acute Respiratory Syndrome with SARS-CoV-2 Infection in Children in South China.** *Pediatr Pulmonol* 2020; Zheng G, Wang B, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579293>
37. **Epidemiological and clinical characteristics of patients with suspected COVID-19 admitted in Metro Manila, Philippines.** *Trop Med Health* 2020; 48:51Salva EP, Villarama JB, Lopez EB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577087>

CNS (39 articles)

1. **Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2.** *Altex* 2020; Bullen CK, Hogberg HT, Bahadirli-Talbott A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591839>
2. **Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2.** *Am J Otolaryngol* 2020; 41:102612Freni F, Meduri A, Gazia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574896>
3. **Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic.** *Brain Behav Immun Health* 2020; 5:100096Debnath M, Berk M, Maes M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566934>
4. **Olfactory and taste disorders in COVID-19: a systematic review.** *Braz J Otorhinolaryngol* 2020; Costa K, Carnauba ATL, Rocha KW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580925>
5. **Neurological features of COVID-19 and their treatment: a review.** *Drugs Context* 2020; 9Orsucci D, Ienco EC, Nocita G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587625>
6. **Olfactory and gustatory abnormalities in COVID-19 cases.** *Eur Arch Otorhinolaryngol* 2020; Altin F, Cingi C, Uzun T, Bal C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577902>
7. **Tinnitus revival during COVID-19 lockdown: how to deal with it?** *Eur Arch Otorhinolaryngol* 2020; Anzivino R, Sciancalepore PI, Petrone P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572563>
8. **Ethyl alcohol threshold test: a fast, reliable and affordable olfactory Assessment tool for COVID-19 patients.** *Eur Arch Otorhinolaryngol* 2020; Calvo-Henriquez C, Maldonado-Alvarado B, Chiesa-Estomba C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583183>
9. **Gustatory dysfunctions in COVID-19.** *Eur Arch Otorhinolaryngol* 2020; Lechien JR, Hsieh JW, Ayad T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577904>
10. **Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health.** *Front Immunol* 2020; 11:1170Raony I, de Figueiredo CS, Pandolfo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574266>

11. **Neurological Manifestations of COVID-19 (SARS-CoV-2): A Review.** *Front. Neurol.* 2020; 11:518Ahmed MU, Hanif M, Ali MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574248>
12. **Acute Neurological Care in the COVID-19 Era: The Pandemic Health System Resilience PROGRAM (REPROGRAM) Consortium Pathway.** *Front. Neurol.* 2020; 11:579Bhaskar S, Sharma D, Walker AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574252>
13. **Evolving Healthcare Delivery in Neurology During the Coronavirus Disease 2019 (COVID-19) Pandemic.** *Front. Neurol.* 2020; 11:578Chen PM, Hemmen TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574251>
14. **Medical and Paramedical Care of Patients With Cerebellar Ataxia During the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19 Cerebellum Task Force.** *Front. Neurol.* 2020; 11:516Manto M, Dupre N, Hadjivassiliou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574247>
15. **An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients.** *Front. Neurol.* 2020; 11:564Piano C, Di Stasio E, Primiano G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574249>
16. **Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis.** *Front. Neurol.* 2020; 11:565Pinzon RT, Wijaya VO, Buana RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574250>
17. **The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review.** *Front. Neurol.* 2020; 11:498Tsai ST, Lu MK, San S, Tsai CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574246>
18. **Disentangling the Hypothesis of Host Dysosmia and SARS-CoV-2: The Bait Symptom That Hides Neglected Neurophysiological Routes.** *Front. Physiol.* 2020; 11:671Briguglio M, Bona A, Porta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581854>
19. **An Online Observational Study of Patients With Olfactory and Gustatory Alterations Secondary to SARS-CoV-2 Infection.** *Front Public Health* 2020; 8:243Gomez-Iglesias P, Porta-Etessam J, Montalvo T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574308>
20. **[Neurological aspects of the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus].** *Ideggy Sz* 2020; 73:171-175Bereczki D, Stang R, Bojti P, Kovacs T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579306>
21. **In Reply: Challenges in interpreting the diagnostic performance of symptoms to predict COVID-19 status: the case of anosmia.** *Int Forum Allergy Rhinol* 2020; Roland LT, Loftus PA, Chang JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583946>
22. **The neurological insights of the emerging coronaviruses.** *J. Clin. Neurosci.* 2020; Msigwa SS, Wang Y, Li Y, Cheng X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563494>
23. **Anosmia and olfactory tract neuropathy in a case of COVID-19.** *J Microbiol Immunol Infect* 2020; Li CW, Syue LS, Tsai YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576457>
24. **Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report.** *J. Neuroimmunol.* 2020; 346:577294Farzi MA, Ayromlou H, Jahanbakhsh N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590125>
25. **First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease.** *J. Neurol.* 2020; Domingues RB, Mendes-Correa MC, de Moura Leite FBV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564153>
26. **Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient.** *J. Neurol.* 2020; Princiotta Cariddi L, Tabaei Damavandi P, Carimati F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583053>
27. **Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic.** *Mov Disord* 2020; Kobylecki C, Jones T, Lim CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583481>
28. **Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.** *Mult Scler Relat Disord* 2020; 44:102310Ricardo A, Edgar CC, Anabel SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590314>
29. **Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.** *Mult Scler Relat Disord* 2020; 42:102259Salama S, Giovannoni G, Hawkes CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571580>
30. **Electroencephalography at the time of Covid-19 pandemic in Italy.** *Neurol Sci* 2020; Assenza G, Lanzone J, Ricci L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588368>
31. **Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.** *Neurol Sci* 2020; Devogelaere J, D'Hooghe M B, Vanderhauwaert F, D'Haeseleer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564270>
32. **A prospective clinical study of detailed neurological manifestations in patients with COVID-19.** *Neurol Sci* 2020; Karadas O, Ozturk B, Sonkaya AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588367>
33. **Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.** *Neurologia* 2020; Valero-Lopez G, Carreon-Guarnizo E, Hernandez-Clares R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591152>
34. **New Horizons: COVID-19 and the Burden of Neuropsychiatric Illness in Pakistan.** *Pak J Med Sci* 2020; 36:S95-s98Hashmi AM, Saleem HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582322>
35. **Characteristic Temporary Loss of Taste and Olfactory Senses in SARS-CoV-2-positive-Individuals with Mild Symptoms.** *Pathog Immun* 2020; 5:117-120Schmithausen RM, Dohla M, Schobetaler H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582871>
36. **Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.** *Seizure* 2020; 80:157-158Gomez-Enjuto S, Hernando-Requejo V, Lapena-Motilva J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574838>
37. **Neurological manifestations and implications of COVID-19 pandemic.** *Ther. Adv. Neurol. Disord.* 2020; 13:1756286420932036Tsvigoulis G, Palaiodimou L, Katsanos AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565914>
38. **Anosmia and dysgeusia in COVID-19: A systematic review.** *Wellcome Open Res* 2020; 5:94Carrillo-Larco RM, Altez-Fernandez C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587902>
39. **Letter to the Editor: Priority considerations of patients with peripheral nerve pathology in the time of COVID-19.** *World Neurosurg* 2020; Murthy NK, Spinner RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592967>

Complications (74 articles)

1. **Protracted course of coronavirus disease with severe acute respiratory distress syndrome: a case report.** *Acute Med Surg* 2020; 7:e521Miyamoto K, Yonemitsu T, Tanaka R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566237>
2. **Lessons from a lumbar burst fracture patient infected with SARS-CoV-2.** *Aging (Albany NY)* 2020; 12Yu S, Zhang H, Chen W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568102>
3. **COVID-19 and HELLP: Overlapping Clinical Pictures in Two Gravid Patients.** *AJP Rep* 2020; 10:e179-e182Futterman I, Toaff M, Navi L, Clare CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566368>
4. **SARS-CoV-2 Infection: Beyond the Interstitial Pneumonia.** *Am. J. Med. Sci.* 2020; Cui R, Wang YL, Li J, Dai SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571518>
5. **Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2.** *Am. J. Otolaryngol.* 2020; 41:102612Freni F, Meduri A, Gazia F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574896>
6. **Emergency front-of-neck airway in the COVID-19 patient: cannula or surgical cricothyroidotomy?** *Anaesth Crit Care Pain Med* 2020; Chua H, Wong T, Lim WY, Wong P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565255>
7. **Could SARS-CoV-2 affect male fertility?** *Andrologia* 2020:e13712Vishvkarma R, Rajender S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578263>
8. **COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.** *Ann. Hematol.* 2020; Marchetti M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583086>
9. **COVID-19 and Total Laryngectomy-A Report of Two Cases.** *Ann. Otol. Rhinol. Laryngol.* 2020:3489420935500Paderno A, Fior M, Berretti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583671>
10. **Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:629Zhou Q, Gao Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566566>
11. **A case of Covid-19 patient with acute limb ischemia and heparin resistance.** *Ann. Vasc. Surg.* 2020; Baccellieri D, Bilman V, Apruzzi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589931>
12. **COVID-19 with acute cholecystitis: a case report.** *BMC Infect. Dis.* 2020; 20:437Ying M, Lu B, Pan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571224>
13. **Prone positioning in COVID-19 acute respiratory failure: just do it?** *Br J Anaesth* 2020; McNicholas B, Cosgrave D, Giacomini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571573>
14. **Videolaryngoscopy for tracheal intubation in patients with COVID-19.** *Br J Anaesth* 2020; Saito T, Taguchi A, Asai T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571574>
15. **Pulmonary embolism in acute medicine: a case-based review incorporating latest guidelines in the COVID-19 era.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-12Stevenson A, Davis S, Murch N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589531>
16. **Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China.** *Cancer* 2020; Zhang H, Wang L, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573776>
17. **Fatal SARS-CoV-2 infection in a renal transplant recipient.** *CEN Case Rep* 2020; Dirim AB, Demir E, Ucar AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564306>
18. **Prediction and analysis of COVID-19 positive cases using deep learning models: A descriptive case study of India.** *Chaos Solitons Fractals* 2020; 139:110017Arora P, Kumar H, Panigrahi BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572310>
19. **The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.** *Circ Res* 2020; McFadyen JD, Stevens H, Peter K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586214>
20. **Is the use of ACE inhibitors/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?** *Clin. Exp. Hypertens.* 2020:1-5Selcuk M, Cinar T, Keskin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569491>
21. **Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.** *Clin Res Hepatol Gastroenterol* 2020; De Gottardi A, Fratila C, Bertoli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565199>
22. **Attenuated early inflammatory response in solid organ recipients with COVID-19.** *Clin. Transplant.* 2020:e14027Bosch F, Borner N, Kemmner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589760>
23. **A Case Report of Rapidly Lethal Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019 Viral Pneumonia.** *Cureus* 2020; 12:e8228Ng MK, Ngo J, Patel A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582489>
24. **Clinical Characteristics and Outcome in Patients with Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State Associated with COVID-19: A Retrospective, Hospital-Based Observational Case Series.** *Diabetes Res Clin Pract* 2020:108279Hoe Chan K, Thimmareddygar D, Ramahi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592843>
25. **Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.** *EBioMedicine* 2020; 57:102833Wang C, Xie J, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574956>
26. **Methemoglobinemia in Patient with G6PD Deficiency and SARS-CoV-2 Infection.** *Emerg Infect Dis* 2020; 26Palmer K, Dick J, French W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579876>
27. **Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?** *Emerg Microbes Infect* 2020:1-26Berthelot JM, Drouet L, Liote F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574107>
28. **Prothrombotic state induced by COVID-19 infection as trigger for stroke in young patients: A dangerous association.** *eNeurologicalSci* 2020; 20:100247Cavallieri F, Marti A, Fasano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566772>
29. **SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.** *Eur. J. Cancer* 2020; Yarza R, Bover M, Paredes D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586724>

30. **Sickle Cell Trait and The Potential Risk of Severe Coronavirus Disease 2019- A Mini-Review.** *Eur. J. Haematol.* 2020; Kehinde TA, Osundiji MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589774>
31. **COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.** *Eur. J. Haematol.* 2020; Langerbeins P, Furstenau M, Gruell H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575156>
32. **Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2.** *Expert Rev. Respir. Med.* 2020;1-4Robba C, Battaglini D, Pelosi P, Rocco PRM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567404>
33. **A Novel Scoring System for Prediction of Disease Severity in COVID-19.** *Front Cell Infect Microbiol* 2020; 10:318Zhang C, Qin L, Li K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582575>
34. **Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm.** *Front. Immunol.* 2020; 11:1130Ruscitti P, Berardicurti O, Di Benedetto P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574264>
35. **HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa.** *Front Med (Lausanne)* 2020; 7:216Cainelli F, Dzudzor B, Lanzafame M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574323>
36. **Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province.** *Front Med (Lausanne)* 2020; 7:249Tian H, Sui Y, Tian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574337>
37. **The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance.** *Front. Microbiol.* 2020; 11:1020Murray AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574253>
38. **A Primary Mediastinal Large B-Cell Lymphoma Patient With COVID-19 Infection After Intensive Immunotherapy: A Case Report.** *Front. Oncol.* 2020; 10:924Li Q, Zhu F, Xiao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574278>
39. **Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.** *Front. Pharmacol.* 2020; 11:836Wehbe Z, Hammoud S, Soudani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581799>
40. **Severe COVID-19: A Review of Recent Progress With a Look Toward the Future.** *Front Public Health* 2020; 8:189Xie P, Ma W, Tang H, Liu D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574292>
41. **Poor outcome of intestinal ischemic manifestations of COVID 19.** *Gastroenterology* 2020; Norsa L, Pietro B, Indriolo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569772>
42. **Unique case of central retinal artery occlusion secondary to COVID-19 disease.** *IDCases* 2020; 21:e00867Acharya S, Diamond M, Anwar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572363>
43. **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?** *Int. J. Cancer* 2020; Assoun S, Bendersa MA, Lotz JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574373>
44. **Air Pollution and Covid-19: The Role of Particulate Matter in the Spread and Increase of Covid-19's Morbidity and Mortality.** *Int J Environ Res Public Health* 2020; 17Comunian S, Dongo D, Milani C, Palestini P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580440>
45. **Acute respiratory distress syndrome due to SARS-CoV-2 and Influenza A co-infection in an Italian patient: mini-review of the literature.** *Int J Infect Dis* 2020; Alessandra D, Lepore L, Palazzolo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565366>
46. **COVID-19 Concomitant Infective Endocarditis: A-Case Report and Review of Management.** *Int J Infect Dis* 2020; Amir M, Djaharuddin I, Sudharsono A, Ramadany S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574691>
47. **Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis.** *Int. J. Lab. Hematol.* 2020; Zhang Y, He L, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592539>
48. **Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.** *Intensive Care Med* 2020; Jerath A, Ferguson ND, Cuthbertson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588067>
49. **Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study.** *J Allergy Clin Immunol Pract* 2020; Vultaggio A, Vivarelli E, Virgili G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565226>
50. **When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection.** *J Am Acad Dermatol* 2020; Damsky W, Peterson D, King B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565206>
51. **Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea.** *J Clin Med* 2020; 9Choi MH, Ahn H, Ryu HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585855>
52. **COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection.** *J Clin Med* 2020; 9Lechowicz K, Drozdal S, Machaj F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575380>
53. **COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation.** *J. Clin. Med. Res.* 2020; 12:352-361Adapa S, Chenna A, Balla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587651>
54. **Clinical feedback from experience with COVID-19: specific considerations for ExtraCorporeal Membrane Oxygenation.** *J Infect* 2020; Fiore A, de Roux Q, Daami N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579990>
55. **What if the worst consequences of COVID-19 concerned non-COVID patients?** *J Infect Public Health* 2020; Goulabchand R, Claret PG, Lattuca B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576501>
56. **The cytokine storm and COVID-19.** *J Med Virol* 2020; Hu B, Huang S, Yin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592501>
57. **Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience.** *J Med Virol* 2020; Riollano-Cruz M, Akkoyun E, Briceno-Brito E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584487>
58. **Guillain-Barre syndrome in a patient infected with SARS-CoV-2, a case report.** *J. Neuroimmunol.* 2020; 346:577294Farzi MA, Ayromlou H, Jahanbakhsh N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590125>
59. **Multiple internal border zone infarcts in a patient with COVID-19 and CADASIL.** *J Neurol Sci* 2020; 416:116980Williams OH, Mohideen S, Sen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574902>
60. **Intracranial hemorrhage complicating anticoagulant prophylactic therapy in three hospitalized COVID-19 patients.** *J. Neurovirol.* 2020; Ghani MU, Kumar M, Ghani U *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572835>
61. **Reply to LTE: COVID-19 and pulmonary embolism: diagnostic imaging trends.** *J Nucl Med* 2020; Zuckier LS, Moadel RM, Haramati LB, Freeman LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576640>
 62. **Pneumococcal superinfection in COVID-19 patients: A series of 5 cases.** *Med Clin (Barc)* 2020; Cucchiari D, Pericas JM, Riera J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591180>
 63. **Microvascular disease confers additional risk to COVID-19 infection.** *Med Hypotheses* 2020; 144:109999Bale BF, Doneen AL, Vigerust DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570168>
 64. **COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS.** *Med. J. Aust.* 2020; Gibson PG, Qin L, Pua SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572965>
 65. **A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.** *medRxiv* 2020; Wang B, Van Oekelen O, Mouhieddine TH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577702>
 66. **COVID-19 associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan.** *Mycoses* 2020; Nasir N, Farooqi J, Mahmood SF, Jabeen K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585069>
 67. **Short-Term Dexamethasone in Sars-CoV-2 Patients.** *R I Med J (2013)* 2020; 103:39-43Selvaraj V, Dapaah-Afriyie K, Finn A, Flanigan TP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570995>
 68. **Suspected case of COVID-19-associated pancreatitis in a child.** *Radiol Case Rep* 2020; 15:1309-1312Alloway BC, Yaeger SK, Mazzaccaro RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572339>
 69. **SARS-CoV-2: diagnostic and design conundrums in the context of male factor infertility.** *Reprod. Biomed. Online* 2020; Bahadur G, Acharya S, Muneer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565229>
 70. **Predictive factors of severe coronavirus disease 2019 in previously healthy young adults: a single-center, retrospective study.** *Respir Res* 2020; 21:157Zhou C, Huang Z, Tan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571410>
 71. **Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.** *Respiration* 2020:1-21Pfeifer M, Ewig S, Voshaar T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564028>
 72. **Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.** *Rheumatol. Int.* 2020; Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591970>
 73. **Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.** *Thromb Res* 2020; 194:36-41Fletcher-Sandersjoo A, Bellander BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569879>
 74. **COVID-19 infection in solid organ transplant recipients: a single center experience with patients immediately after transplantation.** *Transpl Infect Dis* 2020:e13381Kolonko A, Dudzicz S, Wiecek A, Krol R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578289>

Cured – Recovered (3 articles)

1. **Prediction of the rehabilitation duration and risk management for mild-moderate COVID-19.** *Disaster Med Public Health Prep* 2020:1-27Zheng QN, Xu MY, Zheng YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576328>
2. **The Application of Eight-Segment Pulmonary Rehabilitation Exercise in People With Coronavirus Disease 2019.** *Front. Physiol.* 2020; 11:646Chen JM, Wang ZY, Chen YJ, Ni J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574241>
3. **Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients.** *J Infect* 2020; Cento V, Colagrossi L, Nava A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574567>

Cardiovascular disease (45 articles)

1. **Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombolysis and Anticoagulation Strategy.** *Am J Med Case Rep* 2020; 8:262-267Al-Sadawi M, Mohiuddin A, Hossain N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587886>
2. **The potential sudden shift in clinical research and epidemiology of cardiovascular diseases, caused by COVID-19.** *Arch Cardiovasc Dis* 2020; Pezel T, Lima JAC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586675>
3. **Platelets and Immunity: Going Viral.** *Arterioscler. Thromb. Vasc. Biol.* 2020; 40:1605-1607Koupenova M, Freedman JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579477>
4. **Management of acute myocardial injury in patients with confirmed or suspected COVID-19.** *Atherosclerosis* 2020; Chatzizisis YS, Gajanan G, Bhatt DL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586609>
5. **SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management.** *Biochem. Pharmacol.* 2020:114114Wu L, O'Kane AM, Peng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579957>
6. **Cardiopulmonary exercise testing in the COVID-19 endemic phase.** *Br J Anaesth* 2020; Faghy MA, Sylvester KP, Cooper BG, Hull JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571569>
7. **Pulmonary embolism in acute medicine: a case-based review incorporating latest guidelines in the COVID-19 era.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-12Stevenson A, Davis S, Murch N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589531>
8. **Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients.** *Cardiol J* 2020; Lorente-Ros A, Monteagudo Ruiz JM, Rincon LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589258>
9. **In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.** *Cell Metab.* 2020; Zhang XJ, Qin JJ, Cheng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592657>

10. **The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.** *Circ Res* 2020; McFadyen JD, Stevens H, Peter K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586214>
11. **Is the use of ACE Inhibitors/ARBs associated with higher in-hospital mortality in COVID-19 pneumonia patients?** *Clin. Exp. Hypertens.* 2020;1-5 Selcuk M, Cinar T, Keskin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569491>
12. **Atypical Manifestation of COVID-19-Induced Myocarditis.** *Cureus* 2020; 12:e8685 Rehman M, Gondal A, Rehman NU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577331>
13. **COVID-19 pandemic and the impact on the cardiovascular disease patient care.** *Curr. Cardiol. Rev.* 2020; Kulkarni P, Mahadevappa M, Alluri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564757>
14. **Relationship Between ACE2 and Other Components of the Renin-Angiotensin System.** *Curr. Hypertens. Rep.* 2020; 22:44 Cohen JB, Hanff TC, Bress AP, South AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591908>
15. **Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.** *Dermatol Ther* 2020; Recalcati S, Piconi S, Franzetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584431>
16. **Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19.** *Diabetes Metab Syndr* 2020; 14:929-931 Mahajan K, Chand Negi P, Ganju N, Asotra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590335>
17. **Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway?** *Emerg Microbes Infect* 2020;1-26 Berthelot JM, Drouet L, Liote F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574107>
18. **New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people.** *Eur Heart J* 2020; Holt A, Gislason GH, Schou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578859>
19. **Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies.** *Eur Heart J Acute Cardiovasc Care* 2020;2048872620937165 Parohan M, Yaghoubi S, Seraji A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567326>
20. **Electrocardiographic features of patients with COVID-19 pneumonia.** *Eur J Intern Med* 2020; Angeli F, Spanevello A, De Ponti R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586646>
21. **ACE2, Much More Than Just a Receptor for SARS-COV-2.** *Front Cell Infect Microbiol* 2020; 10:317 Samavati L, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582574>
22. **The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.** *Front Med (Lausanne)* 2020; 7:248 Lumbers ER, Delforce SJ, Pringle KG, Smith GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574336>
23. **Interventional Stroke Care in the Era of COVID-19.** *Front. Neurol.* 2020; 11:468 Salahuddin H, Castonguay AC, Zaidi SF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574245>
24. **Congenital heart disease in the era of COVID-19 pandemic.** *Gen. Thorac. Cardiovasc. Surg.* 2020; Giordano R, Cantinotti M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572816>
25. **COVID-19 and Cardiac Arrhythmias.** *Heart Rhythm* 2020; Bhatla A, Mayer MM, Adusumalli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585191>
26. **[COVID-19 and its relationship with hypertension and cardiovascular disease].** *Hipertens Riesgo Vasc* 2020; Salazar M, Barochiner J, Espeche W, Ennis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591283>
27. **Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis.** *Int. J. Lab. Hematol.* 2020; Zhang Y, He L, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592539>
28. **Recommendations for risk stratified use of cardiac computed tomography for congenital heart disease during the COVID-19 pandemic.** *J. Cardiovasc. Comput. Tomogr.* 2020; Farooqi KM, Ghoshhajra BB, Shah AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565094>
29. **COVID-19 and Heart: From Clinical Features to Pharmacological Implications.** *J Clin Med* 2020; 9 Russo V, Bottino R, Carbone A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580344>
30. **Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond.** *J. Natl. Med. Assoc.* 2020; Ferdinand K, Batieste T, Fleurestil M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563685>
31. **COVID-19 Screening with Chest CT in Acute Stroke Imaging: A Clinical Decision Model.** *J. Neuroimaging* 2020; Qureshi AI, French BR, Siddiq F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589348>
32. **Multiple internal border zone infarcts in a patient with COVID-19 and CADASIL.** *J Neurol Sci* 2020; 416:116980 Williams OH, Mohideen S, Sen A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574902>
33. **Intracranial hemorrhage complicating anticoagulant therapy in three hospitalized COVID-19 patients.** *J. Neurovirool.* 2020; Ghani MU, Kumar M, Ghani U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572835>
34. **Reply to LTE: COVID-19 and pulmonary embolism: diagnostic imaging trends.** *J Nucl Med* 2020; Zuckier LS, Moadel RM, Haramati LB, Freeman LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576640>
35. **The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states.** *J Thromb Haemost* 2020; Thachil J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588535>
36. **Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives.** *Korean Circ J* 2020; 50:543-554 Kim IC, Kim HA, Park JS, Nam CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588565>
37. **COVID-19-related strokes in adults below 55 years of age: a case series.** *Neurol Sci* 2020; Ashrafi F, Zali A, Omidi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583169>
38. **Impact of the COVID-19 pandemic on the organisation of stroke care. Madrid Stroke Care Plan.** *Neurologia* 2020; Fuentes B, Alonso de Lecinana M, Calleja-Castano P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563566>
39. **"Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease".** *Nutr. Metab. Cardiovasc. Dis.* 2020; Mattioli AV, Sciomer S, Cocchi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571612>
40. **The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity.** *Obes Rev* 2020; Akoumianakis I, Filippatos T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567171>

41. **COVID-19 pandemic and inherited cardiomyopathies and channelopathies: a short term and long term perspective.** *Orphanet J. Rare Dis.* 2020; 15:157Limongelli G, Crotti L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571376>
42. **Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.** *Pol Merkur Lekarski* 2020; 48:195-198Surma S, Romanczyk M, Labuzek K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564046>
43. **A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.** *Rev Med Virol* 2020; Malek Mahdavi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584474>
44. **Stroke Systems of Care: Current State of Affairs and Future Directions.** *Stroke* 2020; 51:1928-1931Goyal M, Ospel JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568659>
45. **Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.** *Thromb Res* 2020; 194:36-41Fletcher-Sandersjoo A, Bellander BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569879>

Diagnosis (4 articles)

1. **COVID-19 paraclinical diagnostic tools: Updates and future trends.** *Curr Res Transl Med* 2020; Alsuliman T, Sulaiman R, Ismail S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576508>
2. **Developments, Evolution, and Implications of National Diagnostic Criteria for COVID-19 in China.** *Front Med (Lausanne)* 2020; 7:242Ma LL, Li BH, Jin YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574333>
3. **Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series.** *Front Med (Lausanne)* 2020; 7:231Tahvildari A, Arbabi M, Farsi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574328>
4. **COVID-19 Concomitant Infective Endocarditis: A-Case Report and Review of Management.** *Int J Infect Dis* 2020; Amir M, Djaharuddin I, Sudharsono A, Ramadany S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574691>

DM-MS-Obesity (23 articles)

1. **Diabetes increases the mortality of patients with COVID-19: a meta-analysis.** *Acta Diabetol* 2020; Wu ZH, Tang Y, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583078>
2. **[Obesity as a risk factor in COVID-19: Possible mechanisms and implications].** *Aten. Primaria* 2020; Petrova D, Salamanca-Fernandez E, Rodriguez Barranco M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586628>
3. **The potential impacts of obesity on COVID-19.** *Clin Med (Lond)* 2020; Albashir AAD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571783>
4. **Diabetes management during Ramadan amid Covid-19 pandemic.** *Daru* 2020; Tootee A, Esfahani EN, Larijani B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588340>
5. **Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19).** *Diabetes Metab Res Rev* 2020:e3377Zhou Y, Chi J, Lv W, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588943>
6. **Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India.** *Diabetes Metab Syndr* 2020; 14:917-920Ghosh A, Arora B, Gupta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574982>
7. **A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.** *Diabetes Res Clin Pract* 2020:108282Esam Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592841>
8. **Clinical Characteristics and Outcome in Patients with Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State Associated with COVID-19: A Retrospective, Hospital-Based Observational Case Series.** *Diabetes Res Clin Pract* 2020:108279Hoe Chan K, Thimmarreddygari D, Ramahi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592843>
9. **Diabetes and COVID-19: IDF perspective in the Western Pacific Region.** *Diabetes Res Clin Pract* 2020:108278Hwang Y, Khasag A, Jia W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592842>
10. **COVID-19 and Type 1 Diabetes: Challenges and actions.** *Diabetes Res Clin Pract* 2020:108275Klatman EL, Besancon S, Bahendeka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590008>
11. **Retinal outcomes of COVID-19: possible role of CD147 and cytokine storm in infected patients with diabetes mellitus.** *Diabetes Res Clin Pract* 2020:108280Raony I, Saggiore de Figueiredo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592839>
12. **Well-controlled vs Poorly-controlled Diabetes in Patients with COVID-19: Are There Any Differences in Outcomes and Imaging Findings?** *Diabetes Res Clin Pract* 2020:108286Raoufi M, Khalili S, Mansouri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592836>
13. **Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection?** *Front Public Health* 2020; 8:184Finucane FM, Davenport C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574288>
14. **Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.** *Intern Emerg Med* 2020; Pantanetti P, Cangelosi G, Ambrosio G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592113>
15. **Clinical prediction model for mortality of adult diabetes inpatients with COVID-19 in Wuhan, China: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 66:109927Su M, Yuan J, Peng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570072>
16. **Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe Covid-19.** *J Med Virol* 2020; Smith SM, Boppana A, Traupman JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589756>
17. **Challenges of diabetes management during the COVID-19 pandemic.** *Med. J. Aust.* 2020; Scott ES, Jenkins AJ, Fulcher GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583422>
18. **Diabetes, Infection Risk And Covid-19.** *Mol Metab* 2020:101044Erener S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585364>

19. **Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies.** *Nutr. Metab. Cardiovasc. Dis.* 2020; Mantovani A, Byrne CD, Zheng MH, Targher G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571616>
20. **The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity.** *Obes Rev* 2020; Akoumianakis I, Filippatos T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567171>
21. **Should patients with obesity be more afraid of COVID-19?** *Obes Rev* 2020; Rychter AM, Zawada A, Ratajczak AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583537>
22. **Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID-19.** *Obesity (Silver Spring)* 2020; Pettit NN, MacKenzie EL, Ridgway J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589784>
23. **People with Diabetes Mellitus: Soft target for COVID-19 infection.** *Pak J Med Sci* 2020; 36:S3-s5Hussain A, Ali I, Hassan Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582305>

Education and training and science (37 articles)

1. **Innovation Born in Isolation: Rapid Transformation of an In-Person Medical Student Radiology Elective to a Remote Learning Experience During the COVID-19 Pandemic.** *Acad Radiol* 2020; Gomez E, Azadi J, Magid D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565164>
2. **COVID-19 Impact on Well-Being and Education in Radiology Residencies: A Survey of the Association of Program Directors in Radiology.** *Acad Radiol* 2020; Robbins JB, England E, Patel MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571648>
3. **An alarming retraction rate for scientific publications on Coronavirus Disease 2019 (COVID-19).** *Account Res* 2020;1-7Yeo-Teh NSL, Tang BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573274>
4. **Impact of COVID-19 pandemic on general surgery training program: An Italian experience.** *Am. J. Surg.* 2020; Bernardi L, Germani P, Del Zotto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564874>
5. **Appealing for efficient, well organized clinical trials on COVID-19.** *Ann Transl Med* 2020; 8:632Zhao Y, Wei Y, Shen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566569>
6. **The potential sudden shift in clinical research and epidemiology of cardiovascular diseases, caused by COVID-19.** *Arch Cardiovasc Dis* 2020; Pezel T, Lima JAC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586675>
7. **How Do Colleges and Universities Respond to Covid-19: The Experience of Chengdu Sport University.** *Asia Pac. J. Public Health* 2020;1010539520931358Kan M, Zhou J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580564>
8. **Bioanalytical research and training in academia during the COVID-19 pandemic.** *Bioanalysis* 2020; Klont F, Hopfgartner G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589061>
9. **Empowering academic labs and scientists to test for COVID-19.** *Biotechniques* 2020; Steel JJ, Sitko JC, Adkins MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584188>
10. **Rapid publications risk the integrity of science in the era of COVID-19.** *BMC Med* 2020; 18:192Bagdasarian N, Cross GB, Fisher D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586327>
11. **Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19.** *BMC Med. Res. Methodol.* 2020; 20:161Fidahic M, Nujic D, Runjic R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571302>
12. **COVID-19: novel pandemic, novel generation of medical students.** *Br J Anaesth* 2020; Wang JJ, Deng A, Tsui BCH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563493>
13. **Mental health status of the general population, healthcare professionals, and university students during 2019 coronavirus disease outbreak in Jordan: A cross-sectional study.** *Brain Behav* 2020:e01730Naser AY, Dahmash EZ, Al-Rousan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578943>
14. **Pandemics, privacy, and public health research.** *Can. J. Public Health.* 2020; Bernier A, Knoppers BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592023>
15. **Novel coronavirus 2019 transmission risk in educational settings.** *Clin Infect Dis* 2020; Yung CF, Kam KQ, Nadua KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584975>
16. **Awareness among under graduate students of Mangalore city regarding novel coronavirus (COVID-19) - A questionnaire study.** *Disaster Med Public Health Prep* 2020;1-9Das D, Kudpi RS, Mukherjee M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576311>
17. **Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.** *Ethics Hum Res* 2020; Iyer AA, Hendriks S, Rid A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567239>
18. **How Are We Facing It? Dispatches From Pathology Residents in a COVID-19 Lombardy Hospital.** *Front Public Health* 2020; 8:259Cieri M, De Carlo C, Valeri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582614>
19. **Medical Students and COVID-19: Knowledge, Attitudes, and Precautionary Measures. A Descriptive Study From Jordan.** *Front Public Health* 2020; 8:253Khasawneh AI, Humeidan AA, Alsulaiman JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574313>
20. **Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study.** *Front Public Health* 2020; 8:254Olaimat AN, Aolyamat I, Shahbaz HM, Holley RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574314>
21. **The Science of the Future: Establishing a Citizen-Scientist Collaborative Agenda After Covid-19.** *Front Public Health* 2020; 8:282Provenzi L, Barello S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582619>
22. **Trends of publications during COVID-19 pandemic.** *Injury* 2020; Vaishya R, Vaish A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571547>
23. **COVID-19 Pandemic: A Time for Collaboration and A Unified Global Health Front.** *Int. J. Qual. Health Care* 2020; Vervoort D, Ma X, Luc JGY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592480>
24. **Dear Dermatoethicist: Medical Student Dermatology Rotations in the Context of COVID-19.** *J Am Acad Dermatol* 2020; Muzumdar S, Grant-Kels JM, Feng H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592884>
25. **COVID-19 lockdown learning: The uprising of virtual teaching.** *J. Plast. Reconstr. Aesthet. Surg.* 2020; Sleiwah A, Mughal M, Hachach-Haram N, Roblin P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565141>

26. **Application of Universal Design for Learning (UDL) Principles to Surgical Education During the COVID-19 Pandemic.** *J Surg Educ* 2020; Dickinson KJ, Gronseth SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576451>
27. **A need for consensus on mortality reporting related to the COVID-19 pandemic in ongoing and future vascular registries and trials.** *J. Vasc. Surg.* 2020; Valdivia AR, Chaudhuri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592742>
28. **Medical students' dilemma during the Covid-19 pandemic; between the will to help and the fear of contamination.** *Med. Educ. Online* 2020; 25:1784374Hijej G, Fournassi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578522>
29. **Intern year in a developing country amidst COVID-19.** *Med. Educ. Online* 2020; 25:1785115Shrigrivar A, Garg T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586218>
30. **Clinical placements for medical students in the time of COVID-19.** *Med. J. Aust.* 2020; Halbert JA, Jones A, Ramsey LP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583427>
31. **Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing.** *Mol. Cell. Proteomics* 2020; Zecha J, Lee CY, Bayer FP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591346>
32. **Perceptions of students regarding E-learning during Covid-19 at a private medical college.** *Pak J Med Sci* 2020; 36:S57-s61Abbasi S, Ayoob T, Malik A, Memon SI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582315>
33. **Knowledge, Awareness and Practice of Health care Professionals amid SARS-CoV-2, Corona Virus Disease Outbreak.** *Pak J Med Sci* 2020; 36:S49-s56Ahmed N, Shakoor M, Vohra F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582314>
34. **Technology Enhanced Assessment (TEA) in COVID 19 Pandemic.** *Pak J Med Sci* 2020; 36:S108-s110Khan RA, Jawaid M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582325>
35. **COVID-19 Pandemic: Impact of Quarantine on Medical Students' Mental Wellbeing and Learning Behaviors.** *Pak J Med Sci* 2020; 36:S43-s48Meo SA, Abukhalaf AA, Alomar AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582313>
36. **Advantages, Limitations and Recommendations for online learning during COVID-19 pandemic era.** *Pak J Med Sci* 2020; 36:S27-s31Mukhtar K, Javed K, Arooj M, Sethi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582310>
37. **Decrease in Neurosurgical Program Volume During COVID-19: Residency Programs Must Adapt.** *World Neurosurg* 2020; Field NC, Platanitis K, Paul AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592966>

Elderly (21 articles)

1. **[Theory and practice of aging upon COVID-19 pandemic.].** *Adv Gerontol* 2020; 33:397-408Golubev AG, Sidorenko AV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593259>
2. **Epidemiology of COVID-19 in older persons, Wuhan, China.** *Age Ageing* 2020; Guo Y, Liu X, Deng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584953>
3. **Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities.** *Age Ageing* 2020; Richardson SJ, Carroll CB, Close J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584954>
4. **Prevention and infection control of COVID-19 in Nursing Homes: experience from China.** *Age Ageing* 2020; Wang L, Qi N, Zhou Y, Zhang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584961>
5. **Covid-19 in dementia: an insidious pandemic.** *Age Ageing* 2020; Yao JS, Dee EC, Milazzo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584402>
6. **ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19.** *Aging (Albany NY)* 2020; 12Bousquet G, Falgarone G, Deutsch D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576712>
7. **COVID-19: Clinical Challenges in Dutch Geriatric Psychiatry.** *Am J Geriatr Psychiatry* 2020; Naarding P, Oude Voshaar RC, Marijnissen RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565007>
8. **COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease.** *BMC Med* 2020; 18:194Brill SE, Jarvis HC, Ozcan E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586323>
9. **Asymptomatic SARS-CoV-2 Infection in Nursing Homes, Barcelona, Spain, April 2020.** *Emerg Infect Dis* 2020; 26Borras-Bermejo B, Martinez-Gomez X, San Miguel MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574139>
10. **Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era.** *Eur J Intern Med* 2020; Rossi R, Coppi F, Talarico M, Boriani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564905>
11. **If Not Now, When? the Role of Geriatric Leadership as Covid-19 Brings the World to Its Knees.** *Front Med (Lausanne)* 2020; 7:232Dwolatzky T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574329>
12. **Elderly at time of COroNaVirus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.** *Geroscience* 2020; Bencivenga L, Rengo G, Varricchi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578073>
13. **Protecting and Improving the Lives of Older Adults in the COVID-19 Era.** *J Aging Soc Policy* 2020; 32:297-309Miller EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583751>
14. **The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis.** *J. Alzheimers Dis.* 2020; Boutoleau-Brettonniere C, Pouclet-Courtemanche H, Gillet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568211>
15. **Managing Older Adults with Presumed COVID-19 in the Emergency Department: A Rational Approach to Rationing.** *J Am Geriatr Soc* 2020; Rosen T, Ferrante LE, Liu SW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574404>
16. **Older age is associated with sustained detection of SARS-CoV-2 in nasopharyngeal swab samples.** *J Infect* 2020; Hattori T, Amishima M, Morinaga D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579989>
17. **WHO statement - "Older people are at highest risk from COVID-19": Should the hypothesis be corroborated or rejected?** *Med. Hypotheses* 2020; 144:109896Ningthoujam R, Khomdram D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585464>

18. **Decision Making: Physical Therapist Intervention for Patients With COVID-19 in a Geriatric Setting.** *Phys Ther* 2020; Levi N, Ganchrow K, Gheva M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589716>
19. **Covid-19: Adapting the geriatric organisations to respond to the pandemic.** *Respir Med Res* 2020; 78:100774 Celarier T, Lafaie L, Goethals L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563967>
20. **[Evaluation of incidence and risk profile for suffering Covid-19 infection by underlying conditions among middle-aged and older adults in Tarragona.].** *Rev. Esp. Salud Publica* 2020; 94:Vila-Corcoles A, Ochoa-Gondar O, Torrente-Fraga C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588837>
21. **CLINICAL DECISION MAKING IN OLDER ADULTS WITH COVID-19 IN DEVELOPING COUNTRIES: LOOKING BEYOND CHRONOLOGICAL AGE.** *Rev Invest Clin* 2020; 72:127-134 Gomez-Moreno C, Hernandez-Ruiz V, Hernandez-Gilsoul T, Avila-Funes JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584321>

Epidemiology 103 articles)

1. **Epidemiology of COVID-19 in older persons, Wuhan, China.** *Age Ageing* 2020; Guo Y, Liu X, Deng M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584953>
2. **Transformation of a large multi-speciality hospital into a dedicated COVID-19 centre during the coronavirus pandemic.** *Ann. Agric. Environ. Med.* 2020; 27:201-206 Krol Z, Szymanski P, Bochnia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588593>
3. **A Brief Theory of Epidemic Kinetics.** *Biology (Basel)* 2020; 9:Louchet F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580293>
4. **Surge capacity and updated admission criteria: response of the NHS-commissioned national respiratory extracorporeal membrane oxygenation network to the COVID-19 pandemic.** *Br J Anaesth* 2020; Warren A, Camporota L, Vuylsteke A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571572>
5. **Cultural orientation, power, belief in conspiracy theories, and intentions to reduce the spread of COVID-19.** *Br. J. Soc. Psychol.* 2020; Biddlestone M, Green R, Douglas KM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592420>
6. **The importance of (shared) human values for containing the COVID-19 pandemic.** *Br. J. Soc. Psychol.* 2020; Wolf LJ, Haddock G, Manstead ASR, Maio GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572981>
7. **The Spread of COVID-19 in the Italian Population: Anxiety, Depression, and Post-traumatic Stress Symptoms.** *Can. J. Psychiatry.* 2020:706743720938598 Castelli L, Di Tella M, Benfante A, Romeo A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588644>
8. **Comparative analysis and forecasting of COVID-19 cases in various European countries with ARIMA, NARNN and LSTM approaches.** *Chaos Solitons Fractals* 2020; 138:110015 Kirbas I, Sozen A, Tuncer AD, Kazancioğlu FS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565625>
9. **Modeling and prediction of COVID-19 pandemic using Gaussian mixture model.** *Chaos Solitons Fractals* 2020; 138:110023 Singhal A, Singh P, Lall B, Joshi SD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565627>
10. **Characteristics of 1,573 healthcare workers who underwent nasopharyngeal swab for SARS-CoV-2 in Milano, Lombardy, Italy.** *Clin Microbiol Infect* 2020; Lombardi A, Consonni D, Carugno M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569835>
11. **An agent-based model to evaluate the COVID-19 transmission risks in facilities.** *Comput. Biol. Med.* 2020; 121:103827 Cuevas E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568667>
12. **A simplified math approach to predict ICU beds and mortality rate for hospital emergency planning under Covid-19 pandemic.** *Comput. Chem. Eng.* 2020; 140:106945 Manca D, Caldirolì D, Storti E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565584>
13. **Novel COVID-19: A Comprehensive Review of Transmission, Manifestation, and Pathogenesis.** *Cureus* 2020; 12:e8184 Hussain A, Kaler J, Tabrez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566425>
14. **Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India.** *Diabetes Metab Syndr* 2020; 14:917-920 Ghosh A, Arora B, Gupta R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574982>
15. **Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method.** *Diabetes Metab Syndr* 2020; 14:887-892 Maqbool A, Khan NZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563940>
16. **Assessment of Countries' Preparedness and Lockdown Effectiveness in Confronting COVID-19.** *Disaster Med Public Health Prep* 2020:1-15 Amer F, Hammoud S, Farran B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576332>
17. **SPE Approach for Robust Estimation of SIR Model with Limited and Noisy Data: The Case for COVID-19.** *Disaster Med Public Health Prep* 2020:1-22 Senel K, Ozdinc M, Ozturkcan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580814>
18. **Temperature screening has negligible value for control of COVID-19.** *Emerg. Med. Australas.* 2020; Mitra B, Luckhoff C, Mitchell RD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578926>
19. **Epidemiology and clinical course of COVID-19 in Shanghai, China.** *Emerg Microbes Infect* 2020:1-28 Shen Y, Zheng F, Sun D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573353>
20. **Environmental concern regarding the effect of humidity and temperature on 2019-nCoV survival: fact or fiction.** *Environ. Sci. Pollut. Res. Int.* 2020; Harmooshi NN, Shirbandi K, Rahim F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592048>
21. **Follow up investigation of asymptomatic COVID-19 cases at diagnosis in Busan, Korea.** *Epidemiol Health* 2020:e2020046 Lee M, Eun Y, Park K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580531>
22. **Individual-based simulation model for COVID-19 transmission in Daegu, Korea.** *Epidemiol Health* 2020:e2020042 Son WS, Team R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580535>
23. **SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy.** *Eur J Intern Med* 2020; Milani GP, Montomoli E, Bollati V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564906>
24. **Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyang City, China.** *Front Cell Infect Microbiol* 2020; 10:284 Liu L, Lei X, Xiao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574282>

25. **Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?** *Front. Immunol.* 2020; 11:1208Mutti L, Pentimalli F, Baglio G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574270>
26. **HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa.** *Front Med (Lausanne)* 2020; 7:216Cainelli F, Dzudzor B, Lanzafame M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574323>
27. **COVID-19: The Conjunction of Events Leading to the Coronavirus Pandemic and Lessons to Learn for Future Threats.** *Front Med (Lausanne)* 2020; 7:223Frutos R, Lopez Roig M, Serra-Cobo J, Devaux CA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574324>
28. **The Rise and Impact of COVID-19 in India.** *Front Med (Lausanne)* 2020; 7:250Kumar SU, Kumar DT, Christopher BP, Doss CGP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574338>
29. **Impact of Lockdown on the Epidemic Dynamics of COVID-19 in France.** *Front Med (Lausanne)* 2020; 7:274Roques L, Klein EK, Papaix J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582739>
30. **Transmission of SARS-CoV-2 and Other Infections at Large Sports Gatherings: A Surprising Gap in Our Knowledge.** *Front Med (Lausanne)* 2020; 7:277Sassano M, McKee M, Ricciardi W, Boccia S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574343>
31. **Evaluation of the Secondary Transmission Pattern and Epidemic Prediction of COVID-19 in the Four Metropolitan Areas of China.** *Front Med (Lausanne)* 2020; 7:171Su L, Hong N, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574319>
32. **Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China.** *Front Med (Lausanne)* 2020; 7:210Tian S, Chang Z, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574322>
33. **COVID-19 Confinement and Health Risk Behaviors in Spain.** *Front. Psychol.* 2020; 11:1426Lopez-Bueno R, Calatayud J, Casana J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581985>
34. **Comparison of Epidemiological Variations in COVID-19 Patients Inside and Outside of China-A Meta-Analysis.** *Front Public Health* 2020; 8:193Ahmed A, Ali A, Hasan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574293>
35. **Knowledge, Attitude and Practice Toward COVID-19 Among the Public in the Kingdom of Saudi Arabia: A Cross-Sectional Study.** *Front Public Health* 2020; 8:217Al-Hanawi MK, Angawi K, Alshareef N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574300>
36. **The Battle Against COVID-19 in Jordan: An Early Overview of the Jordanian Experience.** *Front Public Health* 2020; 8:188Al-Tammemi AB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574291>
37. **A Simulation of a COVID-19 Epidemic Based on a Deterministic SEIR Model.** *Front Public Health* 2020; 8:230Carcione JM, Santos JE, Bagaini C, Ba J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574303>
38. **On Determining the Age Distribution of COVID-19 Pandemic.** *Front Public Health* 2020; 8:202Cortis D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574295>
39. **COVID-19 UK Lockdown Forecasts and R 0.** *Front Public Health* 2020; 8:256Dropkin G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574315>
40. **Transitioning Out of the Coronavirus Lockdown: A Framework for Evaluating Zone-Based Social Distancing.** *Front Public Health* 2020; 8:266Friedman E, Friedman J, Johnson S, Landsberg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587845>
41. **COVID-19: Emergence, Spread, Possible Treatments, and Global Burden.** *Front Public Health* 2020; 8:216Keni R, Alexander A, Nayak PG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574299>
42. **The Lessons and Experiences That Can Be Learned From China in Fighting Coronavirus Disease 2019.** *Front Public Health* 2020; 8:227Liu J, Zhang G, Zhang F, Song C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574302>
43. **Approaches to Daily Monitoring of the SARS-CoV-2 Outbreak in Northern Italy.** *Front Public Health* 2020; 8:222Moirano G, Richiardi L, Novara C, Maule M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574301>
44. **How and When to End the COVID-19 Lockdown: An Optimization Approach.** *Front Public Health* 2020; 8:262Rawson T, Brewer T, Veltcheva D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587844>
45. **Recommendations for Physical Inactivity and Sedentary Behavior During the Coronavirus Disease (COVID-19) Pandemic.** *Front Public Health* 2020; 8:199Ricci F, Izzicupo P, Moscucci F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574294>
46. **Coronavirus Disease (COVID-19) in the Middle East: A Call for a Unified Response.** *Front Public Health* 2020; 8:209Sawaya T, Ballouz T, Zaraket H, Rizk N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574298>
47. **Coronavirus Disease Pandemic Is a Real Challenge for Brazil.** *Front Public Health* 2020; 8:268Simoes ESAC, Oliveira EA, Martelli H, Jr. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582618>
48. **Clinical and Epidemiological Characteristics of COVID-19 Patients in Chongqing China.** *Front Public Health* 2020; 8:244Yang A, Qiu Q, Kong X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574309>
49. **Analysis of the impact of lockdown on the reproduction number of the SARS-Cov-2 in Spain.** *Gac. Sanit.* 2020; Hyafil A, Morina D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571528>
50. **Describing the pattern of the COVID-19 epidemic in Vietnam.** *Glob Health Action* 2020; 13:1776526Hoang VM, Hoang HH, Khuong QL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588779>
51. **The comparative politics of COVID-19: The need to understand government responses.** *Glob Public Health* 2020; 1-4Greer SL, King EJ, da Fonseca EM, Peralta-Santos A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564670>
52. **Globalisation in the time of COVID-19: repositioning Africa to meet the immediate and remote challenges.** *Global Health* 2020; 16:51Yaya S, Otu A, Labonte R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580728>
53. **Multiple Ensemble Neural Network Models with Fuzzy Response Aggregation for Predicting COVID-19 Time Series: The Case of Mexico.** *Healthcare (Basel)* 2020; 8Melin P, Monica JC, Sanchez D, Castillo O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575622>
54. **Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection.** *Infect Dis (Lond)* 2020; 1-7Gidari A, De Socio GV, Sabbatini S, Francisci D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584161>
55. **Targeted adaptive isolation strategy for COVID-19 pandemic.** *Infect Dis Model* 2020; 5:357-361Neufeld Z, Khataee H, Czironk A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587932>

56. **COVID-19 seeding time and doubling time model: an early epidemic risk assessment tool.** *Infect Dis Poverty* 2020; 9:76Zhou L, Liu JM, Dong XP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576256>
57. **Will the COVID-19 pandemic slow down in the Northern hemisphere by the onset of summer? An epidemiological hypothesis.** *Infection* 2020; Dzien A, Dzien-Bischinger C, Lechleitner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578052>
58. **Differences in Preventive Behaviors of COVID-19 between Urban and Rural Residents: Lessons Learned from A Cross-Sectional Study in China.** *Int J Environ Res Public Health* 2020; 17Chen X, Chen H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575700>
59. **Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy.** *Int J Environ Res Public Health* 2020; 17Lahner E, Dilaghi E, Prestigiaco C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575505>
60. **Potential Years of Life Lost Due to COVID-19 in the United States, Italy, and Germany: An Old Formula with Newer Ideas.** *Int J Environ Res Public Health* 2020; 17Mitra AK, Payton M, Kabir N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570888>
61. **How Much Support Is There for the Recommendations Made to the General Population during Confinement? A Study during the First Three Days of the COVID-19 Quarantine in Spain.** *Int J Environ Res Public Health* 2020; 17Suso-Ribera C, Martin-Brufau R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570832>
62. **Coronavirus Outbreak in Nigeria: Burden and Socio-Medical Response during the First 100 Days.** *Int J Infect Dis* 2020; Amzat J, Aminu K, Kolo VI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585282>
63. **All Hands on Deck: A Synchronized Whole-of-World Approach for COVID-19 Mitigation.** *Int J Infect Dis* 2020; Ebrahim SH, Zhuo J, Gozzer E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565364>
64. **COVID-19 preventive measures showing an unintended decline in infectious diseases in Taiwan.** *Int J Infect Dis* 2020; Galvin CJ, Li Jack YC, Malwade S, Syed-Abdul S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585283>
65. **Estimating a breakpoint in the spread pattern of COVID-19 in South Korea.** *Int J Infect Dis* 2020; Kim YJ, Seo MH, Yeom HE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569839>
66. **The Epidemiology of COVID-19 cases and the Successful Containment Strategy in Hong Kong - January to May 2020.** *Int J Infect Dis* 2020; Lam HY, Lam TS, Wong CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579906>
67. **COVID-19 in Italy: considerations on official data.** *Int J Infect Dis* 2020; Sartor G, Riccio MD, Poz ID *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574692>
68. **Herd Immunity and Vaccination of children for COVID19.** *Int J Infect Dis* 2020; Velavan TP, Pollard AJ, Kremsner PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585285>
69. **Knowledge, attitudes, risk perceptions, and practices of adults toward COVID-19: a population and field-based study from Iran.** *Int J Public Health* 2020; Honarvar B, Lankarani KB, Kharmandar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583009>
70. **Understanding variation in covid-19 reported deaths with a novel Shewhart chart application.** *Int. J. Qual. Health Care* 2020; Perla RJ, Provost SM, Parry GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589224>
71. **Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19.** *J. Alzheimers Dis.* 2020; Schindler SE, Jicha GA, Nelson PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568212>
72. **Challenges in Preparing and Managing the Critical Care Services for a Large Urban Area During COVID-19 Outbreak: Perspective From Delhi.** *J Cardiothorac Vasc Anesth* 2020; Tempe DK, Khilnani GC, Passey JC, Sherwal BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565047>
73. **Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World.** *J Clin Med* 2020; 9Hisaka A, Yoshioka H, Hatakeyama H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570833>
74. **Epidemic Trend of COVID-19 Transmission in India During Lockdown-1 Phase.** *J. Community Health* 2020; Mahajan P, Kaushal J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578006>
75. **Positive Correlation Between General Public Knowledge and Attitudes Regarding COVID-19 Outbreak 1 Month After First Cases Reported in Indonesia.** *J. Community Health* 2020; Sari DK, Amelia R, Dharmajaya R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583360>
76. **Clinical characteristics of the coronavirus disease 2019 (COVID-19) outbreak on a cruise ship.** *J Infect Chemother* 2020; Yoshimura Y, Sasaki H, Horiuchi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565152>
77. **Mortality statistics in England and Wales: the SARS-CoV-2 paradox.** *J. Int. Med. Res.* 2020; 48:300060520931298Harrison G, Newport D, Robbins T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564639>
78. **Epidemiological Characteristics and Forecast of COVID-19 Outbreak in the Republic of Kazakhstan.** *J Korean Med Sci* 2020; 35:e227Semenova Y, Glushkova N, Pivina L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567261>
79. **A 95-year-old patient with unexpected coronavirus disease 2019 masked by aspiration pneumonia: a case report.** *J Med Case Rep* 2020; 14:82Spannella F, Ristori L, Giulietti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576232>
80. **Establishing prison-led contact tracing to prevent outbreaks of COVID-19 in prisons in Ireland.** *J Public Health (Oxf)* 2020; Clarke M, Devlin J, Conroy E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567653>
81. **Fate of respiratory droplets in tropical vs temperate environments and implications for SARS-CoV-2 transmission.** *Med. Hypotheses* 2020; 144:109958Rohit A, Rajasekaran S, Karunasagar I, Karunasagar I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575016>
82. **Tracking, tracing, trust: contemplating mitigating the impact of COVID-19 through technological interventions.** *Med. J. Aust.* 2020; Coghlan S, Cheong M, Coghlan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570292>
83. **Reconsidering the immediate release of prisoners during COVID-19 community restrictions.** *Med. J. Aust.* 2020; Shepherd S, Spivak BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570279>
84. **Containment of future waves of COVID-19: simulating the impact of different policies and testing capacities for contact tracing, testing, and isolation.** *medRxiv* 2020; Fiore VG, DeFelice N, Glicksberg BS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577688>

85. **Asymptomatic COVID-19 Patients Can Contaminate Their Surroundings: an Environment Sampling Study.** *mSphere* 2020; 5Wei L, Lin J, Duan X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581071>
86. **"Quarantine during COVID-19 outbreak: Changes in diet and physical activity increase the risk of cardiovascular disease".** *Nutr. Metab. Cardiovasc. Dis.* 2020; Mattioli AV, Sciomer S, Cocchi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571612>
87. **Epidemiology of CoVID-19 Pandemic: Recovery and mortality ratio around the globe.** *Pak J Med Sci* 2020; 36:S79-s84Noor AU, Maqbool F, Bhatti ZA, Khan AU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582319>
88. **Are Animals a Neglected Transmission Route of SARS-CoV-2?** *Pathogens* 2020; 9Hernandez M, Abad D, Eiros JM, Rodriguez-Lazaro D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570713>
89. **Emerging Prevention and Treatment Strategies to Control COVID-19.** *Pathogens* 2020; 9Singh VK, Mishra A, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585805>
90. **Who complies with the restrictions to reduce the spread of COVID-19?: Personality and perceptions of the COVID-19 situation.** *Pers. Individ. Dif.* 2020; 166:110199Zajenkowski M, Jonason PK, Leniarska M, Kozakiewicz Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565591>
91. **National age and coresidence patterns shape COVID-19 vulnerability.** *Proc Natl Acad Sci U S A* 2020; Esteve A, Permanyer I, Boertien D, Vaupel JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576696>
92. **Early assessment of the impact of mitigation measures on the COVID-19 outbreak in Italy.** *Public Health* 2020; 185:99-101Vicentini C, Bordino V, Gardois P, Zotti CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593056>
93. **Risk of SARS-CoV-2 infection among contacts of individuals with COVID-19 in Hangzhou, China.** *Public Health* 2020; 185:57-59Wu Y, Song S, Kao Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563739>
94. **Underestimation of COVID-19 cases in Japan: an analysis of RT-PCR testing for COVID-19 among 47 prefectures in Japan.** *QJM* 2020; Sawano T, Kotera Y, Ozaki A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573730>
95. **DISPERSION OF A NEW CORONAVIRUS SARS-COV-2 BY AIRLINES IN 2020: TEMPORAL ESTIMATES OF THE OUTBREAK IN MEXICO.** *Rev Invest Clin* 2020; 72:138-143Cruz-Pacheco G, Bustamante-Castaneda JF, Caputo JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584328>
96. **Spatial Analysis of Global Variability in Covid-19 Burden.** *Risk Manag. Healthc. Policy* 2020; 13:519-522Miller LE, Bhattacharyya R, Miller AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581614>
97. **How Did Chinese Government Implement Unconventional Measures Against COVID-19 Pneumonia.** *Risk Manag. Healthc. Policy* 2020; 13:491-499Yu X, Li N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581611>
98. **A mechanism-based parameterisation scheme to investigate the association between transmission rate of COVID-19 and meteorological factors on plains in China.** *Sci Total Environ* 2020; 737:140348Lin C, Lau AKH, Fung JCH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569904>
99. **[Contact tracing in patients infected with SARS-CoV-2. The fundamental role of Primary Health Care and Public Health].** *Semergen* 2020; Bellmunt JM, Cayla JA, Millet JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571677>
100. **Fatalism in the context of COVID-19: Perceiving coronavirus as a death sentence predicts reluctance to perform recommended preventive behaviors.** *SSM Popul Health* 2020; 11:100615Jimenez T, Restar A, Helm PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572381>
101. **Mask wearing in pre-symptomatic patients prevents SARS-CoV-2 transmission: An epidemiological analysis.** *Travel Med Infect Dis* 2020:101803Hong LX, Lin A, He ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592903>
102. **Epidemiological and clinical characteristics of patients with suspected COVID-19 admitted in Metro Manila, Philippines.** *Trop Med Health* 2020; 48:51Salva EP, Villarama JB, Lopez EB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577087>
103. **Using country-level variables to classify countries according to the number of confirmed COVID-19 cases: An unsupervised machine learning approach.** *Wellcome Open Res* 2020; 5:56Carrillo-Larco RM, Castillo-Cara M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587900>

Gastro-enterology-hepatology (19 articles)

1. **Management of liver diseases during the pandemic of coronavirus disease-19.** *Clin Mol Hepatol* 2020; Cho JY, Kim SS, Lee YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570302>
2. **Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.** *Clin Res Hepatol Gastroenterol* 2020; De Gottardi A, Fratila C, Bertoli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565199>
3. **Recommendations for the Operation of Endoscopy Centers in the setting of the COVID19 pandemic - A WEO guidance document.** *Dig Endosc* 2020; Guda NM, Emura F, Reddy DN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569438>
4. **Returning to digestive endoscopy normality will be slow and must include novelty and telemedicine.** *Dig. Liver Dis.* 2020; Koulaouzidis A, Marlicz W, Wenzek H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571667>
5. **Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group.** *Ecancermedicalscience* 2020; 14:1048Riechelmann RP, Peixoto RD, Fernandes GDS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565901>
6. **Intervention effects in the transmission of COVID-19 depending on the detection rate and extent of isolation.** *Epidemiol Health* 2020:e2020045Kwon O, Son WS, Kim JY, Kim JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580532>
7. **Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.** *Front. Microbiol.* 2020; 11:1388He LH, Ren LF, Li JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582138>
8. **Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.** *Front. Microbiol.* 2020; 11:1302He Y, Wang J, Li F, Shi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582134>
9. **Coronavirus Disease Pandemic Is a Real Challenge for Brazil.** *Front Public Health* 2020; 8:268Simoes ESAC, Oliveira EA, Martelli H, Jr. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582618>

10. **Poor outcome of intestinal ischemic manifestations of COVID 19.** *Gastroenterology* 2020; Norsa L, Pietro B, Indriolo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569772>
11. **From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area.** *Inflamm. Bowel Dis.* 2020; Axelrad JE, Malter L, Hong S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578843>
12. **Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China.** *Int J Epidemiol* 2020; Nie Y, Li J, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588051>
13. **Inflammatory Bowel Disease in the COVID-19 Pandemic - the Patients' Perspective.** *J Crohns Colitis* 2020; Grunert PC, Reuken PA, Stallhofer J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564068>
14. **Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis?** *J Hepatol* 2020; Assante G, Williams R, Youngson NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574578>
15. **Characteristics of pregnant COVID-19 patients with liver injury.** *J Hepatol* 2020; Deng G, Zeng F, Zhang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569609>
16. **What gastroenterologists should know during COVID-19 Pandemic!** *Pak J Med Sci* 2020; 36:S124-s125Kamani L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582330>
17. **Suspected case of COVID-19-associated pancreatitis in a child.** *Radiol Case Rep* 2020; 15:1309-1312Alloway BC, Yaeger SK, Mazzaccaro RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572339>
18. **Patterns of liver injury in COVID-19 - a German case series.** *United European Gastroenterol J* 2020;2050640620931657Schattenberg JM, Labenz C, Worns MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588791>
19. **COVID-19 pandemic: Its impact on liver disease and liver transplantation.** *World J. Gastroenterol.* 2020; 26:2987-2999Sahin TT, Akbulut S, Yilmaz S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587443>

Guidelines - Consensus (22 articles)

1. **Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA Group(A) in cooperation with the Austrian ARIA Group(B), the Swiss ARIA Group(C), German Society for Applied Allergology (AEDA) (D), German Society for Allergology and Clinical Immunology (DGAKI)(E), Society for Pediatric Allergology (GPA)(F) in cooperation with AG Clinical Immunology, Allergology and Environmental Medicine of the DGHNO-KHC(G) and the European Academy of Allergy and Clinical Immunology (EAACI)(H).** *Allergol Select* 2020; 4:44-52Klimek L, Pfaar O, Worm M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568272>
2. **Saudi Society for Cardiac Surgeons consensus document on COVID-19, April 1, 2020.** *Asian Cardiovasc. Thorac. Ann.* 2020;218492320933442Albacker TB, Eskandar K, Ismail H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586103>
3. **Pulmonary embolism in acute medicine: a case-based review incorporating latest guidelines in the COVID-19 era.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-12Stevenson A, Davis S, Murch N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589531>
4. **A joint action in times of pandemic: the German Bioluming recommendations for operating imaging core facilities during the SARS-Cov-2 emergency.** *Cytometry A* 2020; Dietzel S, Ferrando-May E, Fried H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583531>
5. **Diabetes and COVID-19: IDF perspective in the Western Pacific Region.** *Diabetes Res Clin Pract* 2020;108278Hwang Y, Khasag A, Jia W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592842>
6. **Recommendations for the Operation of Endoscopy Centers in the setting of the COVID19 pandemic - A WEO guidance document.** *Dig Endosc* 2020; Guda NM, Emura F, Reddy DN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569438>
7. **Multidisciplinary approach to COVID-19 and cancer: consensus from scientific societies in Argentina.** *Ecancelmedalscience* 2020; 14:1044Ismael J, Losco F, Quildrian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565897>
8. **A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.** *Eur. J. Cancer* 2020; 135:130-146Belkacemi Y, Grellier N, Ghith S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580130>
9. **COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation.** *Eur. J. Haematol.* 2020; Farmakis D, Giakoumis A, Cannon L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573838>
10. **Penn Medicine Head and Neck Cancer Service Line COVID-19 management guidelines.** *Head Neck* 2020; Weinstein GS, Cohen R, Lin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584447>
11. **Critical Care for COVID-19 Affected Patients: Position Statement of the Indian Society of Critical Care Medicine.** *Indian J. Crit. Care Med.* 2020; 24:222-241Mehta Y, Chaudhry D, Abraham OC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565632>
12. **Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus.** *Indian J Ophthalmol* 2020; 68:1281-1291Manjandavida FP, Honavar SG, Kim U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587152>
13. **All India Ophthalmological Society - Eye Bank Association of India consensus statement on guidelines for cornea and eye banking during COVID-19 era.** *Indian J Ophthalmol* 2020; 68:1258-1262Sharma N, D'Souza S, Nathawat R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587148>
14. **All India Ophthalmological Society - Preferred practice in refractive surgery during the COVID-19 pandemic.** *Indian J Ophthalmol* 2020; 68:1263-1268Sharma N, Khamar P, Sachdev MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587149>
15. **Community eye-health and vision center guidelines during COVID-19 pandemic in India.** *Indian J Ophthalmol* 2020; 68:1306-1311Vashist P, Senjam SS, Gupta V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587155>
16. **Navigating Immunosuppression in a Pandemic: A Guide for the Dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists.** *J Am Acad Dermatol* 2020; Niaki OZ, Anadkat MJ, Chen ST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569797>

17. **Radiologist Reporting and Operational Management for Patients With Suspected COVID-19.** *J Am Coll Radiol* 2020; Hammer MM, Zhao AH, Hunsaker AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590015>
18. **Recommendations for risk stratified use of cardiac computed tomography for congenital heart disease during the COVID-19 pandemic.** *J Cardiovasc. Comput. Tomogr.* 2020; Farooqi KM, Ghoshhajra BB, Shah AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565094>
19. **Reporting radiographers' interpretation and use of the British Society of Thoracic Imaging's coding system when reporting COVID-19 chest x-rays.** *Radiography (Lond)* 2020; Stevens BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591286>
20. **Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.** *Respiration* 2020;1-21 Pfeifer M, Ewig S, Voshaar T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564028>
21. **SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection.** *Rev. Esp. Anesthesiol. Reanim.* 2020; Llau JV, Ferrandis R, Sierra P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591185>
22. **UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.** *Undersea Hyperb. Med.* 2020; 47:297-298. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574446>

Imaging (41 articles)

1. **Lung ultrasound as an extension of medical examination for COVID-19 pneumonia: much more than an imaging technique.** *Am J Obstet Gynecol* 2020; Inchingolo R, Smargiassi A, Soldati G, Demi L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565235>
2. **A 56-year-old man with RT-PCR negative nasopharyngeal swabs with Coronavirus Disease 2019 (COVID-19) Pneumonia.** *Ann. Agric. Environ. Med.* 2020; 27:317-318 Dworzanska A, Tudrujek-Zdunek M, Mosiewicz J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588614>
3. **Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:622 Lv M, Wang M, Yang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566559>
4. **Quantitative analysis of chest CT imaging findings with the risk of ARDS in COVID-19 patients: a preliminary study.** *Ann Transl Med* 2020; 8:594 Wang Y, Chen Y, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566621>
5. **Clinical and CT findings of COVID-19: differences among three age groups.** *BMC Infect. Dis.* 2020; 20:434 Wang J, Zhu X, Xu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571228>
6. **CT findings of patients infected with SARS-CoV-2.** *BMC Med. Imaging* 2020; 20:70 Wang X, Liu C, Hong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576224>
7. **Radiological manifestations of COVID-19: key points for the physician.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-11 Gravell RJ, Theodoreson MD, Buonsenso D, Curtis J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589534>
8. **Chest CT imaging signature of COVID-19 infection: in pursuit of the scientific evidence.** *Chest* 2020; Adams HJA, Kwee TC, Yakar D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592709>
9. **Bringing radiology to patient's home using mobile equipment: A weapon to fight COVID-19 pandemic.** *Clin Imaging* 2020; 68:99-101 Zanardo M, Schiaffino S, Sardanelli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585417>
10. **Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks.** *Comput. Biol. Med.* 2020; 121:103795 Ardakani AA, Kanafi AR, Acharya UR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568676>
11. **Automated detection of COVID-19 cases using deep neural networks with X-ray images.** *Comput. Biol. Med.* 2020; 121:103792 Ozturk T, Talo M, Yildirim EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568675>
12. **COVID-19 detection using deep learning models to exploit Social Mimic Optimization and structured chest X-ray images using fuzzy color and stacking approaches.** *Comput. Biol. Med.* 2020; 121:103805 Togacar M, Ergen B, Comert Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568679>
13. **Response of UK interventional radiologists to the COVID-19 pandemic - survey findings.** *CVIR Endovasc* 2020; 3:41 Rostampour S, Cleveland T, White H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592080>
14. **A joint action in times of pandemic: the German Bioluminescence recommendations for operating imaging core facilities during the SARS-Cov-2 emergency.** *Cytometry A* 2020; Dietzel S, Ferrando-May E, Fried H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583531>
15. **Well-controlled vs Poorly-controlled Diabetes in Patients with COVID-19: Are There Any Differences in Outcomes and Imaging Findings?** *Diabetes Res Clin Pract* 2020:108286 Raoufi M, Khalili S, Mansouri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592836>
16. **Chest CT in COVID-19 pneumonia: A review of current knowledge.** *Diagn Interv Imaging* 2020; Jalaber C, Lapotre T, Morcet-Delattre T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571748>
17. **Incidental diagnosis of Covid-19 pneumonia on chest computed tomography.** *Diagn Interv Imaging* 2020; Neveu S, Saab I, Dangeard S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571747>
18. **The role of initial chest X-ray in triaging patients with suspected COVID-19 during the pandemic.** *Emerg Radiol* 2020; Kim HW, Capaccione KM, Li G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572707>
19. **FDG-PET/CT imaging during the Covid-19 emergency: a southern Italian perspective.** *Eur J Nucl Med Mol Imaging* 2020; Maurea S, Mainolfi CG, Bombace C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572561>
20. **Quantitative chest CT analysis in COVID-19 to predict the need for oxygenation support and intubation.** *Eur Radiol* 2020; Lanza E, Muglia R, Bolengo I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591888>
21. **Cohort study of chest CT and clinical changes in 29 patients with coronavirus disease 2019 (COVID-19).** *Eur Radiol* 2020; Zhou Y, Zheng Y, Yang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591890>
22. **Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome.** *Eur Radiol Exp* 2020; 4:39 Matos J, Paparo F, Mussetto I *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592118>
23. **The role of chest computed tomography in the management of COVID-19: A review of results and recommendations.** *Exp. Biol. Med. (Maywood)* 2020;1535370220938315Wong MD, Thai T, Li Y, Liu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588660>
 24. **Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China.** *Front Med (Lausanne)* 2020; 7:209Liu Z, Ding L, Chen G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574321>
 25. **Preferred practice guidelines for glaucoma management during COVID-19 pandemic.** *Indian J Ophthalmol* 2020; 68:1277-1280Tejwani S, Angmo D, Nayak BK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587151>
 26. **Utility of CT scan in patients with initial negative PCR for SARS-CoV2: a report of three cases.** *Infection* 2020; Bouiller K, Humbert S, Payet-Revest C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583171>
 27. **Radiologist Reporting and Operational Management for Patients With Suspected COVID-19.** *J Am Coll Radiol* 2020; Hammer MM, Zhao AH, Hunsaker AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590015>
 28. **Recommendations for risk stratified use of cardiac computed tomography for congenital heart disease during the COVID-19 pandemic.** *J Cardiovasc. Comput. Tomogr.* 2020; Farooqi KM, Ghoshhajra BB, Shah AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565094>
 29. **Meta-analysis of chest CT features of patients with COVID-19 pneumonia.** *J Med Virol* 2020; Zheng Y, Wang L, Ben S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579236>
 30. **COVID-19 Screening with Chest CT in Acute Stroke Imaging: A Clinical Decision Model.** *J. Neuroimaging* 2020; Qureshi AI, French BR, Siddiq F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589348>
 31. **Reply to LTE: COVID-19 and pulmonary embolism: diagnostic imaging trends.** *J Nucl Med* 2020; Zuckier LS, Moadel RM, Haramati LB, Freeman LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576640>
 32. **Differentiating pneumonia with and without COVID-19 using chest CT images: from qualitative to quantitative.** *J Xray Sci Technol* 2020; Li Z, Zeng B, Lei P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568167>
 33. **Chest computed tomography findings of COVID-19 pneumonia: pictorial essay with literature review.** *Jpn J Radiol* 2020; Cellina M, Orsi M, Valenti Pittino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588277>
 34. **(18)F-FDG PET/CT in asymptomatic patients with COVID-19: the submerged iceberg surfaces.** *Jpn J Radiol* 2020; Colandrea M, Gilardi L, Travaini LL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577869>
 35. **Challenges for the dental radiology clinic in times of the COVID-19 pandemic.** *Oral Radiol* 2020; Doriguetto PVT, Americano JP, Devito KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564186>
 36. **Anesthesia and potential aerosol generation during Magnetic Resonance Imaging in Children with COVID-19.** *Paediatr Anaesth* 2020; Drum E, McClung Pasqualino H, Subramanyam R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564492>
 37. **Chest X-rays findings in COVID 19 patients at a University Teaching Hospital - A descriptive study.** *Pak J Med Sci* 2020; 36:S22-s26Durrani M, Haq IU, Kalsoom U, Yousaf A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582309>
 38. **Rational and practical use of imaging in COVID-19 pneumonia.** *Pak J Med Sci* 2020; 36:S130-s133Sohail S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582332>
 39. **Truncated inception net: COVID-19 outbreak screening using chest X-rays.** *Phys Eng Sci Med* 2020; Das D, Santosh KC, Pal U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588200>
 40. **Reporting radiographers' interpretation and use of the British Society of Thoracic Imaging's coding system when reporting COVID-19 chest x-rays.** *Radiography (Lond)* 2020; Stevens BJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591286>
 41. **A Review of Early Experience in Lung Ultrasound in the Diagnosis and Management of COVID-19.** *Ultrasound Med. Biol.* 2020; Sultan LR, Sehgal CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591166>

Immune response (29 articles)

1. **Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI).** *Allergy* 2020; Sokolowska M, Lukaszik Z, Agache I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584441>
2. **Characterization of the Inflammatory Response to Severe COVID-19 Illness.** *Am J Respir Crit Care Med* 2020; McElvaney OJ, McEvoy N, McElvaney OF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584597>
3. **Perspectives on the development of neutralizing antibodies against SARS-CoV-2.** *Antib Ther* 2020; 3:109-114Ho M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566896>
4. **Platelets and Immunity: Going Viral.** *Arterioscler. Thromb. Vasc. Biol.* 2020; 40:1605-1607Koupenova M, Freedman JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579477>
5. **Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic.** *Brain Behav Immun Health* 2020; 5:100096Debnath M, Berk M, Maes M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566934>
6. **COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential.** *Clin Immunol* 2020;108516Jiang Y, Wei X, Guan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574709>
7. **Retinal outcomes of COVID-19: possible role of CD147 and cytokine storm in infected patients with diabetes mellitus.** *Diabetes Res Clin Pract* 2020;108280Raony I, Saggiore de Figueiredo C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592839>
8. **Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.** *EBioMedicine* 2020; 57:102836Martin TR, Wurfel MM, Zanoni I, Ulevitch R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574958>
9. **Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.** *EBioMedicine* 2020; 57:102833Wang C, Xie J, Zhao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574956>

10. **Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.** *Elife* 2020; 9Klasse PJ, Moore JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573433>
11. **Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.** *Emerg Infect Dis* 2020; 26Choe PG, Kang CK, Suh HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579877>
12. **Immune response in children with COVID-19 is characterized by lower levels of T cell activation than infected adults.** *Eur. J. Immunol.* 2020; Moratto D, Giacomelli M, Chiarini M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592406>
13. **Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.** *Front. Immunol.* 2020; 11:1294Abid MA, Nunley L, Abid MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582221>
14. **Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation.** *Front. Immunol.* 2020; 11:1131Cardone M, Yano M, Rosenberg AS, Puig M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574265>
15. **Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS.** *Front. Immunol.* 2020; 11:1120Fierz W, Walz B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582200>
16. **COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.** *Front. Immunol.* 2020; 11:1196Halstead SB, Akkina R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574267>
17. **Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?** *Front. Immunol.* 2020; 11:1229Sallenave JM, Guillot L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574272>
18. **Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.** *Front. Immunol.* 2020; 11:1021Shah A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574259>
19. **Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.** *Front. Immunol.* 2020; 11:1049Siracusano G, Pastori C, Lopalco L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574261>
20. **Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:301Feng X, Li S, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582743>
21. **Navigating Immunosuppression in a Pandemic: A Guide for the Dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists.** *J Am Acad Dermatol* 2020; Niaki OZ, Anadkat MJ, Chen ST *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569797>
22. **Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.** *J Autoimmun* 2020:102506Rodriguez Y, Novelli L, Rojas M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563547>
23. **The cytokine storm and COVID-19.** *J Med Virol* 2020; Hu B, Huang S, Yin L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592501>
24. **COVID-19 Multisystem Inflammatory Syndrome in Three Teenagers with Confirmed SARS-CoV-2 Infection.** *J Med Virol* 2020; Ng KF, Kothari T, Bandi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568434>
25. **Reversible Encephalopathy Syndrome (PRES) in a COVID-19 patient.** *J. Neurol.* 2020; Princiotta Cariddi L, Tabaei Damavandi P, Carimati F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583053>
26. **Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.** *Microbes Infect* 2020; Coish JM, MacNeil AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590062>
27. **COVID-19 Hyperinflammation: What about Neutrophils?** *mSphere* 2020; 5Didangelos A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581077>
28. **Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.** *Mult Scler Relat Disord* 2020; 44:102315Conte WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593144>
29. **Deciphering the TCR Repertoire to Solve the COVID-19 Mystery.** *Trends Pharmacol Sci* 2020; Gutierrez L, Beckford J, Alachkar H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576386>

Management – misc. diseases (101 articles)

1. **Transfusion Service Response to the COVID-19 Pandemic.** *Am J Clin Pathol* 2020; Gehrie E, Tormey CA, Sanford KW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584950>
2. **The SARS-CoV-2 pandemic impact on rhinology research: A survey of the American Rhinologic Society.** *Am. J. Otolaryngol.* 2020; 41:102617Grayson JW, McCormick JP, Thompson HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574897>
3. **Sense and sensibility through confusing surgical practices during COVID-19 pandemic.** *ANZ J Surg* 2020; Koh CE, Brown KG, Fisher O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583595>
4. **Arthroplasty during the COVID-19 Pandemic.** *Arthroplast Today* 2020; 6:427-430North T, Bullock MW, Danoff JR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572379>
5. **Safe cancer surgery during the COVID-19 pandemic.** *Asian J. Surg.* 2020; Colak E, Uyanik MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586601>
6. **ENT manifestation in COVID-19 patients.** *Auris Nasus Larynx* 2020; El-Anwar MW, Elzayat S, Fouad YA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586739>
7. **Diagnostic considerations for COVID-19 in recipients of allogeneic hematopoietic cell transplantation.** *Biol Blood Marrow Transplant* 2020; Chhabra S, Abedin S, Graham MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589922>
8. **Letter to the Editor Regarding "Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation".** *Biol Blood Marrow Transplant* 2020; Chhabra S, Abedin S, Graham MB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589922>
9. **Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.** *Biosci Trends* 2020; Xue M, Zheng P, Bian X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565512>

10. **Head and neck oncological ablation and reconstruction in the COVID-19 era - our experience to date.** *Br. J. Oral Maxillofac. Surg.* 2020; Butler D, Davies-Husband C, Dhanda J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576467>
11. **Are you surgically current? Lessons from aviation for returning to non-urgent surgery following COVID-19.** *Br. J. Oral Maxillofac. Surg.* 2020; Hardie JA, Brennan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576468>
12. **Inequalities and identity processes in crises: Recommendations for facilitating safe response to the COVID-19 pandemic.** *Br. J. Soc. Psychol.* 2020; Templeton A, Guven ST, Hoerst C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583423>
13. **Surgical treatment of thoracolumbar fracture with incomplete lower limb paralysis in a patient with COVID-19.** *Chin. J. Traumatol.* 2020; Cao YL, Han YJ, Chen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571532>
14. **Lessons learned during the COVID-19 pandemic: a single institution radiology chief resident experience.** *Clin Imaging* 2020; 68:90-93Roytman M, Shah S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580107>
15. **Management of liver diseases during the pandemic of coronavirus disease-19.** *Clin Mol Hepatol* 2020; Cho JY, Kim SS, Lee YS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570302>
16. **Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model.** *Clin Transl Allergy* 2020; 10:23Malipiero G, Heffler E, Pelaia C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566128>
17. **Inpatient Dermatology Consultations during Covid 19 Pandemic in a Tertiary Referral Center.** *Dermatol Ther* 2020; Uzuncakmak TK, Bayazit S, Askin O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578309>
18. **Teledentistry during COVID-19 pandemic.** *Diabetes Metab Syndr* 2020; 14:933-935Ghai S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593116>
19. **Multidisciplinary approach to COVID-19 and cancer: consensus from scientific societies in Argentina.** *Ecancelmedscience* 2020; 14:1044Ismael J, Losco F, Quildrian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565897>
20. **COVID-19: hypofractionation in the Radiation Oncology Department during the 'state of alarm': first 100 patients in a private hospital in Spain.** *Ecancelmedscience* 2020; 14:1052Larrea L, Lopez E, Antonini P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565905>
21. **A practical approach to the management of breast cancer in the COVID-19 era and beyond.** *Ecancelmedscience* 2020; 14:1059Luther A, Agrawal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582374>
22. **Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group.** *Ecancelmedscience* 2020; 14:1048Riechelmann RP, Peixoto RD, Fernandes GDS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565901>
23. **Oncofertility and COVID-19-cancer does not wait.** *Ecancelmedscience* 2020; 14:ed101Sirohi B, Rohatgi TB, Lambertini M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565906>
24. **Treatment of cancer patients during the COVID-19 pandemic in the Philippines.** *Ecancelmedscience* 2020; 14:1040Ting FI, Sacdalan DB, Abarquez HS, Uson AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565893>
25. **Should breast reconstruction and breast oncoplastic procedures be performed during the coronavirus pandemic?** *Ecancelmedscience* 2020; 14:1041Vidya R, Rubio IT, Paulinelli RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565894>
26. **Operating Protocols of a Community Treatment Center for Isolation of Patients with Coronavirus Disease, South Korea.** *Emerg Infect Dis* 2020; 26Kang E, Lee SY, Jung H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568665>
27. **Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform.** *ESMO Open* 2020; 5Peeters M, van Dam P, Rasschaert MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571785>
28. **Impact of the first month of Covid-19 lockdown on oncologic surgical activity in the Ile de France region university hospital otorhinolaryngology departments.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Laccourreye O, Mirghani H, Evrard D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565242>
29. **Otolaryngology in the COVID-19 pandemic era: the impact on our clinical practice.** *Eur Arch Otorhinolaryngol* 2020; Anagiotos A, Petrikkos G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577905>
30. **Mortality risk in post-operative head and neck cancer patients during the SARS-Cov2 pandemic: early experiences.** *Eur Arch Otorhinolaryngol* 2020; Hintze JM, Fitzgerald CW, Lang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572564>
31. **A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.** *Eur. J. Cancer* 2020; 135:130-146Belkacemi Y, Grellier N, Ghith S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580130>
32. **Myeloma care adaptations in the UK during SARS-CoV-2 pandemic: challenges and measurable outcomes.** *Eur. J. Haematol.* 2020; Djebbari F, Panitsas F, Sharpley FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592210>
33. **Fight against novel coronavirus: A perspective of medicinal chemists.** *Eur. J. Med. Chem.* 2020; 201:112559Amin SA, Jha T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563814>
34. **Reflections from London's Level-1 Major Trauma Centres during the COVID crisis.** *Eur. J. Orthop. Surg. Traumatol.* 2020; Tahmassebi R, Bates P, Trompeter A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591913>
35. **COVID-19 and breast cancer: Impact on patients and breast care centers.** *Eur. J. Surg. Oncol.* 2020; Ghidinelli F, Bianchi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571635>
36. **The short-term impact of COVID-19 pandemic on spine surgeons: a cross-sectional global study.** *Eur. Spine J.* 2020; Khattab MF, Kannan TMA, Morsi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591880>
37. **Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines.** *Eur Urol Focus* 2020; Gravas S, Fournier G, Oya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571743>
38. **Impact of the COVID-19 Pandemic on Urologists in Germany.** *Eur Urol Focus* 2020; Paffenholz P, Peine A, Fischer N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576530>

39. **Managing patients with hematological malignancies during COVID-19 pandemic.** *Expert Rev. Hematol.* 2020; Sahu KK, Cerny J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580592>
40. **Management of Hemoglobin Disorders During the COVID-19 Pandemic.** *Front Med (Lausanne)* 2020; 7:306Chowdhury SF, Anwar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582745>
41. **The Novel Coronavirus COVID-19 Outbreak: Global Implications for Antimicrobial Resistance.** *Front. Microbiol.* 2020; 11:1020Murray AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574253>
42. **Acute Neurological Care in the COVID-19 Era: The Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium Pathway.** *Front. Neurol.* 2020; 11:579Bhaskar S, Sharma D, Walker AH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574252>
43. **Evolving Healthcare Delivery in Neurology During the Coronavirus Disease 2019 (COVID-19) Pandemic.** *Front. Neurol.* 2020; 11:578Chen PM, Hemmen TM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574251>
44. **Medical and Paramedical Care of Patients With Cerebellar Ataxia During the COVID-19 Outbreak: Seven Practical Recommendations of the COVID 19 Cerebellum Task Force.** *Front. Neurol.* 2020; 11:516Manto M, Dupre N, Hadjivassiliou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574247>
45. **An Italian Neurology Outpatient Clinic Facing SARS-CoV-2 Pandemic: Data From 2,167 Patients.** *Front. Neurol.* 2020; 11:564Piano C, Di Stasio E, Primiano G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574249>
46. **Treatment Strategies for Cancer Patients in Post-Peak of the Novel Coronavirus Disease (COVID-19) Period in China.** *Front. Oncol.* 2020; 10:925Liu B, Mo H, Ma F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574279>
47. **Breast Cancer Diagnosis in Coronavirus-Era: Alert From Italy.** *Front. Oncol.* 2020; 10:938Vanni G, Pellicciaro M, Materazzo M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574281>
48. **Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologists.** *Future Oncol* 2020; Mrabti H, Berrada N, Raiss G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583680>
49. **A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer?** *Future Oncol* 2020; Yekeduz E, Karcioğlu AM, Utkan G, Urun Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564611>
50. **Congenital heart disease in the era of COVID-19 pandemic.** *Gen. Thorac. Cardiovasc. Surg.* 2020; Giordano R, Cantinotti M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572816>
51. **Penn Medicine Head and Neck Cancer Service Line COVID-19 management guidelines.** *Head Neck* 2020; Weinstein GS, Cohen R, Lin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584447>
52. **The Crisis Close at Hand: How COVID-19 Challenges Long-Term Care Planning for Adults with Intellectual Disability.** *Health Equity* 2020; 4:247-248Wright C, Steinway C, Jan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587937>
53. **Treatment of Hepatocellular Carcinoma (HCC) during the COVID-19 Outbreak: The Working Group Report of JAMTT-HCC.** *Hepatol. Res.* 2020; Kudo M, Kurosaki M, Ikeda M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583525>
54. **COVID-19 pandemic and lacrimal practice: Multipronged resumption strategies and getting back on our feet.** *Indian J Ophthalmol* 2020; 68:1292-1299Ali MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587153>
55. **A review of long-term corneal preservation techniques: Relevance and renewed interests in the COVID-19 era.** *Indian J Ophthalmol* 2020; 68:1357-1363Chaurasia S, Das S, Roy A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587163>
56. **Demographics and clinical presentation of patients with ocular disorders during the COVID-19 lockdown in India: A report.** *Indian J Ophthalmol* 2020; 68:1393-1399Das AV, Narayanan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587174>
57. **Perspectives of physicians in general and ophthalmologists in particular about restarting services post-COVID-19 lockdown.** *Indian J Ophthalmol* 2020; 68:1401-1406Madanagopalan VG, Sriram Gopal MR, Sengupta S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587176>
58. **Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus.** *Indian J Ophthalmol* 2020; 68:1281-1291Manjandavida FP, Honavar SG, Kim U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587152>
59. **A new normal with cataract surgery during COVID-19 pandemic.** *Indian J Ophthalmol* 2020; 68:1269-1276Reddy JC, Vaddavalli PK, Sharma N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587150>
60. **Impact of COVID-19 pandemic on people living with visual disability.** *Indian J Ophthalmol* 2020; 68:1367-1370Senjam SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587166>
61. **All India Ophthalmological Society - Preferred practice in refractive surgery during the COVID-19 pandemic.** *Indian J Ophthalmol* 2020; 68:1263-1268Sharma N, Khamar P, Sachdev MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587149>
62. **Preferred practice guidelines for glaucoma management during COVID-19 pandemic.** *Indian J Ophthalmol* 2020; 68:1277-1280Tejwani S, Angmo D, Nayak BK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587151>
63. **Community eye-health and vision center guidelines during COVID-19 pandemic in India.** *Indian J Ophthalmol* 2020; 68:1306-1311Vashist P, Senjam SS, Gupta V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587155>
64. **Epidemiologic characteristics of traumatic fractures during the outbreak of coronavirus disease 2019 (COVID-19) in China: A retrospective & comparative multi-center study.** *Injury* 2020; Lv H, Zhang Q, Yin Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563519>
65. **Impact of Covid-19 on the urology service in United States: perspectives and strategies to face a Pandemic.** *Int Braz J Urol* 2020; 46Cacciamani GE, Shah M, Yip W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568500>
66. **Therapeutic and Surgical Indications for Patients with Penile Cancer in the COVID-19 era.** *Int Braz J Urol* 2020; 46Casco NC, Carmona MJ, Soto AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568497>
67. **COVID-19's Impact on Italian Urology.** *Int Braz J Urol* 2020; 46Esperto F, Papalia R, Autran-Gomez AM, Scarpa RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568494>
68. **Impact of COVID-19 in Female Urology.** *Int Braz J Urol* 2020; 46Palma PCR, Brito LGO, Ghigo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568498>

69. **Endourology (Lithiasis). Management, surgical considerations and follow-up of patients in the COVID-19 era.** *Int Braz J Urol* 2020; 46:Socarras MER, Esperto F, Bapstistussi MD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568495>
70. **The effect of the Covid-19 Pandemic on pediatric urology.** *Int Braz J Urol* 2020; 46:Tur AB, Prieto JC, Gomez-Fraile A, Corbetta JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568499>
71. **Management of chronic rhinosinusitis with steroid nasal irrigations: a viable non-surgical alternative in the COVID-19 Era.** *Int Forum Allergy Rhinol* 2020; Sweis AM, Locke TB, Douglas JE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573106>
72. **The Perception of COVID-19 among Italian Dentists: An Orthodontic Point of View.** *Int J Environ Res Public Health* 2020; 17:Martina S, Amato A, Rongo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570842>
73. **Ophthalmology in the time of COVID-19: experience from Hong Kong Eye Hospital.** *Int J Ophthalmol* 2020; 13:851-859Cheung SSL, Wong CYK, Chan JCK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566494>
74. **Transforming laparoendoscopic surgical protocols during COVID-19 pandemic; big data analytics, resource allocation and operational considerations; a review article.** *Int J Surg* 2020; Guraya SY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590073>
75. **The orthopaedic and traumatology scenario during Covid-19 outbreak in Italy: chronicles of a silent war.** *Int Orthop* 2020; Benazzo F, Rossi SMP, Maniscalco P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591960>
76. **Analysis of patients undergoing urological intervention amid the COVID-19: experience from the pandemic hospital.** *Int. Urol. Nephrol.* 2020; Soytaş M, Boz MY, Guzelburc V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583371>
77. **How the COVID-19 pandemic is affecting paediatric orthopaedics practice: a preliminary report.** *J. Child. Orthop.* 2020; 14:154-160Peiro-Garcia A, Corominas L, Coelho A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582381>
78. **COVID-19 and Heart: From Clinical Features to Pharmacological Implications.** *J Clin Med* 2020; 9:Russo V, Bottino R, Carbone A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580344>
79. **Clinical management of psoriasis patients during the COVID-19 pandemic.** *J Dermatolog Treat* 2020;1-2Chat VS, Uppal SK, Kearns DG, Wu JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568009>
80. **Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw.** *J Dermatolog Treat* 2020;1-15Dopytalska K, Mikucka-Wituszynska A, Ciechanowicz P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569493>
81. **Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.** *J Eur Acad Dermatol Venereol* 2020; Fougousse AC, Perrussel M, Becherel PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564417>
82. **The Impact of the Coronavirus Disease 2019 Outbreak on the Attendance of Patients with Surgical Complaints at a Tertiary Hospital Emergency Department.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Anteby R, Zager Y, Barash Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589496>
83. **Planning for a pandemic: Mitigating risk to radiation therapy service delivery in the COVID-19 era.** *J Med Radiat Sci* 2020; Anderson N, Thompson K, Andrews J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567800>
84. **Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations.** *J. Oncol. Pharm. Pract.* 2020;1078155220935564Alshamrani M, AlHarbi A, Alkhudair N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580641>
85. **Pharmacists and COVID-19.** *J Pharm Policy Pract* 2020; 13:36Elbeddini A, Prabakaran T, Almasalkhi S, Tran C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572350>
86. **Unusually High Rates of Acute Rejection During the COVID-19 Pandemic: Cause for Concern?** *Kidney Int* 2020; Aziz F, Muth B, Parajuli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569652>
87. **Resumption of laser/IPL skin services post COVID-19 lockdown-British Medical Laser Association (BMLA) guidance document.** *Lasers Med. Sci.* 2020; Madan V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592132>
88. **Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.** *Lung Cancer* 2020; 146:230-235Liao Z, Rivin Del Campo E, Salem A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585497>
89. **Collateral benefits on other respiratory infections during fighting COVID-19.** *Med Clin (Barc)* 2020; Chan KS, Liang FW, Tang HJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586667>
90. **Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey.** *Mult Scler Relat Disord* 2020; 44:102310Ricardo A, Edgar CC, Anabel SB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590314>
91. **Electroencephalography at the time of Covid-19 pandemic in Italy.** *Neurol Sci* 2020; Assenza G, Lanzone J, Ricci L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588368>
92. **Impact of the COVID-19 pandemic on the organisation of stroke care. Madrid Stroke Care Plan.** *Neurologia* 2020; Fuentes B, Alonso de Lecinana M, Calleja-Castano P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563566>
93. **Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.** *Neurologia* 2020; Valero-Lopez G, Carreon-Guarnizo E, Hernandez-Clares R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591152>
94. **Challenges for the dental radiology clinic in times of the COVID-19 pandemic.** *Oral Radiol* 2020; Doriguetto PVT, Americano JP, Devito KL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564186>
95. **Return to Normalcy? Principles on Resuming Surgical Services in the COVID-19 Era.** *OTO Open* 2020; 4:2473974x20936658Valika TS, Billings KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577606>
96. **Covid-19 Outbreak - Immediate and long-term impacts on the dental profession.** *Pak J Med Sci* 2020; 36:S126-s129Ghani F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582331>
97. **Organization of a radiotherapy service during the COVID-19 epidemic: Experience of Regional Center of Oncology of Agadir, Morocco.** *Radiography (Lond)* 2020; Amaoui B, Semghouli S, Benjaafar N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586678>
98. **COVID-19: Overview of Rheumatology Fellows.** *Reumatol. Clin.* 2020; Garcia-Guillen A, Jeria S, Lobo-Prat D, Sainz L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565030>

99. **SEDAR-SEMICYUC consensus recommendations on the management of haemostasis disorders in severely ill patients with COVID-19 infection.** *Rev. Esp. Anesthesiol. Reanim.* 2020; Llau JV, Ferrandis R, Sierra P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591185>
100. **The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey.** *Rheumatol. Int.* 2020; Seyahi E, Poyraz BC, Sut N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572609>
101. **How the COVID-19 Pandemic Changed Cellular Therapy at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital.** *Transfusion* 2020; Tanhehco YC, Schwartz J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583465>

Management (38 articles)

1. **Transformation of a large multi-speciality hospital into a dedicated COVID-19 centre during the coronavirus pandemic.** *Ann. Agric. Environ. Med.* 2020; 27:201-206Krol Z, Szymanski P, Bochnia A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588593>
2. **Prone positioning in COVID-19 acute respiratory failure: just do it?** *Br J Anaesth* 2020; McNicholas B, Cosgrave D, Giacomini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571573>
3. **Videolaryngoscopy for tracheal intubation in patients with COVID-19.** *Br J Anaesth* 2020; Saito T, Taguchi A, Asai T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571574>
4. **Surge capacity and updated admission criteria: response of the NHS-commissioned national respiratory extracorporeal membrane oxygenation network to the COVID-19 pandemic.** *Br J Anaesth* 2020; Warren A, Camporota L, Vuylsteke A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571572>
5. **Moving From Robotic to Personalized COVID-19 Care.** *Circ Heart Fail* 2020;Circheartfailure120007303Le Jemtel TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580656>
6. **Is the oral cavity relevant in SARS-CoV-2 pandemic?** *Clin Oral Investig* 2020; Herrera D, Serrano J, Roldan S, Santos M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577830>
7. **Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.** *Comput. Methods Programs Biomed.* 2020; 196:105617Albahri OS, Al-Obaidi JR, Zaidan AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593060>
8. **The trajectory of COVID-19 scenario in Malaysia: facing the unprecedented.** *Curr. Med. Res. Opin.* 2020;1Minhat HS, Shahar HK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569488>
9. **Zambia's National Cancer Centre response to the COVID-19 pandemic-an opportunity for improved care.** *Ecancermedalscience* 2020; 14:1051Lombe DC, Mwaba CK, Msadabwe SC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565904>
10. **Community Treatment Centers for Isolation of Asymptomatic and Mildly Symptomatic Patients with Coronavirus Disease, South Korea.** *Emerg Infect Dis* 2020; 26Choi WS, Kim HS, Kim B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568663>
11. **Cystic Fibrosis: Fighting Together Against Coronavirus Infection.** *Front Med (Lausanne)* 2020; 7:307Manti S, Parisi GF, Papale M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582746>
12. **Critical Care for COVID-19 Affected Patients: Position Statement of the Indian Society of Critical Care Medicine.** *Indian J. Crit. Care Med.* 2020; 24:222-241Mehta Y, Chaudhry D, Abraham OC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565632>
13. **Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection.** *Infect Dis (Lond)* 2020;1-7Gidari A, De Socio GV, Sabbatini S, Francisci D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584161>
14. **Priorities in testis cancer care during Covid-19 Pandemic.** *Int Braz J Urol* 2020; 46Secin FP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568496>
15. **Prioritization of Proton Patients in the COVID-19 Pandemic: Recommendations from The New York Proton Center.** *Int J Part Ther* 2020; 6:38-44Chhabra AM, Choi JI, Hasan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582818>
16. **Nursing in the COVID-19 pandemic and beyond: protecting, saving, supporting and honouring nurses.** *Int Nurs Rev* 2020; 67:157-159Cotton H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578250>
17. **COVID-19 pandemic in France: health emergency experiences from the field.** *Int Nurs Rev* 2020; Chamboredon P, Roman C, Colson S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567057>
18. **Challenging times: ethics, nursing and the COVID-19 pandemic.** *Int Nurs Rev* 2020; 67:164-167Turale S, Meechamnan C, Kunaviktikul W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578249>
19. **Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.** *Intensive Care Med* 2020; Jerath A, Ferguson ND, Cuthbertson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588067>
20. **COVID-19 Collaborative Model for an Academic Hospital and Long-Term Care Facilities.** *J. Am. Med. Dir. Assoc.* 2020; Archbald-Pannone LR, Harris DA, Albergo K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563752>
21. **Challenges in Preparing and Managing the Critical Care Services for a Large Urban Area During COVID-19 Outbreak: Perspective From Delhi.** *J Cardiothorac Vasc Anesth* 2020; Tempe DK, Khilnani GC, Passey JC, Sherwal BL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565047>
22. **Clinical feedback from experience with COVID-19: specific considerations for ExtraCorporeal Membrane Oxygenation.** *J Infect* 2020; Fiore A, de Roux Q, Daami N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579990>
23. **The Impact of COVID-19 on the Health-Care Workforce: From Heroes to Zeroes?** *J Nucl Med* 2020; Czernin J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591489>
24. **Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.** *Neurol Sci* 2020; Devogelaere J, D'Hooghe M B, Vanderhauwaert F, D'Haeseleer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564270>
25. **Inter-hospital communication and transfer practices during COVID-19 Pandemic in Karachi, Pakistan. A brief overview.** *Pak J Med Sci* 2020; 36:S118-s120Salman S, Saleem SG, Khatri A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582328>
26. **End-of-life care in COVID-19: An audit of pharmacological management in hospital inpatients.** *Palliat. Med.* 2020;269216320935361Jackson T, Hobson K, Clare H *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588748>
27. **Preparing a young palliative care unit for the COVID-19 pandemic in a teaching hospital in Ghana.** *Palliat Support Care* 2020;1-3Ofosu-Poku R, Anyane G, Agbeko AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576325>
 28. **Emerging Prevention and Treatment Strategies to Control COVID-19.** *Pathogens* 2020; 9Singh VK, Mishra A, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585805>
 29. **Decision Making: Physical Therapist Intervention for Patients With COVID-19 in a Geriatric Setting.** *Phys Ther* 2020; Levi N, Ganchrow K, Gheva M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589716>
 30. **Patient flow in the largest French psychiatric emergency centre in the context of the COVID-19 pandemic.** *Psychiatry Res* 2020; 291:113205Pham-Scottet A, Silva J, Barruel D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593065>
 31. **Short-Term Dexamethasone in Sars-CoV-2 Patients.** *R I Med J (2013)* 2020; 103:39-43Selvaraj V, Dapaah-Afriyie K, Finn A, Flanigan TP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570995>
 32. **Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.** *Respiration* 2020;1-21Pfeifer M, Ewig S, Voshaar T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564028>
 33. **CLINICAL DECISION MAKING IN OLDER ADULTS WITH COVID-19 IN DEVELOPING COUNTRIES: LOOKING BEYOND CHRONOLOGICAL AGE.** *Rev Invest Clin* 2020; 72:127-134Gomez-Moreno C, Hernandez-Ruiz V, Hernandez-Gilsoul T, Avila-Funes JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584321>
 34. **Outpatient Management of Kidney Transplant Recipients with Suspected COVID-19- Single Center Experience during the New York City Surge.** *Transpl Infect Dis* 2020:e13383Mehta SA, Leonard J, Labella P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578324>
 35. **Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.** *Trials* 2020; 21:574Marietta M, Vandelli P, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586394>
 36. **UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.** *Undersea Hyperb. Med.* 2020; 47:297-298. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574446>
 37. **Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.** *Undersea Hyperb. Med.* 2020; 47:181-187Guo D, Pan S, Wang M, Guo Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574433>
 38. **Hyperbaric oxygen as a treatment for COVID-19 infection?** *Undersea Hyperb. Med.* 2020; 47:177-179Moon RD, Weaver LK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574432>

Mental – public health (85 articles)

1. **Academic Emergency Medicine Physicians' Anxiety Levels, Stressors and Potential Stress Mitigation Measures during the Acceleration Phase of the COVID-19 Pandemic.** *Acad Emerg Med* 2020; Rodriguez RM, Medak AJ, Baumann BM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569419>
2. **The psychological and cognitive impact of Covid-19 on individuals with neurocognitive impairments: research topics and remote intervention proposals.** *Aging Clin. Exp. Res.* 2020; Devita M, Bordignon A, Sergi G, Coin A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583375>
3. **COVID-19: Clinical Challenges in Dutch Geriatric Psychiatry.** *Am J Geriatr Psychiatry* 2020; Naarding P, Oude Voshaar RC, Marijnissen RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565007>
4. **Telehealth in Psychiatry of Old Age: Ordinary Care in Extraordinary Times in Rural North-West Ireland.** *Am J Geriatr Psychiatry* 2020; Patel S, Gannon A, Dolan C, McCarthy G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591171>
5. **Stress, Anxiety, and Depression in People Aged Over 60 in the COVID-19 Outbreak in a Sample Collected in Northern Spain.** *Am J Geriatr Psychiatry* 2020; Picaza Gorrochategi M, Eiguren Munitis A, Dosil Santamaria M, Ozamiz Etxebarria N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576424>
6. **The implication of ocular manifestation of COVID-19 for medical staff and patients - systematic review.** *Ann. Agric. Environ. Med.* 2020; 27:165-170Latalska M, Mackiewicz J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588588>
7. **Public health education for parents during the outbreak of COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:628Li W, Liao J, Li Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566565>
8. **COVID 19 pandemic: Mental health challenges of internal migrant workers of India.** *Asian J Psychiatr* 2020; 54:102254Choudhari R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593122>
9. **Mental health and psychological impact of COVID-19: Potential high-risk factors among different groups.** *Asian J Psychiatr* 2020; 53:102212Mi L, Jiang Y, Xuan H, Zhou Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570100>
10. **COVID-19 and stigma: Social discrimination towards frontline healthcare providers and COVID-19 recovered patients in Nepal.** *Asian J Psychiatr* 2020; 53:102222Singh R, Subedi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570096>
11. **Prenatal anxiety and obstetric decisions among pregnant women in Wuhan and Chongqing during the COVID-19 outbreak: a cross-sectional study.** *Bjog* 2020; Liu X, Chen M, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583536>
12. **Why the COVID-19 pandemic should be a call for action to advance equitable access to medicines.** *BMC Med* 2020; 18:193Kohler JC, Mackey TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586387>
13. **Daily emotional well-being during the COVID-19 pandemic.** *Br. J. Health Psychol.* 2020; Lades LK, Laffan K, Daly M, Delaney L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573074>
14. **Pylons ablaze: Examining the role of 5G COVID-19 conspiracy beliefs and support for violence.** *Br. J. Soc. Psychol.* 2020; Jolley D, Paterson JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564418>
15. **'Distancers' and 'non-distancers'? The potential social psychological impact of moralizing COVID-19 mitigating practices on sustained behaviour change.** *Br. J. Soc. Psychol.* 2020; Prosser AMB, Judge M, Bolderdijk JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584437>
16. **Mental health status of the general population, healthcare professionals, and university students during 2019 coronavirus disease outbreak in Jordan: A cross-sectional study.** *Brain Behav*

- 2020:e01730Naser AY, Dahmash EZ, Al-Rousan R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578943>
17. **Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic.** *Brain Behav Immun Health* 2020; 5:100096Debnath M, Berk M, Maes M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566934>
 18. **Management of COVID-19 Response in a Secure Forensic Mental Health Setting.** *Can. J. Psychiatry*. 2020;706743720935648Simpson AIF, Chatterjee S, Darby P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573397>
 19. **Depression, Anxiety and Stress Among Indians in Times of Covid-19 Lockdown.** *Community Ment. Health J.* 2020; Rehman U, Shah Nawaz MG, Khan NH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577997>
 20. **Callous attitude towards doctors during COVID-19.** *Dermatol Ther* 2020; Jakhar D, Kaur I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578355>
 21. **Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method.** *Diabetes Metab Syndr* 2020; 14:887-892Maqbool A, Khan NZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563940>
 22. **Psychological effects and associated factors of COVID-19 in a Mexican sample.** *Disaster Med Public Health Prep* 2020:1-27Cortes-Alvarez NY, Pineiro-Lamas R, Vuelvas-Olmos CR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576317>
 23. **Complete Title: Use of Incident Command System for Disaster Preparedness: A Model for an Emergency Department COVID-19 Response.** *Disaster Med Public Health Prep* 2020:1-17Farcas A, Ko J, Chan J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576330>
 24. **"How much do young Italians know about COVID-19 and what are their attitudes towards the Sars-CoV-2? Results of a cross-sectional study".** *Disaster Med Public Health Prep* 2020:1-14La Torre G, Lia L, Dorelli B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576335>
 25. **Public-Private-People Partnerships (4P) for Improving the Response to COVID-19 in Iran.** *Disaster Med Public Health Prep* 2020:1-17Seddighi H, Seddighi S, Salmani I, Sharifi Sedeh M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576337>
 26. **'Quit During COVID-19'-staying smokefree in mental health in-patient settings.** *Ecancermedicalscience* 2020; 14:ed102Patwardhan P, Driscoll R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582377>
 27. **Identity in lockdown: supporting primary care professional identity development in the COVID-19 generation.** *Educ. Prim. Care* 2020:1-5Cullum RJ, Shaughnessy A, Mayat NY, Brown ME. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589524>
 28. **Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health.** *Front. Immunol.* 2020; 11:1170Raony I, de Figueiredo CS, Pandolfo P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574266>
 29. **Covid-19 Outbreak In Italy: Are We Ready for the Psychosocial and the Economic Crisis? Baseline Findings From the PsyCovid Study.** *Front Psychiatry* 2020; 11:556Cerami C, Santi GC, Galandra C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587539>
 30. **The Need for a Mental Health Technology Revolution in the COVID-19 Pandemic.** *Front Psychiatry* 2020; 11:523Figueroa CA, Aguilera A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581891>
 31. **Complicated Grief: What to Expect After the Coronavirus Pandemic.** *Front Psychiatry* 2020; 11:489Gesi C, Carmassi C, Cerveri G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574243>
 32. **Online Mental Health Survey in a Medical College in China During the COVID-19 Outbreak.** *Front Psychiatry* 2020; 11:459Liu J, Zhu Q, Fan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574242>
 33. **The Impact of COVID-19 on Anxiety in Chinese University Students.** *Front. Psychol.* 2020; 11:1168Wang C, Zhao H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574244>
 34. **How the Italian NHS Is Fighting Against the COVID-19 Emergency.** *Front Public Health* 2020; 8:167Boccia S, Cascini F, McKee M, Ricciardi W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573563>
 35. **Status and Challenges of Public Health Emergency Management in China Related to COVID-19.** *Front Public Health* 2020; 8:250Cao Y, Shan J, Gong Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574311>
 36. **The Status of Psychological Issues Among Frontline Health Workers Confronting the Coronavirus Disease 2019 Pandemic.** *Front Public Health* 2020; 8:265Hu Z, Chen B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582616>
 37. **Knowledge, Attitudes, Impact, and Anxiety Regarding COVID-19 Infection Among the Public in China.** *Front Public Health* 2020; 8:236Lin Y, Hu Z, Alias H, Wong LP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574305>
 38. **Psychological distress, coping behaviors, and preferences for support among New York healthcare workers during the COVID-19 pandemic.** *Gen. Hosp. Psychiatry* 2020; 66:1-8Shechter A, Diaz F, Moise N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590254>
 39. **The enclosed ward management strategies in psychiatric hospitals during COVID-19 outbreak.** *Global Health* 2020; 16:53Chen J, Xiong M, He Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580774>
 40. **Rethinking COVID-19 Vulnerability: A Call for LGBTQ+ Im/migrant Health Equity in the United States During and After a Pandemic.** *Health Equity* 2020; 4:239-242Kline NS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587935>
 41. **Community eye-health and vision center guidelines during COVID-19 pandemic in India.** *Indian J Ophthalmol* 2020; 68:1306-1311Vashist P, Senjam SS, Gupta V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587155>
 42. **Using Mind-Body Modalities via Telemedicine during the COVID-19 Crisis: Cases in the Republic of Korea.** *Int J Environ Res Public Health* 2020; 17Kwon CY, Kwak HY, Kim JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580396>
 43. **Demand for Health Information on COVID-19 among Vietnamese.** *Int J Environ Res Public Health* 2020; 17Le HT, Nguyen DN, Beydoun AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570819>
 44. **COVID-19-Related Factors Associated with Sleep Disturbance and Suicidal Thoughts among the Taiwanese Public: A Facebook Survey.** *Int J Environ Res Public Health* 2020; 17Li DJ, Ko NY, Chen YL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580433>
 45. **Health equity and COVID-19: global perspectives.** *Int J Equity Health* 2020; 19:104Shadmi E, Chen Y, Dourado I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586388>

46. **The coronavirus (COVID-19) pandemic's impact on mental health.** *Int. J. Health Plann. Manage.* 2020; Javed B, Sarwer A, Soto EB, Mashwani ZU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567725>
47. **Coronavirus Outbreak in Nigeria: Burden and Socio-Medical Response during the First 100 Days.** *Int J Infect Dis* 2020; Amzat J, Aminu K, Kolo VI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585282>
48. **Navigating COVID-19 with emotional intelligence.** *Int J Soc Psychiatry* 2020:20764020934519Baba MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583710>
49. **Increased stressful impact among general population in mainland China amid the COVID-19 pandemic: A nationwide cross-sectional study conducted after Wuhan city's travel ban was lifted.** *Int J Soc Psychiatry* 2020:20764020935489Ma ZF, Zhang Y, Luo X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564637>
50. **Depression, anxiety, and stress and socio-demographic correlates among general Indian public during COVID-19.** *Int J Soc Psychiatry* 2020:20764020934508Verma S, Mishra A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567466>
51. **Mental status of patients with chronic insomnia in China during COVID-19 epidemic.** *Int J Soc Psychiatry* 2020:20764020937716Yang L, Yu Z, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586205>
52. **"I'm Kinda Stuck at Home With Unsupportive Parents Right Now": LGBTQ Youths' Experiences With COVID-19 and the Importance of Online Support.** *J. Adolesc. Health* 2020; Fish JN, McInroy LB, Pacey MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591304>
53. **The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis.** *J. Alzheimers Dis.* 2020; Boutoleau-Brettonniere C, Pouclet-Courtemanche H, Gillet A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568211>
54. **Teleanalytic Therapy in the Era of Covid-19: Dissociation in the Countertransference.** *J. Am. Psychoanal. Assoc.* 2020:3065120938772Svenson K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589054>
55. **Analysis of Risk Perceptions and Related Factors Concerning COVID-19 Epidemic in Chongqing, China.** *J. Community Health* 2020; He S, Chen S, Kong L, Liu W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592160>
56. **An analytical study on the awareness, attitude and practice during the COVID-19 pandemic in Riyadh, Saudi Arabia.** *J Infect Public Health* 2020; Alahdal H, Basingab F, Alotaibi R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563674>
57. **Distress and anxiety associated with COVID-19 among Jewish and Arab pregnant women in Israel.** *J. Reprod. Infant Psychol.* 2020:1-9Taubman-Ben-Ari O, Chasson M, Abu Sharkia S, Weiss E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573258>
58. **An Evaluation of Florida's Zika Response Using the WHO Health Systems Framework: Can We Apply These Lessons to COVID-19?** *Matern Child Health J* 2020; Marshall J, Scott B, Delva J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583172>
59. **Medical students' dilemma during the Covid-19 pandemic; between the will to help and the fear of contamination.** *Med. Educ. Online* 2020; 25:1784374Hjiej G, Fourtassi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578522>
60. **Flattening the curve of mental ill-health: the importance of primary prevention in managing the mental health impacts of COVID-19.** *Ment Health Prev* 2020; 19:200185Carbone SR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566473>
61. **Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients.** *Oncol. Lett.* 2020; 20:441-447Tsamakias K, Gavriatopoulou M, Schizas D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565968>
62. **Impact of the COVID-19 Pandemic on Adult Mental Health.** *Pak J Med Sci* 2020; 36:S90-s94Haider, II, Tiwana F, Tahir SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582321>
63. **Potential Barriers amongst Health Care Professionals of Pakistan in managing COVID-19 patients.** *Pak J Med Sci* 2020; 36:S17-s21Haq MIU, Shafiq F, Sheikh H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582308>
64. **New Horizons: COVID-19 and the Burden of Neuropsychiatric Illness in Pakistan.** *Pak J Med Sci* 2020; 36:S95-s98Hashmi AM, Saleem HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582322>
65. **Mental health considerations for children & adolescents in COVID-19 Pandemic.** *Pak J Med Sci* 2020; 36:S67-s72Imran N, Zeshan M, Pervaiz Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582317>
66. **Self-control Mediates the Relationship between Psychosocial Strengths and Perceived Severity of COVID-19 among Frontline Healthcare Professionals of Pakistan: A Single Center Experience.** *Pak J Med Sci* 2020; 36:S62-s66Saleem M, Dastgeer S, Durrani AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582316>
67. **Impact of Coronavirus disease (COVID-19) pandemic on health professionals.** *Pak J Med Sci* 2020; 36:S6-s11Sethi BA, Sethi A, Ali S, Aamir HS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582306>
68. **Expectations, Fears and Perceptions of doctors during Covid-19 Pandemic.** *Pak J Med Sci* 2020; 36:S37-s42Urooj U, Ansari A, Siraj A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582312>
69. **COVID-19-related conspiracy beliefs and their relationship with perceived stress and pre-existing conspiracy beliefs.** *Pers. Individ. Dif.* 2020; 166:110201Georgiou N, Delfabbro P, Balzan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565592>
70. **Mental Health Effects of COVID-19 Pandemia: A Review of Clinical and Psychological Traits.** *Psychiatry Investig* 2020; 17:491-505Kontoangelos K, Economou M, Papageorgiou C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570296>
71. **Fear and agony of the pandemic leading to stress and mental illness: An emerging crisis in the novel coronavirus (COVID-19) outbreak.** *Psychiatry Res* 2020; 291:113230Fofana NK, Latif F, Sarfraz S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593067>
72. **The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis.** *Psychiatry Res* 2020; 291:113190Luo M, Guo L, Yu M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563745>
73. **The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis.** *Psychiatry Res* 2020; 291:113190Luo M, Guo L, Yu M, Wang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563745>
74. **Patient flow in the largest French psychiatric emergency centre in the context of the COVID-19 pandemic.** *Psychiatry Res* 2020; 291:113205Pham-Scottez A, Silva J, Barruel D *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593065>
75. **COVID-19 related depression and anxiety among quarantined respondents.** *Psychol. Health* 2020;1-15 Tang F, Liang J, Zhang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567952>
 76. **Physical activity in a pandemic: A new treatment target for psychological therapy.** *Psychol. Psychother.* 2020; Diamond R, Waite F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588499>
 77. **The psychological impact of COVID-19 on the mental health in the general population.** *QJM* 2020; Serafini G, Parmigiani B, Amerio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569360>
 78. **Social trust in the midst of pandemic crisis: Implications from COVID-19 of South Korea.** *Res Soc Stratif Mobil* 2020; 68:100523Kye B, Hwang SJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572302>
 79. **How Did Chinese Government Implement Unconventional Measures Against COVID-19 Pneumonia.** *Risk Manag. Healthc. Policy* 2020; 13:491-499Yu X, Li N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581611>
 80. **[From one epidemic to the next: how can the learned experience serve to alleviate the psychosocial impact of Covid-19 confinement?].** *Soins* 2020; 65:59-62Tourette-Turgis C, Rebillon M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563514>
 81. **Fatalism in the context of COVID-19: Perceiving coronavirus as a death sentence predicts reluctance to perform recommended preventive behaviors.** *SSM Popul Health* 2020; 11:100615Jimenez T, Restar A, Helm PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572381>
 82. **Associations among state-level physical distancing measures and suicidal thoughts and behaviors among U.S. adults during the early COVID-19 pandemic.** *Suicide Life Threat. Behav.* 2020; Bryan CJ, Bryan AO, Baker JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589801>
 83. **How Bad Is It? Suicidality in the Middle of the COVID-19 Pandemic.** *Suicide Life Threat. Behav.* 2020; Fitzpatrick KM, Harris C, Drawve G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589799>
 84. **Waiting and Care in Pandemic Times Collection.** *Wellcome Open Res* 2020; 5:128Baraitser L, Salisbury L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566762>
 85. **Segmenting communities as public health strategy: a view from the social sciences and humanities.** *Wellcome Open Res* 2020; 5:104Ganguli-Mitra A, Young I, Engelmann L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587904>

Meta-analyses - systematic reviews (19 articles)

1. **Diabetes increases the mortality of patients with COVID-19: a meta-analysis.** *Acta Diabetol* 2020; Wu ZH, Tang Y, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583078>
2. **Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis.** *Aging (Albany NY)* 2020; 12Xu L, Mao Y, Chen G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575078>
3. **Application of telemedicine during the coronavirus disease epidemics: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:626Gao Y, Liu R, Zhou Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566563>
4. **Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:627Lu S, Zhou Q, Huang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566564>
5. **Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:622Lv M, Wang M, Yang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566559>
6. **Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:624Shi Q, Zhou Q, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566561>
7. **Clinical characteristics of children with COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:620Wang Z, Zhou Q, Wang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566557>
8. **Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:629Zhou Q, Gao Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566566>
9. **Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis.** *Diabetes Obes. Metab.* 2020; Singh AK, Gillies CL, Singh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573903>
10. **Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies.** *Eur Heart J Acute Cardiovasc Care* 2020;2048872620937165Parohan M, Yaghoubi S, Seraji A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567326>
11. **Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis.** *Front Med (Lausanne)* 2020; 7:301Feng X, Li S, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582743>
12. **Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis.** *Front. Neurol.* 2020; 11:565Pinzon RT, Wijaya VO, Buana RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574250>
13. **Comparison of Epidemiological Variations in COVID-19 Patients Inside and Outside of China-A Meta-Analysis.** *Front Public Health* 2020; 8:193Ahmed A, Ali A, Hasan S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574293>
14. **CD4+T, CD8+T counts and severe COVID-19: A meta-analysis.** *J Infect* 2020; Zhang H, Wu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569604>
15. **Meta-analysis of chest CT features of patients with COVID-19 pneumonia.** *J Med Virol* 2020; Zheng Y, Wang L, Ben S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579236>
16. **Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.** *Med Clin (Barc)* 2020; Soraya GV, Ulhaq ZS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586670>
17. **Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies.** *Nutr. Metab. Cardiovasc. Dis.* 2020; Mantovani A, Byrne CD, Zheng MH, Targher G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571616>

18. **Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.** *PeerJ* 2020; 8:e9357 Loganathan T, Ramachandran S, Shankaran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566414>
19. **The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis.** *Psychiatry Res* 2020; 291:113190 Luo M, Guo L, Yu M, Wang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563745>

Mortality (28 articles)

1. **Diabetes increases the mortality of patients with COVID-19: a meta-analysis.** *Acta Diabetol* 2020; Wu ZH, Tang Y, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583078>
2. **ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19.** *Aging (Albany NY)* 2020; 12Bousquet G, Falgarone G, Deutsch D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576712>
3. **Fatal SARS-CoV-2 infection in a renal transplant recipient.** *CEN Case Rep* 2020; Dirim AB, Demir E, Ucar AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564306>
4. **Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.** *Clin Chem Lab Med* 2020; 58:1100-1105 Bonetti G, Manelli F, Patroni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573995>
5. **Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?** *Clin. Exp. Hypertens.* 2020:1-5 Selcuk M, Cinar T, Keskin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569491>
6. **Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.** *Dermatol Ther* 2020; Recalcati S, Piconi S, Franzetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584431>
7. **Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis.** *Diabetes Obes. Metab.* 2020; Singh AK, Gillies CL, Singh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573903>
8. **Mortality risk in post-operative head and neck cancer patients during the SARS-Cov2 pandemic: early experiences.** *Eur Arch Otorhinolaryngol* 2020; Hintze JM, Fitzgerald CW, Lang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572564>
9. **SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death.** *Eur. J. Cancer* 2020; Yarza R, Bover M, Paredes D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586724>
10. **Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?** *Front. Immunol.* 2020; 11:1208 Mutti L, Pentimalli F, Baglio G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574270>
11. **Official Data and Analytical Forecasts: Differences and Similarities Among Coronavirus Disease (COVID-19) Confirmed Cases and Deaths.** *Front Med (Lausanne)* 2020; 7:239 Ferraro OE, Puci MV, Montomoli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574330>
12. **Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19.** *Front Med (Lausanne)* 2020; 7:246 Shao L, Li X, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574334>
13. **Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation.** *Front. Pharmacol.* 2020; 11:796 Uckun FM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574237>
14. **Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.** *Hypertension* 2020; Hypertensionaha12015324 Iaccarino G, Grassi G, Borghi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564693>
15. **Air Pollution and Covid-19: The Role of Particulate Matter in the Spread and Increase of Covid-19's Morbidity and Mortality.** *Int J Environ Res Public Health* 2020; 17Comunian S, Dongo D, Milani C, Palestini P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580440>
16. **Deaths in SARS-Cov-2 Positive Patients in Italy: The Influence of Underlying Health Conditions on Lethality.** *Int J Environ Res Public Health* 2020; 17Deiana G, Azara A, Dettori M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575825>
17. **Potential Years of Life Lost Due to COVID-19 in the United States, Italy, and Germany: An Old Formula with Newer Ideas.** *Int J Environ Res Public Health* 2020; 17Mitra AK, Payton M, Kabir N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570888>
18. **Understanding variation in covid-19 reported deaths with a novel Shewhart chart application.** *Int. J. Qual. Health Care* 2020; Perla RJ, Provost SM, Parry GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589224>
19. **Clinical prediction model for mortality of adult diabetes inpatients with COVID-19 in Wuhan, China: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 66:109927 Su M, Yuan J, Peng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570072>
20. **Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World.** *J Clin Med* 2020; 9Hisaka A, Yoshioka H, Hatakeyama H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570833>
21. **The first few cases and fatalities of Corona Virus Disease 2019 (COVID-19) in the Eastern Mediterranean Region of the World Health Organization: A rapid review.** *J Infect Public Health* 2020; Abed Alah M, Abdeen S, Kehyayan V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586684>
22. **Mortality statistics in England and Wales: the SARS-CoV-2 paradox.** *J. Int. Med. Res.* 2020; 48:300060520931298 Harrison G, Newport D, Robbins T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564639>
23. **Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas.** *J Transl Med* 2020; 18:251 Benedetti F, Pachetti M, Marini B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576227>
24. **A need for consensus on mortality reporting related to the COVID-19 pandemic in ongoing and future vascular registries and trials.** *J. Vasc. Surg.* 2020; Valdivia AR, Chaudhuri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592742>

25. **Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).** *Microbes Infect* 2020; Lohse A, Klopfenstein T, Bablanc JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574789>
26. **End-of-life care in COVID-19: An audit of pharmacological management in hospital inpatients.** *Palliat. Med.* 2020;269216320935361 Jackson T, Hobson K, Clare H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588748>
27. **Decreased in-hospital mortality in patients with COVID-19 pneumonia.** *Pathog Glob Health* 2020;1-2 Ciceri F, Ruggeri A, Lembo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584660>
28. **[Democracy and Covid-19 mortality in Europe.].** *Rev. Esp. Salud Publica* 2020; 94 Mazzucchelli R, Agudo Dieguez A, Dieguez Costa EM, Crespi Villarias N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576811>

Online – IT – Apps (35 articles)

1. **Telehealth in Psychiatry of Old Age: Ordinary Care in Extraordinary Times in Rural North-West Ireland.** *Am J Geriatr Psychiatry* 2020; Patel S, Gannon A, Dolan C, McCarthy G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591171>
2. **Patient Satisfaction with Telemedicine Encounters in an Allergy/Immunology Practice During the COVID-19 Pandemic.** *Ann. Allergy. Asthma. Immunol.* 2020; Mustafa SS, Yang L, Mortezaei M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585178>
3. **Application of telemedicine during the coronavirus disease epidemics: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:626 Gao Y, Liu R, Zhou Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566563>
4. **Pylons ablaze: Examining the role of 5G COVID-19 conspiracy beliefs and support for violence.** *Br. J. Soc. Psychol.* 2020; Jolley D, Paterson JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564418>
5. **Bringing radiology to patient's home using mobile equipment: A weapon to fight COVID-19 pandemic.** *Clin Imaging* 2020; 68:99-101 Zarnardo M, Schiaffino S, Sardanelli F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585417>
6. **Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks.** *Comput. Biol. Med.* 2020; 121:103795 Ardakani AA, Kanafi AR, Acharya UR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568676>
7. **Automated detection of COVID-19 cases using deep neural networks with X-ray images.** *Comput. Biol. Med.* 2020; 121:103792 Ozturk T, Talo M, Yildirim EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568675>
8. **COVID-19 detection using deep learning models to exploit Social Mimic Optimization and structured chest X-ray images using fuzzy color and stacking approaches.** *Comput. Biol. Med.* 2020; 121:103805 Togacar M, Ergen B, Comert Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568679>
9. **A simplified math approach to predict ICU beds and mortality rate for hospital emergency planning under Covid-19 pandemic.** *Comput. Chem. Eng.* 2020; 140:106945 Manca D, Caldiroli D, Storti E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565584>
10. **Application of cognitive Internet of Medical Things for COVID-19 pandemic.** *Diabetes Metab Syndr* 2020; 14:911-915 Swayamsiddha S, Mohanty C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570016>
11. **Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: a WhatsApp messenger-based report from the Italian College of Chief Medical Oncologists.** *Ecancermedicalscience* 2020; 14:1046 Blasi L, Bordonaro R, Borsellino N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565899>
12. **Can artificial intelligence identify effective COVID-19 therapies?** *EMBO Mol Med* 2020:e202012817 Schultz MB, Vera D, Sinclair DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569446>
13. **The Need for a Mental Health Technology Revolution in the COVID-19 Pandemic.** *Front Psychiatry* 2020; 11:523 Figueroa CA, Aguilera A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581891>
14. **An Online Observational Study of Patients With Olfactory and Gustatory Alterations Secondary to SARS-CoV-2 Infection.** *Front Public Health* 2020; 8:243 Gomez-Iglesias P, Porta-Etessam J, Montalvo T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574308>
15. **Hyperlocal Postcode Based Crowdsourced Surveillance Systems in the COVID-19 Pandemic Response.** *Front Public Health* 2020; 8:286 Hegde A, Masthi R, Krishnappa D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582620>
16. **Pivoting to teleconsultation for paediatric ophthalmology and strabismus: Our experience during COVID-19 times.** *Indian J Ophthalmol* 2020; 68:1387-1391 Deshmukh AV, Badakere A, Sheth J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587172>
17. **Tele-consultations in the wake of COVID-19 - Suggested guidelines for clinical ophthalmology.** *Indian J Ophthalmol* 2020; 68:1316-1327 Jayadev C, Mahendradas P, Vinekar A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587157>
18. **Differential diagnosis of acute ocular pain: Teleophthalmology during COVID-19 pandemic - A perspective.** *Indian J Ophthalmol* 2020; 68:1371-1379 Murthy SI, Das S, Deshpande P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587167>
19. **Teleconsultation at a tertiary care government medical university during COVID-19 Lockdown in India - A pilot study.** *Indian J Ophthalmol* 2020; 68:1381-1384 Pandey N, Srivastava RM, Kumar G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587169>
20. **Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.** *Infect Disord Drug Targets* 2020; Mali SN, Pratap AP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568026>
21. **Using Mind-Body Modalities via Telemedicine during the COVID-19 Crisis: Cases in the Republic of Korea.** *Int J Environ Res Public Health* 2020; 17:Kwon CY, Kwak HY, Kim JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580396>
22. **Extensions and adaptations of existing medical information system in order to reduce social contacts during COVID-19 pandemic.** *Int. J. Med. Inform.* 2020; 141:104224 Milenkovic A, Jankovic D, Rajkovic P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570196>
23. **Inherent privacy limitations of decentralized contact tracing apps.** *J Am Med Inform Assoc* 2020; Bengio Y, Ippolito D, Janda R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584990>

24. **COVID-19 TestNorm - A tool to normalize COVID-19 testing names to LOINC codes.** *J Am Med Inform Assoc* 2020; Dong X, Li J, Soysal E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569358>
25. **Telehealth in Response to the Covid-19 Pandemic: Implications for Rural Health Disparities.** *J Am Med Inform Assoc* 2020; Hirko KA, Kerver JM, Ford S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589735>
26. **Teleanalytic Therapy in the Era of Covid-19: Dissociation in the Countertransference.** *J. Am. Psychoanal. Assoc.* 2020:3065120938772Svenson K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589054>
27. **Teleconsultation in primary ophthalmic emergencies during the COVID-19 lockdown in Paris: Experience with 500 patients in March and April 2020.** *J. Fr. Ophthalmol.* 2020; Bourdon H, Jaillant R, Ballino A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564983>
28. **How to Fight an Infodemic: The Four Pillars of Infodemic Management.** *J Med Internet Res* 2020; 22:e21820Eysenbach G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589589>
29. **Integrating Telemedicine for Medication Treatment for Opioid Use Disorder in Rural Primary Care: Beyond the COVID Pandemic.** *J Rural Health* 2020; Hser YI, Mooney LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579751>
30. **Virtual empathy and liver cancer.** *Liver Int* 2020; Debes JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573921>
31. **Implementation of Obstetric Telehealth During COVID-19 and Beyond.** *Matern Child Health J* 2020; Fryer K, Delgado A, Foti T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564248>
32. **Tracking, tracing, trust: contemplating mitigating the impact of COVID-19 through technological interventions.** *Med. J. Aust.* 2020; Coghlan S, Cheong M, Coghlan B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570292>
33. **Tracking, tracing, trust: contemplating mitigating the impact of COVID-19 through technological interventions.** *Med. J. Aust.* 2020; Culnane C, Leins K, Rubinstein BI. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583470>
34. **[Digital surveillance tools for contact tracking of infected persons by SARS-CoV-2.].** *Rev. Esp. Salud Publica* 2020; 94Garcia-Iglesias JJ, Martin-Pereira J, Fagundo-Rivera J, Gomez-Salgado J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572019>
35. **The Italian Fight Against the COVID-19 Pandemic in the Second Phase: The Renewed Opportunity of Telemedicine.** *Telemed J E Health* 2020; Giansanti D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579866>

Other – Miscellaneous (28 articles)

1. **Is 2020 the year when primatologists should cancel fieldwork?** *Am. J. Primatol.* 2020:e23161Reid MJC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583538>
2. **Perception of the 2020 SARS-CoV-2 pandemic among medical professionals in Germany: results from a nationwide online survey.** *Emerg Microbes Infect* 2020:1-30Paffenholz P, Peine A, Hellmich M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573350>
3. **Indirect impact of COVID-19 on environment: A brief study in Indian context.** *Environ. Res.* 2020; 188:109807Lokhandwala S, Gautam P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574854>
4. **Environmental concern regarding the effect of humidity and temperature on 2019-nCoV survival: fact or fiction.** *Environ. Sci. Pollut. Res. Int.* 2020; Harmooshi NN, Shirbandi K, Rahim F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592048>
5. **The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world?** *F1000Res* 2020; 9:225Guerin PJ, Singh-Phulgenda S, Strub-Wourgaft N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566139>
6. **COVID-19 Interconnectedness: Health Inequity, the Climate Crisis, and Collective Trauma.** *Fam. Process* 2020; Watson MF, Bacigalupe G, Daneshpour M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589267>
7. **What Does Food Retail Research Tell Us About the Implications of Coronavirus (COVID-19) for Grocery Purchasing Habits?** *Front. Psychol.* 2020; 11:1448Martin-Neuning R, Ruby MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581987>
8. **Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term Economic Security.** *Front Public Health* 2020; 8:235Allen MB, Mirsaedi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574304>
9. **Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness.** *Front Public Health* 2020; 8:241Pak A, Adegboye OA, Adekunle AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574307>
10. **Globalisation in the time of COVID-19: repositioning Africa to meet the immediate and remote challenges.** *Global Health* 2020; 16:51Yaya S, Otu A, Labonte R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580728>
11. **Primary Care Practice Finances In The United States Amid The COVID-19 Pandemic.** *Health Aff (Millwood)* 2020:101377hlthaff202000794Basu S, Phillips RS, Phillips R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584605>
12. **A close look at the biology of SARS-CoV-2, and the potential influence of weather conditions and seasons on COVID-19 case spread.** *Infect Dis Poverty* 2020; 9:77Adedokun KA, Olarinmoye AO, Mustapha JO, Kamorudeen RT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586369>
13. **Will the COVID-19 pandemic decrease the FatMax?** *J Appl Physiol (1985)* 2020; 129:1Dutheil F, Esquirol Y, Navel V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574528>
14. **Reply to Dutheil et al.** *J Appl Physiol (1985)* 2020; 129:2Frandsen J, Pistoljevic N, Quesada JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574527>
15. **"Masking" our Emotions: Botulinum Toxin, Facial Expression and Well-Being in the Age of COVID-19.** *J Cosmet Dermatol* 2020; Nestor MS, Fischer D, Arnold D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592268>
16. **SARS-CoV-2 and biomimetics: What saves the planet will save our health.** *J Intern Med* 2020; Stenvinkel P, Painer J, Shiels PG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583447>

17. **Food System Workers are the Unexpected but Under Protected COVID Heroes.** *J. Nutr.* 2020; Parks CA, Nugent NB, Fleischhacker SE, Yaroch AL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584977>
18. **Beyond the Linguistic/Medical Anthropology Divide: Retooling Anthropology to Face COVID-19.** *Med. Anthropol.* 2020;1-10Briggs CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579045>
19. **First impressions of the foundation interim year 1 postings: positives, pitfalls, and perils.** *Med. Educ. Online* 2020; 25:1785116Youssef S, Zaidi S, Shrestha S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584167>
20. **Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.** *Microorganisms* 2020; 8Shinde T, Hansbro PM, Sohal SS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570850>
21. **Hazard Pay for COVID-19? Yes, But It's Not a Substitute for a Living Wage and Enforceable Worker Protections.** *New Solut.* 2020:1048291120933814Hecker S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567480>
22. **The Impact of the COVID-19 Pandemic on Unhealthy Eating in Populations with Obesity.** *Obesity (Silver Spring)* 2020; Ashby NJS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589788>
23. **Coronavirus Disease 2019 (COVID-19) Pandemic and Economic Impact.** *Pak J Med Sci* 2020; 36:S73-s78Ahmad T, Haroon, Baig M, Hui J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582318>
24. **COVID-19-related conspiracy beliefs and their relationship with perceived stress and pre-existing conspiracy beliefs.** *Pers. Individ. Dif.* 2020; 166:110201Georgiou N, Delfabbro P, Balzan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565592>
25. **Can the summer temperatures reduce COVID-19 cases?** *Public Health* 2020; 185:72-79Mandal CC, Panwar MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574871>
26. **A mechanism-based parameterisation scheme to investigate the association between transmission rate of COVID-19 and meteorological factors on plains in China.** *Sci Total Environ* 2020; 737:140348Lin C, Lau AKH, Fung JCH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569904>
27. **Imprints of pandemic lockdown on subsurface water quality in the coastal industrial city of Tuticorin, South India: A revival perspective.** *Sci Total Environ* 2020; 738:139848Selvam S, Jesuraja K, Venkatramanan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574914>
28. **Comorbid Medical Conditions in Young Athletes: Considerations for Preparticipation Guidance During the COVID-19 Pandemic.** *Sports Health* 2020:1941738120939079Harmon KG, Pottinger PS, Baggish AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579436>

Pathology (4 articles)

1. **Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications.** *Eur Urol Focus* 2020; Yang M, Chen S, Huang B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563676>
2. **How Are We Facing It? Dispatches From Pathology Residents in a COVID-19 Lombardy Hospital.** *Front Public Health* 2020; 8:259Cieri M, De Carlo C, Valeri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582614>
3. **Over view for the truth of COVID -19 pandemic: A guide for the Pathologists, Health care workers and community'.** *Pak J Med Sci* 2020; 36:S111-s114Bukhari MH, Mahmood K, Zahra SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582326>
4. **Peripheral Blood Smear Findings in COVID-19.** *Turk J Haematol* 2020; Ahnach M, Ousti F, Nejari S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586086>

Protection (59 articles)

1. **Plasmonic and Superhydrophobic Self-Decontaminating N95 Respirators.** *ACS Nano* 2020; Zhong H, Zhu Z, You P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578981>
2. **[Respiratory and Facial Protection: Current Perspectives in the Context of the COVID-19 Pandemic].** *Acta Med Port* 2020; Peres D, Boleo-Tome JP, Santos G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568064>
3. **Prevention and infection control of COVID-19 in Nursing Homes: experience from China.** *Age Ageing* 2020; Wang L, Qi N, Zhou Y, Zhang H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584961>
4. **Hand Sanitizers: A Review of Ingredients, Mechanisms of Action, Modes of Delivery, and Efficacy Against Coronaviruses.** *Am. J. Infect. Control* 2020; Golin AP, Choi D, Ghahary A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565272>
5. **Persistent Value of the Stethoscope in the Age of COVID-19.** *Am. J. Med.* 2020; Vasudevan RS, Horiuchi Y, Torriani FJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569591>
6. **Preliminary information on prevention of infections caused by SARS-COV-2 virus in endoscopic laboratories.** *Ann. Agric. Environ. Med.* 2020; 27:171-174Gruszecka J, Filip R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588589>
7. **The implication of ocular manifestation of COVID-19 for medical staff and patients - systematic review.** *Ann. Agric. Environ. Med.* 2020; 27:165-170Latalaska M, Mackiewicz J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588588>
8. **Understanding face mask use to prevent coronavirus and other illnesses: Development of a multidimensional face mask perceptions scale.** *Br. J. Health Psychol.* 2020; Howard MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588949>
9. **Looking out for myself: Exploring the relationship between conspiracy mentality, perceived personal risk, and COVID-19 prevention measures.** *Br. J. Health Psychol.* 2020; Marinthe G, Brown G, Delouvee S, Jolley D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583540>
10. **Eye care in the intensive care unit during the COVID-19 pandemic.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-10Sansome SG, Lin PF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589541>
11. **Should nasogastric tube insertion during the COVID-19 pandemic be considered as an aerosol-generating procedure?** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-6Sturrock BR, Fanning SJ, Khan M, Sajid MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589539>

12. **'Distancers' and 'non-distancers'? The potential social psychological impact of moralizing COVID-19 mitigating practices on sustained behaviour change.** *Br. J. Soc. Psychol.* 2020; Prosser AMB, Judge M, Bolderdijk JW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584437>
13. **Can wearing face masks in public affect transmission route and viral load in COVID-19?** *Cent. Eur. J. Public Health* 2020; 28:161-162 Strizova Z, Bartunkova J, Smrz D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592550>
14. **[SARS-CoV-2/COVID-19: systematic review of requirements for personal protective equipment in primary patient contact and organization of the operating area].** *Chirurg* 2020; Schnitzbauer AA, Kempf VAJ, Hack D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588105>
15. **Novel coronavirus 2019 transmission risk in educational settings.** *Clin Infect Dis* 2020; Yung CF, Kam KQ, Nadua KD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584975>
16. **Characteristics of 1,573 healthcare workers who underwent nasopharyngeal swab for SARS-CoV-2 in Milano, Lombardy, Italy.** *Clin Microbiol Infect* 2020; Lombardi A, Consonni D, Carugno M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569835>
17. **Gas Aerosol Jetstreams from Trocars during Laparoscopic Surgery- A Video Vignette.** *Colorectal Dis* 2020; Khan MF, Dalli J, Cahill RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579264>
18. **Experience for use of modified full-face snorkel mask as personal protective equipment during endoscopic procedures in the era of coronavirus disease pandemic.** *Dig Endosc* 2020; Kusano C, Goddard J, Gotoda T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593195>
19. **Face masks for all and all for face masks in the COVID-19 pandemic: community level production to face the global shortage and shorten the epidemic.** *Disaster Med Public Health Prep* 2020:1-13 Missoni E, Armocida B, Formenti B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576310>
20. **Caring for the carers: safeguarding oncologists' mental health in the time of COVID-19.** *Ecancermedicalscience* 2020; 14:1057 Leones LMB, Berba CMP, Chua AV, Jr., Sandoval-Tan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582372>
21. **Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions.** *Emerg Infect Dis* 2020; 26:Fears AC, Klimstra WB, Duprex P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568661>
22. **Operating Protocols of a Community Treatment Center for Isolation of Patients with Coronavirus Disease, South Korea.** *Emerg Infect Dis* 2020; 26:Kang E, Lee SY, Jung H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568665>
23. **COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020.** *Emerg Infect Dis* 2020; 26:Moses FW, Gonzalez-Rothi R, Schmidt G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579875>
24. **Prolonged Infectivity of SARS-CoV-2 in Fomites.** *Emerg Infect Dis* 2020; 26:Pastorino B, Touret F, Gilles M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579874>
25. **Factors related to SARS-CoV-2 infection in healthcare professionals in Spain. The SANICOVI project.** *Enferm. Clin.* 2020; Moreno-Casbas MT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571661>
26. **The nasal tent: an adjuvant for performing endoscopic endonasal surgery in the Covid era and beyond.** *Eur Arch Otorhinolaryngol* 2020; Maharaj SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577897>
27. **Textile Masks and Surface Covers-A Spray Simulation Method and a "Universal Droplet Reduction Model" Against Respiratory Pandemics.** *Front Med (Lausanne)* 2020; 7:260 Rodriguez-Palacios A, Cominelli F, Basson AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574342>
28. **Caring for Health Professionals in the COVID-19 Pandemic Emergency: Toward an "Epidemic of Empathy" in Healthcare.** *Front. Psychol.* 2020; 11:1431 Barello S, Graffigna G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581986>
29. **Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals.** *Front Public Health* 2020; 8:249 Yang C, Ke C, Yue D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574310>
30. **COVID19: A Systematic Approach to Early Identification and Healthcare Worker Protection.** *Front Public Health* 2020; 8:205 Zhao Y, Cui C, Zhang K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574296>
31. **Understanding Surgical Risk During COVID-19 Pandemic: The Rationale Behind the Decisions.** *Front Surg* 2020; 7:33 Blouhos K, Boulas KA, Paraskeva A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574344>
32. **Airborne pathogen projection during ophthalmic examination.** *Graefes Arch Clin Exp Ophthalmol* 2020; Bostanci Ceran B, Karakoc A, Taciroglu E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588166>
33. **Risk of SARS-CoV-2 transmission to medical staff and patients from an exposure to a COVID-19-positive ophthalmologist.** *Graefes Arch Clin Exp Ophthalmol* 2020; Saban O, Levy J, Chowers I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567041>
34. **Development of a highly effective low-cost vaporized hydrogen peroxide-based method for disinfection of personal protective equipment for their selective reuse during pandemics.** *Gut Pathog* 2020; 12:29 Saini V, Sikri K, Batra SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572338>
35. **All India Ophthalmological Society - Eye Bank Association of India consensus statement on guidelines for cornea and eyebanking during COVID-19 era.** *Indian J Ophthalmol* 2020; 68:1258-1262 Sharma N, D'Souza S, Nathawat R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587148>
36. **Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals.** *Indian J Ophthalmol* 2020; 68:1349-1356 Shetty R, Lalgudi VG, Khamar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587162>
37. **Reshaping of Neonatal Intensive Care Units to avoid the spread of COVID-19 to high-risk infants.** *Infect Control Hosp Epidemiol* 2020:1-8 De Rose DU, Auriti C, Landolfo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576333>
38. **Examining the need for eye protection for COVID-19 prevention in the community.** *Infect Control Hosp Epidemiol* 2020:1-6 Marra AR, Edmond MB, Popescu SV, Perencevich EN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576322>
39. **Impact of 3D printed medical equipment on the management of the Covid19 pandemic.** *Int. J. Health Plann. Manage.* 2020; Belhouideg S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567722>
40. **Extensions and adaptations of existing medical information system in order to reduce social contacts during COVID-19 pandemic.** *Int. J. Med. Inform.* 2020; 141:104224 Milenkovic A, Jankovic D, Rajkovic P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570196>

41. **Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19.** *J. Alzheimers Dis.* 2020; Schindler SE, Jicha GA, Nelson PT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568212>
42. **A pilot study of the impact of facial skin protectants on qualitative fit testing of N95 masks.** *J Am Acad Dermatol* 2020; Bui AN, Yu Z, Lee K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592881>
43. **N95 Usage During the COVID-19 Pandemic.** *J. Am. Podiatr. Med. Assoc.* 2020; DeLauro NM, Ghobrial N, Yu D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569357>
44. **Hygienic and cosmetic care habits in polish women during COVID-19 pandemic.** *J Cosmet Dermatol* 2020; Moscicka P, Chrost N, Terlikowski R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573966>
45. **Ultraviolet and COVID-19 pandemic.** *J Cosmet Dermatol* 2020; Tursen U, Tursen B, Lotti T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573919>
46. **Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey.** *J Crit Care* 2020; 59:70-75 Tabah A, Ramanan M, Laupland KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570052>
47. **COVID-19 infections among Healthcare Workers in an Infectious Diseases specialized setting in Naples, Southern Italy: results of a cross-sectional surveillance study.** *J Hosp Infect* 2020; Fusco FM, Pisaturo M, Iodice V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565367>
48. **Protecting children from iatrogenic harm during COVID19 pandemic.** *J. Paediatr. Child Health* 2020; Camporesi A, Diaz-Rubio F, Carroll CL, Gonzalez-Dambrasuskas S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568444>
49. **Facial pressure ulcers in COVID-19 patients undergoing prone positioning: How to prevent an underestimated epidemic?** *J Stomatol Oral Maxillofac Surg* 2020; Perrillat A, Foletti JM, Lacagne AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565264>
50. **Microwave-Generated Steam Decontamination of N95 Respirators Utilizing Universally Accessible Materials.** *mBio* 2020; 11Zulauf KE, Green AB, Nguyen Ba AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587063>
51. **Protecting the rare during a rare pandemic.** *Med. J. Aust.* 2020; Baynam GS, Wicking C, Bhattacharya K, Millis N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570278>
52. **[What is the importance of the conjunctiva as a potential transmission pathway for SARS-CoV-2 infections?].** *Ophthalmologe* 2020; Lange C, Wolf J, Auw-Haedrich C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572552>
53. **[Seroprevalence and SARS-CoV-2 testing in healthcare occupations].** *Ophthalmologe* 2020; Ziemssen F, Bayyoud T, Bartz-Schmidt KU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588125>
54. **Safe surgical tracheostomy during the COVID-19 pandemic: A protocol based on experiences with Middle East Respiratory Syndrome and COVID-19 outbreaks in South Korea.** *Oral Oncol* 2020; 109:104861 Choi SY, Shin J, Park W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590297>
55. **The Difficult Airway and Aerosol-Generating Procedures in COVID-19: Timeless Principles for Uncertain Times.** *Otolaryngol Head Neck Surg* 2020; 194:599820936615 Smith JD, Chen MM, Balakrishnan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571147>
56. **Anesthesia and potential aerosol generation during Magnetic Resonance Imaging in Children with COVID-19.** *Paediatr Anaesth* 2020; Drum E, McClung Pasqualino H, Subramanyam R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564492>
57. **Risk Assessment of Healthcare Workers at the Frontline against COVID-19.** *Pak J Med Sci* 2020; 36:S99-s103 Ali S, Noreen S, Farooq I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582323>
58. **Lessons from SARS-CoV-2 screening in a Brazilian Organ Transplant Unit.** *Transpl Infect Dis* 2020; e13376 de Sandes-Freitas TV, Regina Canito Brasil I, de Mattos Brito Oliveira ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573894>
59. **Mask wearing in pre-symptomatic patients prevents SARS-CoV-2 transmission: An epidemiological analysis.** *Travel Med Infect Dis* 2020; 101803 Hong LX, Lin A, He ZB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592903>

Pulmonary disease (18 articles)

1. **Reply to: Hedenstierna et al, Haouzi et al, Maley et al, Fowler et al, Bhatia and Mohammed, Bos, & Koumbourlis and Motoyama.** *Am J Respir Crit Care Med* 2020; Gattinoni L, Coppola S, Cressoni M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579036>
2. **Reply by Xu et al: Haouzi et al.** *Am J Respir Crit Care Med* 2020; Xu Y, Liu X, Xu Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579027>
3. **Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.** *Ann. Clin. Lab. Sci.* 2020; 50:308-313 Brown RE, Wolf DA, Hunter RL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581017>
4. **Supportive care for patient with respiratory diseases: an umbrella review.** *Ann Transl Med* 2020; 8:621 Luo X, Lv M, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566558>
5. **Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic.** *Eur. J. Cancer* 2020; 135:147-149 Souza IL, Fernandes I, Taranto P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585589>
6. **Methylation Pathways and SARS-CoV-2 Lung Infiltration and Cell Membrane-Virus Fusion Are Both Subject to Epigenetics.** *Front Cell Infect Microbiol* 2020; 10:290 Pruimboom L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574283>
7. **The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.** *Front Med (Lausanne)* 2020; 7:248 Lumbers ER, Delforce SJ, Pringle KG, Smith GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574336>
8. **Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.** *Front Med (Lausanne)* 2020; 7:241 Wada T, Shimode K, Hoshiyama T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574332>
9. **Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19.** *Front. Pharmacol.* 2020; 11:870 Narasaraaju T, Tang BM, Herrmann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581816>

10. **Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.** *Intensive Care Med* 2020; Verweij PE, Rijnders BJA, Bruggemann RJM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572532>
11. **GINA 2020: What's new and why?** *J. Asthma* 2020;1-7Ish P, Malhotra N, Gupta N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586146>
12. **COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection.** *J Clin Med* 2020; 9Lechowicz K, Drozdal S, Machaj F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575380>
13. **Chest computed tomography findings of COVID-19 pneumonia: pictorial essay with literature review.** *Jpn J Radiol* 2020; Cellina M, Orsi M, Valenti Pittino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588277>
14. **Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.** *Lung Cancer* 2020; Chang HL, Wei PJ, Wu KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576385>
15. **COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS.** *Med. J. Aust.* 2020; Gibson PG, Qin L, Puah SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572965>
16. **Decreased in-hospital mortality in patients with COVID-19 pneumonia.** *Pathog Glob Health* 2020:1-2Ciceri F, Ruggeri A, Lembo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584660>
17. **COVID-19 Pneumonia in Kidney Transplant Recipients: Focus on Immunosuppression Management.** *Transpl Infect Dis* 2020:e13378Chen TY, Farghaly S, Cham S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573882>
18. **[Medical rehabilitation of patients with pneumonia associated with the new COVID-19 coronavirus infection].** *Vopr. Kurortol. Fizioter. Lech. Fiz. Kult.* 2020; 97:5-13Razumov AN, Ponomarenko GN, Badtieva VA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592564>

Renal disease (5 articles)

1. **Fatal SARS-CoV-2 infection in a renal transplant recipient.** *CEN Case Rep* 2020; Dirim AB, Demir E, Ucar AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564306>
2. **COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation.** *J. Clin. Med. Res.* 2020; 12:352-361Adapa S, Chenna A, Balla M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587651>
3. **Unusually High Rates of Acute Rejection During the COVID-19 Pandemic: Cause for Concern?** *Kidney Int* 2020; Aziz F, Muth B, Parajuli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569652>
4. **COVID-19 Pneumonia in Kidney Transplant Recipients: Focus on Immunosuppression Management.** *Transpl Infect Dis* 2020:e13378Chen TY, Farghaly S, Cham S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573882>
5. **Outpatient Management of Kidney Transplant Recipients with Suspected COVID-19- Single Center Experience during the New York City Surge.** *Transpl Infect Dis* 2020:e13383Mehta SA, Leonard J, Labella P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578324>

Reviews (65 articles)

1. **Review of Current Advances in Serologic Testing for COVID-19.** *Am J Clin Pathol* 2020; Espejo AP, Akgun Y, Al Mana AF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583852>
2. **The implication of ocular manifestation of COVID-19 for medical staff and patients - systematic review.** *Ann. Agric. Environ. Med.* 2020; 27:165-170Latalska M, Mackiewicz J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588588>
3. **Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:627Lu S, Zhou Q, Huang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566564>
4. **Supportive care for patient with respiratory diseases: an umbrella review.** *Ann Transl Med* 2020; 8:621Luo X, Lv M, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566558>
5. **Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:622Lv M, Wang M, Yang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566559>
6. **Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:624Shi Q, Zhou Q, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566561>
7. **Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:619Wang J, Tang Y, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566556>
8. **Clinical characteristics of children with COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:620Wang Z, Zhou Q, Wang C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566557>
9. **Breastfeeding of infants born to mothers with COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:618Yang N, Che S, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566555>
10. **Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:625Zhang J, Yang Y, Yang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566562>
11. **Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:629Zhou Q, Gao Y, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566566>
12. **Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review.** *Arch Med Res* 2020; Vakili S, Savardashtaki A, Jamalnia S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571605>
13. **SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management.** *Biochem. Pharmacol.* 2020:114114Wu L, O'Kane AM, Peng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579957>

14. **Rapid systematic review of neonatal COVID-19 including a case of presumed vertical transmission.** *BMJ Paediatr Open* 2020; 4:e000718Gordon M, Kagalwala T, Rezk K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574345>
15. **Radiological manifestations of COVID-19: key points for the physician.** *Br. J. Hosp. Med. (Lond.)* 2020; 81:1-11Gravell RJ, Theodoreson MD, Buonsenso D, Curtis J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589534>
16. **Olfactory and taste disorders in COVID-19: a systematic review.** *Braz. J. Otorhinolaryngol.* 2020; Costa K, Carnauba ATL, Rocha KW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580925>
17. **[SARS-CoV-2/COVID-19: systematic review of requirements for personal protective equipment in primary patient contact and organization of the operating area].** *Chirurg* 2020; Schnitzbauer AA, Kempf VAJ, Hack D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588105>
18. **Coronavirus Disease 2019-COVID-19.** *Clin. Microbiol. Rev.* 2020; 33Dhama K, Khan S, Tiwari R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580969>
19. **Novel COVID-19: A Comprehensive Review of Transmission, Manifestation, and Pathogenesis.** *Cureus* 2020; 12:e8184Hussain A, Kaler J, Tabrez E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566425>
20. **COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies.** *Cureus* 2020; 12:e8206Khan K, Dimtri F, Vargas C, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577324>
21. **Coronavirus Disease 2019 (COVID-19) in Children: Vulnerable or Spared? A Systematic Review.** *Cureus* 2020; 12:e8207Saleem H, Rahman J, Aslam N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577325>
22. **Literature-based review of the drugs used for the treatment of COVID-19.** *Curr Med Res Pract* 2020; 10:100-109Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572376>
23. **Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19).** *Diabetes Metab Res Rev* 2020:e3377Zhou Y, Chi J, Lv W, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588943>
24. **COVID-19 and Type 1 Diabetes: Challenges and actions.** *Diabetes Res Clin Pract* 2020:108275Klatman EL, Besancon S, Bahendeka S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590008>
25. **Chest CT in COVID-19 pneumonia: A review of current knowledge.** *Diagn Interv Imaging* 2020; Jalaber C, Lapotre T, Morcet-Delattre T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571748>
26. **Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19).** *Diagnosis (Berl)* 2020; Ciaccio M, Agnello L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589600>
27. **Current and future therapeutical approaches for COVID-19.** *Drug Discov Today* 2020; Duan Y, Yao Y, Kumar SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574697>
28. **Discovering small-molecule therapeutics against SARS-CoV-2.** *Drug Discov Today* 2020; Tiwari V, Beer JC, Sankaranarayanan NV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574699>
29. **Sickle Cell Trait and The Potential Risk of Severe Coronavirus Disease 2019- A Mini-Review.** *Eur. J. Haematol.* 2020; Kehinde TA, Osundiji MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589774>
30. **COVID-19, a viral endocrinological disease?** *Eur J Intern Med* 2020; Grassi T, Varotto E, Galassi FM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571582>
31. **A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.** *Eur. J. Med. Chem.* 2020; 201:112527Liang C, Tian L, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563812>
32. **The role of chest computed tomography in the management of COVID-19: A review of results and recommendations.** *Exp. Biol. Med. (Maywood)* 2020:1535370220938315Wong MD, Thai T, Li Y, Liu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588660>
33. **Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside.** *Front Cell Dev Biol* 2020; 8:476Yu J, Chai P, Ge S, Fan X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582719>
34. **ACE2, Much More Than Just a Receptor for SARS-COV-2.** *Front Cell Infect Microbiol* 2020; 10:317Samavati L, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582574>
35. **Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.** *Front. Immunol.* 2020; 11:1294Abid MA, Nunley L, Abid MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582221>
36. **The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review.** *Front. Neurol.* 2020; 11:498Tsai ST, Lu MK, San S, Tsai CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574246>
37. **Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis.** *Gene Rep* 2020; 20:100752Junejo Y, Ozaslan M, Safdar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566803>
38. **Update on the target structures of SARS-CoV-2: A systematic review.** *Indian J. Pharmacol.* 2020; 52:142-149Prajapat M, Sarma P, Shekhar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565603>
39. **Acute respiratory distress syndrome due to SARS-CoV-2 and Influenza A co-infection in an Italian patient: mini-review of the literature.** *Int J Infect Dis* 2020; Alessandra D, Lepore L, Palazzolo C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565366>
40. **Transforming laparoendoscopic surgical protocols during COVID-19 pandemic; big data analytics, resource allocation and operational considerations; a review article.** *Int J Surg* 2020; Guraya SY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590073>
41. **Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.** *Intensive Care Med* 2020; Verweij PE, Rijnders BJA, Bruggemann RJM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572532>
42. **Protecting and Improving the Lives of Older Adults in the COVID-19 Era.** *J Aging Soc Policy* 2020; 32:297-309Miller EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583751>
43. **Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.** *J. Altern. Complement. Med.* 2020; Lopez-Alcalde J, Yan Y, Witt CM, Barth J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589449>
44. **Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.** *J Autoimmun* 2020:102506Rodriguez Y, Novelli L, Rojas M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563547>

45. **Cholesterol in Relation to COVID-19: Should We Care about It?** *J Clin Med* 2020; 9Radenkovic D, Chawla S, Pirro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570882>
46. **The neurological insights of the emerging coronaviruses.** *J. Clin. Neurosci.* 2020; Msigwa SS, Wang Y, Li Y, Cheng X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563494>
47. **Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).** *J Clin Virol* 2020; 129:104511Nicol T, Lefeuvre C, Serri O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593133>
48. **The mystery of the COVID toes - turning evidence-based medicine on its head.** *J Foot Ankle Res* 2020; 13:38Bristow IR, Borthwick AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576291>
49. **The first few cases and fatalities of Corona Virus Disease 2019 (COVID-19) in the Eastern Mediterranean Region of the World Health Organization: A rapid review.** *J Infect Public Health* 2020; Abed Alah M, Abdeen S, Kehyayan V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586684>
50. **Care of newborns born to mothers with COVID-19 infection; a review of existing evidence.** *J Matern Fetal Neonatal Med* 2020;1-13Shahbazi Sighaldehy S, Ebrahimi Kalan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576055>
51. **A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer" on <https://doi.org/10.1111/jnc.15021>.** *J. Neurochem.* 2020; Steinman L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574379>
52. **Chest computed tomography findings of COVID-19 pneumonia: pictorial essay with literature review.** *Jpn J Radiol* 2020; Cellina M, Orsi M, Valenti Pittino C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588277>
53. **Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives.** *Korean Circ J* 2020; 50:543-554Kim IC, Kim HA, Park JS, Nam CW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588565>
54. **Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence.** *Laryngoscope Investig Otolaryngol* 2020; 5:354-359Gengler I, Wang JC, Speth MM, Sedaghat AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587887>
55. **Human and novel coronavirus infections in children: a review.** *Paediatr Int Child Health* 2020;1-20Rajapakse N, Dixit D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584199>
56. **Coronavirus Disease 2019 (COVID-19): A Short Review on Hematological Manifestations.** *Pathogens* 2020; 9Slomka A, Kowalewski M, Zekanowska E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575786>
57. **COVID-19 in Pregnant Women and Neonates: A Systematic Review of the Literature with Quality Assessment of the Studies.** *Pathogens* 2020; 9Trippella G, Ciarcia M, Ferrari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570959>
58. **Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.** *Pol Merkur Lekarski* 2020; 48:195-198Surma S, Romanczyk M, Labuzek K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564046>
59. **Mental Health Effects of COVID-19 Pandemia: A Review of Clinical and Psychological Traits.** *Psychiatry Investig* 2020; 17:491-505Kontoangelos K, Economou M, Papageorgiou C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570296>
60. **COVID-19: Overview of Rheumatology Fellows.** *Rheumatol. Clin.* 2020; Garcia-Guillen A, Jeria S, Lobo-Prat D, Sainz L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565030>
61. **Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review.** *Thromb Res* 2020; 194:36-41Fletcher-Sandersjoo A, Bellander BM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569879>
62. **A Review of Early Experience in Lung Ultrasound in the Diagnosis and Management of COVID-19.** *Ultrasound Med. Biol.* 2020; Sultan LR, Sehgal CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591166>
63. **SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.** *Vaccines (Base)* 2020; 8Elshabrawy HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585913>
64. **COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.** *Virus Res.* 2020:198070Magro G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569708>
65. **Anosmia and dysgeusia in COVID-19: A systematic review.** *Wellcome Open Res* 2020; 5:94Carrillo-Larco RM, Altez-Fernandez C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587902>

Risk factors (66 articles)

1. **Diabetes increases the mortality of patients with COVID-19: a meta-analysis.** *Acta Diabetol* 2020; Wu ZH, Tang Y, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583078>
2. **Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019.** *Aging (Albany NY)* 2020; 12Sun JK, Zhang WH, Zou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589164>
3. **Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis.** *Aging (Albany NY)* 2020; 12Xu L, Mao Y, Chen G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575078>
4. **Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.** *Ann Transl Med* 2020; 8:635Liu YP, Li GM, He J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566572>
5. **Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters.** *Ann Transl Med* 2020; 8:593Wang C, Deng R, Gou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566620>
6. **Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.** *Antioxidants (Basel)* 2020; 9Wagener F, Pickkers P, Peterson SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575554>
7. **Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.** *Biol. Proced.*

- Online 2020; 22:11Zolfaghari Emameh R, Falak R, Bahreini E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572334>
8. **Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients.** *Cardiol J* 2020; Lorente-Ros A, Monteagudo Ruiz JM, Rincon LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589258>
 9. **Prediction and analysis of COVID-19 positive cases using deep learning models: A descriptive case study of India.** *Chaos Solitons Fractals* 2020; 139:110017Arora P, Kumar H, Panigrahi BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572310>
 10. **Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.** *Clin Chem Lab Med* 2020; 58:1100-1105Bonetti G, Manelli F, Patroni A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573995>
 11. **COVID-19 in Immunocompromised Hosts: What We Know So Far.** *Clin Infect Dis* 2020; Fung M, Babik JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592461>
 12. **Relationship Between ACE2 and Other Components of the Renin-Angiotensin System.** *Curr Hypertens Rep* 2020; 22:44Cohen JB, Hanff TC, Bress AP, South AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591908>
 13. **Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.** *Dermatol Ther* 2020; Recalcati S, Piconi S, Franzetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584431>
 14. **Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (COVID-19).** *Diabetes Metab Res Rev* 2020:e3377Zhou Y, Chi J, Lv W, Wang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588943>
 15. **Letter in response to the article: Vitamin D concentrations and COVID-19 infection in UK biobank (Hastie et al.).** *Diabetes Metab Syndr* 2020; 14:893-894Grant WB, McDonnell SL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563941>
 16. **Cardiac biomarker-based risk stratification algorithm in patients with severe COVID-19.** *Diabetes Metab Syndr* 2020; 14:929-931Mahajan K, Chand Negi P, Ganju N, Asotra S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590335>
 17. **Prevalence of comorbidities and their association with mortality in patients with COVID-19: A Systematic Review and Meta-analysis.** *Diabetes Obes. Metab.* 2020; Singh AK, Gillies CL, Singh R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573903>
 18. **Well-controlled vs Poorly-controlled Diabetes in Patients with COVID-19: Are There Any Differences in Outcomes and Imaging Findings?** *Diabetes Res Clin Pract* 2020:108286Raoufi M, Khalili S, Mansouri M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592836>
 19. **Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis.** *Ecancermedicalscience* 2020; 14:1047Ofori-Asenso R, Ogundipe O, Agyeman AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565900>
 20. **COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.** *Faseb j* 2020; Sorokin AV, Karathanasis SK, Yang ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588493>
 21. **Could Sex/Gender Differences in ACE2 Expression in the Lungs Contribute to the Large Gender Disparity in the Morbidity and Mortality of Patients Infected With the SARS-CoV-2 Virus?** *Front Cell Infect Microbiol* 2020; 10:327Majdic G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582576>
 22. **ACE2, Much More Than Just a Receptor for SARS-CoV-2.** *Front Cell Infect Microbiol* 2020; 10:317Samavati L, Uhal BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582574>
 23. **A Novel Scoring System for Prediction of Disease Severity in COVID-19.** *Front Cell Infect Microbiol* 2020; 10:318Zhang C, Qin L, Li K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582575>
 24. **Neutrophils, Crucial, or Harmful Immune Cells Involved in Coronavirus Infection: A Bioinformatics Study.** *Front Genet* 2020; 11:641Hemmat N, Derakhshani A, Bannazadeh Baghi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582303>
 25. **Lack of Association Between Genetic Variants at ACE2 and TMPRSS2 Genes Involved in SARS-CoV-2 Infection and Human Quantitative Phenotypes.** *Front Genet* 2020; 11:613Lopera Maya EA, van der Graaf A, Lanting P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582302>
 26. **Coronavirus Disease (COVID-19-SARS-CoV-2) and Nutrition: Is Infection in Italy Suggesting a Connection?** *Front. Immunol.* 2020; 11:944Cena H, Chieppa M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574257>
 27. **The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.** *Front Med (Lausanne)* 2020; 7:248Lumbers ER, Delforce SJ, Pringle KG, Smith GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574336>
 28. **Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19.** *Front Med (Lausanne)* 2020; 7:246Shao L, Li X, Zhou Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574334>
 29. **Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.** *Front. Microbiol.* 2020; 11:1302He Y, Wang J, Li F, Shi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582134>
 30. **Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19.** *Front. Pharmacol.* 2020; 11:870Narasaraju T, Tang BM, Herrmann M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581816>
 31. **Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling.** *Front. Pharmacol.* 2020; 11:836Wehbe Z, Hammoud S, Soudani N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581799>
 32. **Coronavirus and Obesity: Could Insulin Resistance Mediate the Severity of Covid-19 Infection?** *Front Public Health* 2020; 8:184Finucane FM, Davenport C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574288>
 33. **The Clinical Characteristics and Prognosis Factors of Mild-Moderate Patients With COVID-19 in a Mobile Cabin Hospital: A Retrospective, Single-Center Study.** *Front Public Health* 2020; 8:264Zhang J, Wang M, Zhao M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582615>
 34. **COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?** *Heart Lung Circ.* 2020; Arnold RH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564908>

35. **[COVID-19 and its relationship with hypertension and cardiovascular disease].** *Hipertens Riesgo Vasc* 2020; Salazar M, Barochiner J, Espeche W, Ennis I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591283>
36. **Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.** *Hypertension* 2020;Hypertensionaha12015324Iaccarino G, Grassi G, Borghi C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564693>
37. **SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients.** *Influenza Other Respir Viruses* 2020; Lei H, Ye F, Liu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32578948>
38. **The Role of Genetic Sex and Mitochondria in Response to COVID-19 Infection.** *Int. Arch. Allergy Immunol.* 2020;1-6Kloc M, Ghobrial RM, Kubiak JZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564017>
39. **Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) infection in cancer population: Are patient-related symptoms helpful to track a harmful invisible?** *Int. J. Cancer* 2020; Assoun S, Benderra MA, Lotz JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574373>
40. **Air Pollution and Covid-19: The Role of Particulate Matter in the Spread and Increase of Covid-19's Morbidity and Mortality.** *Int J Environ Res Public Health* 2020; 17Comunian S, Dongo D, Milani C, Palestini P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580440>
41. **Ramadan Fasting and Risk of Covid-19.** *Int. J. Prev. Med.* 2020; 11:60Javanmard SH, Otrouj Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577190>
42. **Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study.** *J Allergy Clin Immunol Pract* 2020; Vultaggio A, Vivarelli E, Virgili G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565226>
43. **Clinical prediction model for mortality of adult diabetes inpatients with COVID-19 in Wuhan, China: A retrospective pilot study.** *J. Clin. Anesth.* 2020; 66:109927Su M, Yuan J, Peng J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570072>
44. **Cholesterol in Relation to COVID-19: Should We Care about It?** *J Clin Med* 2020; 9Radenkovic D, Chawla S, Pirro M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570882>
45. **Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.** *J Eur Acad Dermatol Venereol* 2020; Fougousse AC, Perrussel M, Becherel PA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564417>
46. **Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe Covid-19.** *J Med Virol* 2020; Smith SM, Boppana A, Traupman JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589756>
47. **Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond.** *J. Natl. Med. Assoc.* 2020; Ferdinand K, Batieste T, Fleurestil M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563685>
48. **Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas.** *J Transl Med* 2020; 18:251Benedetti F, Pachetti M, Marini B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576227>
49. **WHO statement - "Older people are at highest risk from COVID-19": Should the hypothesis be corroborated or rejected?** *Med. Hypotheses* 2020; 144:109896Ningthoujam R, Khomdram D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585464>
50. **Is periodontal disease a risk factor for severe COVID-19 illness?** *Med. Hypotheses* 2020; 144:109969Pitones-Rubio V, Chavez-Cortez EG, Hurtado-Camarena A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592918>
51. **Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).** *Microbes Infect* 2020; Lohse A, Klopfenstein T, Balblanc JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574789>
52. **Diabetes, Infection Risk And Covid-19.** *Mol Metab* 2020:101044Erener S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585364>
53. **Rampant C-->U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories.** *mSphere* 2020; 5Simmonds P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581081>
54. **The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity.** *Obes Rev* 2020; Akoumianakis I, Filippatos T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567171>
55. **Should patients with obesity be more afraid of COVID-19?** *Obes Rev* 2020; Rychter AM, Zawada A, Ratajczak AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583537>
56. **Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID-19.** *Obesity (Silver Spring)* 2020; Pettit NN, MacKenzie EL, Ridgway J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589784>
57. **Tobacco Smoking a Potential Risk Factor in Transmission of COVID-19 Infection.** *Pak J Med Sci* 2020; 36:S104-s107Ahmed N, Maqsood A, Abduljabbar T, Vohra F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582324>
58. **Coronavirus SARS-Cov-2 and arterial hypertension - facts and myths.** *Pol Merkur Lekarski* 2020; 48:195-198Surma S, Romanczyk M, Labuzek K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564046>
59. **National age and coresidence patterns shape COVID-19 vulnerability.** *Proc Natl Acad Sci U S A* 2020; Esteve A, Permanyer I, Boertien D, Vaupel JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576696>
60. **Identifying phenotypes of COVID-19, defining their pathogenesis, and targeting treatments could improve outcomes.** *Respir. Physiol. Neurobiol.* 2020:103477Rajendram R, Kharal GA, Mahmood N, Kharal M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592752>
61. **Predictive factors of severe coronavirus disease 2019 in previously healthy young adults: a single-center, retrospective study.** *Respir Res* 2020; 21:157Zhou C, Huang Z, Tan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571410>
62. **[Evaluation of incidence and risk profile for suffering Covid-19 infection by underlying conditions among middle-aged and older adults in Tarragona.].** *Rev. Esp. Salud Publica* 2020; 94Vila-Corcoles A, Ochoa-Gondar O, Torrente-Fraga C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588837>
63. **A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.** *Rev Med Virol* 2020; Malek Mahdavi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584474>

64. **Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases.** *Sci China Life Sci* 2020; Huang W, Li C, Wang Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567003>
65. **Association of particulate matter pollution and case fatality rate of COVID-19 in 49 Chinese cities.** *Sci Total Environ* 2020; 741:140396 Yao Y, Pan J, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592974>
66. **Effects of meteorological conditions and air pollution on COVID-19 transmission: Evidence from 219 Chinese cities.** *Sci Total Environ* 2020; 741:140244 Zhang Z, Xue T, Jin X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592975>

Safety (15 articles)

1. **COVID-19 Phenotypes and Potential Harm of Conventional Treatments: How to Prove the Hypothesis.** *Am J Respir Crit Care Med* 2020; Fowler AJ, Wan YI, Careno L, Haines RW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579024>
2. **Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:619 Wang J, Tang Y, Ma Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566556>
3. **Is the use of ACE Inhib/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?** *Clin. Exp. Hypertens.* 2020:1-5 Selcuk M, Cinar T, Keskin M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569491>
4. **Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.** *Clin Transl Sci* 2020; Humeniuk R, Mathias A, Cao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589775>
5. **Gas Aerosol Jetstreams from Trocars during Laparoscopic Surgery- A Video Vignette.** *Colorectal Dis* 2020; Khan MF, Dallij J, Cahill RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579264>
6. **Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.** *Cytotherapy* 2020; Cancio M, Ciccocioppo R, Rocco PRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565132>
7. **Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.** *Dermatol Ther* 2020; Recalcati S, Piconi S, Franzetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584431>
8. **Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.** *Diabetes Metab Res Rev* 2020; Stoian AP, Catrinou D, Rizzo M, Ceriello A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592507>
9. **Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic.** *Eur. J. Cancer* 2020; 135:147-149 Souza IL, Fernandes I, Taranto P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585589>
10. **Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?** *Front. Immunol.* 2020; 11:1239 Murck H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574273>
11. **Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.** *Front Med (Lausanne)* 2020; 7:200 Bonzano C, Borroni D, Lancia A, Bonzano E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574320>
12. **Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.** *Front Public Health* 2020; 8:252 Prayuenyong P, Kasbekar AV, Baguley DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574312>
13. **A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.** *J Korean Med Sci* 2020; 35:e231 Ahn BY, Kang CK, Seo JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567262>
14. **Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?** *J Nucl Med* 2020; Bodei L, Bergsland EK, de Herder WK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576637>
15. **Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19.** *Microbes Infect* 2020; Coish JM, MacNeil AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590062>

Treatment options (116 articles)

1. **Treatment of COVID-19 by Inhaled NO to Reduce Shunt?** *Am J Respir Crit Care Med* 2020; Hedenstierna G, Chen L, Hedenstierna M, Scaramuzza G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579020>
2. **Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?** *Am J Respir Crit Care Med* 2020; Koumbourlis AC, Motoyama EK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579022>
3. **Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:627 Lu S, Zhou Q, Huang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566564>
4. **Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis.** *Ann Transl Med* 2020; 8:624 Shi Q, Zhou Q, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566561>
5. **Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:625 Zhang J, Yang Y, Yang N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566562>
6. **Amantadine Treatment for People with COVID-19.** *Arch Med Res* 2020; Araujo R, Aranda-Martinez JD, Aranda-Abreu GE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571606>
7. **Repurposing old drugs as antiviral agents for coronaviruses.** *Biomed J* 2020; Yang CW, Peng TT, Hsu HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563698>
8. **Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.** *bioRxiv* 2020; Tandon R, Sharp JS, Zhang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577638>
9. **Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.** *Br. J. Gen. Pract.* 2020; Coenen S, van der Velden AW, Cianci D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571773>

10. **In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.** Cell Metab. 2020; Zhang XJ, Qin JJ, Cheng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592657>
11. **Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.** Cell Tissue Bank 2020; Parhizkar Roudsari P, Alavi-Moghadam S, Payab M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588163>
12. **Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.** Clin Chem Lab Med 2020; Alvarez JC, Moine P, Etting I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573468>
13. **Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.** Clin Immunol 2020;108517Yeleswaram S, Smith P, Burn T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585295>
14. **Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.** Clin Infect Dis 2020; Jordan SC, Zakowski P, Tran HP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575124>
15. **Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.** Clin Transl Sci 2020; Humeniuk R, Mathias A, Cao H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589775>
16. **Literature-based review of the drugs used for the treatment of COVID-19.** Curr Med Res Pract 2020; 10:100-109Venkatasubbaiah M, Dwarakanadha Reddy P, Satyanarayana SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572376>
17. **Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.** Cytotherapy 2020; Cancio M, Ciccocioppo R, Rocco PRM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565132>
18. **Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.** Dermatol Ther 2020; Recalcati S, Piconi S, Franzetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584431>
19. **COVID-19 infection on IL-23 inhibition.** Dermatol Ther 2020; Wang CJ, Truong AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32584451>
20. **Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.** Diabetes Metab Res Rev 2020; Stoian AP, Catrinou D, Rizzo M, Ceriello A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592507>
21. **A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.** Diabetes Res Clin Pract 2020;108282Esam Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592841>
22. **Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?** Drug Discov Ther 2020; Kazama I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581194>
23. **Current and future therapeutical approaches for COVID-19.** Drug Discov Today 2020; Duan Y, Yao Y, Kumar SA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574697>
24. **Discovering small-molecule therapeutics against SARS-CoV-2.** Drug Discov Today 2020; Tiwari V, Beer JC, Sankaranarayanan NV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574699>
25. **Exportin 1 inhibition as antiviral therapy.** Drug Discov Today 2020; Uddin MH, Zonder JA, Azmi AS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569833>
26. **Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.** EBioMedicine 2020; 57:102836Martin TR, Wurfel MM, Zanoni I, Ulevitch R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574958>
27. **Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.** Elife 2020; 9Klasse PJ, Moore JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573433>
28. **Can artificial intelligence identify effective COVID-19 therapies?** EMBO Mol Med 2020:e202012817Schultz MB, Vera D, Sinclair DA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569446>
29. **Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic.** Eur. J. Cancer 2020; 135:147-149Souza IL, Fernandes I, Taranto P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585589>
30. **What about COVID-19 and arachidonic acid pathway?** Eur. J. Clin. Pharmacol. 2020; Hoxha M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583353>
31. **Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.** Eur. J. Haematol. 2020; Koschmieder S, Jost E, Cornelissen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593209>
32. **Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era.** Eur J Intern Med 2020; Rossi R, Coppi F, Talarico M, Boriani G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564905>
33. **A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.** Eur. J. Med. Chem. 2020; 201:112527Liang C, Tian L, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563812>
34. **Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.** Expert Rev. Respir. Med. 2020; Tahamtan A, Tavakoli-Yaraki M, Salimi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576053>
35. **COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.** Faseb j 2020; Sorokin AV, Karathanasis SK, Yang ZH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588493>
36. **Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.** Front. Immunol. 2020; 11:1294Abid MA, Nunley L, Abid MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582221>
37. **Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation.** Front. Immunol. 2020; 11:1131Cardone M, Yano M, Rosenberg AS, Puig M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574265>
38. **Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?** Front. Immunol. 2020; 11:970Covian C, Retamal-Diaz A, Bueno SM, Kalergis AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574258>
39. **COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.** Front. Immunol. 2020; 11:1196Halstead SB, Akkina R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574267>

40. **Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?** *Front. Immunol.* 2020; 11:1248Khalil A, Kamar A, Nemer G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574274>
41. **Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm.** *Front. Immunol.* 2020; 11:1130Ruscitti P, Berardicurti O, Di Benedetto P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574264>
42. **Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?** *Front. Immunol.* 2020; 11:1229Sallenave JM, Guillot L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574272>
43. **Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.** *Front. Immunol.* 2020; 11:1021Shah A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574259>
44. **Interferon-alpha2b Treatment for COVID-19.** *Front. Immunol.* 2020; 11:1061Zhou Q, Chen V, Shannon CP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574262>
45. **May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence.** *Front Med (Lausanne)* 2020; 7:240Annunziata G, Sanduzzi Zamparelli M, Santoro C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574331>
46. **Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.** *Front Med (Lausanne)* 2020; 7:200Bonzano C, Borroni D, Lancia A, Bonzano E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574320>
47. **Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia.** *Front Med (Lausanne)* 2020; 7:254Mirastschijski U, Dembinski R, Maedler K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574339>
48. **Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.** *Front Med (Lausanne)* 2020; 7:226Reiter RJ, Abreu-Gonzalez P, Marik PE, Dominguez-Rodriguez A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574327>
49. **Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series.** *Front Med (Lausanne)* 2020; 7:231Tahvildari A, Arbabi M, Farsi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574328>
50. **Case Report: Clinical Treatment of the First Critical Patient With Coronavirus Disease (COVID-19) in Liaocheng, Shandong Province.** *Front Med (Lausanne)* 2020; 7:249Tian H, Sui Y, Tian S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574337>
51. **Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.** *Front Med (Lausanne)* 2020; 7:241Wada T, Shimode K, Hoshiyama T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574332>
52. **Guideline-Based Chinese Herbal Medicine Treatment Plus Standard Care for Severe Coronavirus Disease 2019 (G-CHAMPS): Evidence From China.** *Front Med (Lausanne)* 2020; 7:256Ye YA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574340>
53. **Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.** *Front. Microbiol.* 2020; 11:1388He LH, Ren LF, Li JF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582138>
54. **Biosurfactants: A Covid-19 Perspective.** *Front. Microbiol.* 2020; 11:1341Smith ML, Gandolfi S, Coshall PM, Rahman P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582137>
55. **Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients.** *Front. Oncol.* 2020; 10:993Spalek MJ, Rutkowski P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582558>
56. **Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.** *Front. Pharmacol.* 2020; 11:857Giudice V, Pagliano P, Vatrella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581810>
57. **Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.** *Front. Pharmacol.* 2020; 11:854Sestili P, Stocchi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581809>
58. **Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?** *Front. Pharmacol.* 2020; 11:791Sisay M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574236>
59. **An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?** *Front. Pharmacol.* 2020; 11:856Terrazzano G, Rubino V, Palatucci AT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574238>
60. **Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation.** *Front. Pharmacol.* 2020; 11:796Uckun FM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574237>
61. **Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.** *Front Public Health* 2020; 8:186Baud D, Dimopoulou Agri V, Gibson GR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574290>
62. **Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?** *Front Public Health* 2020; 8:185Mary A, Henaut L, Schmit JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574289>
63. **Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review.** *Front Public Health* 2020; 8:252Prayuenyong P, Kasbekar AV, Baguley DM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574312>
64. **Tackling SARS-CoV-2: proposed targets and repurposed drugs.** *Future Med. Chem.* 2020; Joshi S, Joshi M, Degani MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564623>
65. **Vesicular drug-delivery systems as theranostics in COVID-19.** *Future Med. Chem.* 2020; Satija S, Mehta M, Sharma M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589055>
66. **Doxycycline as a potential partner of COVID-19 therapies.** *IDCases* 2020; 21:e00864Malek AE, Granwehr BP, Kontoyiannis DP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566483>
67. **Update on the target structures of SARS-CoV-2: A systematic review.** *Indian J. Pharmacol.* 2020; 52:142-149Prajapat M, Sarma P, Shekhar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32565603>
68. **Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.** *Inflamm. Regen.* 2020; 40:14Tsuchiya A, Takeuchi S, Iwasawa T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582401>

69. **Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.** *Int J Infect Dis* 2020; Khamis F, Al-Zakwani I, Al Hashmi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585284>
70. **Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.** *Int J Infect Dis* 2020; Tariq A, Mateen RM, Afzal MS, Saleem M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579907>
71. **Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?** *Int. J. Radiat. Biol.* 2020:1-19Salomaa S, Bouffler SD, Atkinson MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579043>
72. **Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence.** *Int J Surg* 2020; Wiwanitkit V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585194>
73. **Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.** *Intern Emerg Med* 2020; Pantanetti P, Cangelosi G, Ambrosio G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592113>
74. **Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19): A Scoping Review.** *J. Altern. Complement. Med.* 2020; Lopez-Alcalde J, Yan Y, Witt CM, Barth J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32589449>
75. **Inhibition of SARS-CoV-2 by type I and type III interferons.** *J Biol Chem* 2020; Felgenhauer U, Schoen A, Gad HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587093>
76. **Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.** *J Biomol Struct Dyn* 2020:1-10Amin SA, Ghosh K, Gayen S, Jha T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568618>
77. **Remdesivir (GS-5734) as a therapeutic option of 2019-nCoV main protease - in silico approach.** *J Biomol Struct Dyn* 2020:1-14Naik VR, Munikumar M, Ramakrishna U *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568620>
78. **Clinical pharmacology considerations for developing small molecule treatments for COVID-19.** *J. Clin. Pharmacol.* 2020; Brunsdon P, Saluja B, Sahajwalla C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579707>
79. **Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.** *J Clin Virol* 2020; 129:104444Quartuccio L, Sonaglia A, McGonagle D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570043>
80. **COVID-19 effect on phototherapy treatment utilization in dermatology.** *J Dermatolog Treat* 2020:1-3Fisher S, Ziv M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586156>
81. **Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.** *J Infect* 2020; Cantini F, Niccoli L, Nannini C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592703>
82. **Validity of the UK Early Access to Medicines Scheme Criteria for Remdesivir use in patients with COVID-19 disease.** *J Infect* 2020; Daunt A, Perez-Guzman PN, Liew F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579980>
83. **SARS-CoV-2-reactive interferon-gamma-producing CD8(+) T cells in patients hospitalized with Coronavirus Disease 2019.** *J Med Virol* 2020; Gimenez E, Albert E, Torres I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579268>
84. **SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).** *J Med Virol* 2020; Ruan Z, Liu C, Guo Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579254>
85. **Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?** *J Nucl Med* 2020; Bodei L, Bergsland EK, de Herder WK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576637>
86. **Emerging pharmacotherapy for COVID-19.** *J. R. Coll. Physicians Edinb.* 2020; 50:133-137Lipworth B, Kuo CR, Chan R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568282>
87. **Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?** *J. R. Coll. Physicians Edinb.* 2020; 50:159-161Thalha AMM, Lee YY, Besari A, Omar SFS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568289>
88. **[Drug treatment of coronavirus disease COVID-19: evidence exists?].** *Khirurgiia (Mosk.)* 2020:90-97Timerbulatov SV, Timerbulstov MV, Gainullina EN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573538>
89. **Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.** *Med. Hypotheses* 2020; 144:110012Abouelkhair MA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590324>
90. **Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?** *Med. Hypotheses* 2020; 144:109903Basic-Jukic N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32563969>
91. **Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19.** *Med. Hypotheses* 2020; 144:109973Karaahmet F, Kocaman SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590321>
92. **Pirfenidone: A novel hypothetical treatment for COVID-19.** *Med. Hypotheses* 2020; 144:110005Seifirad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575019>
93. **Tocilizumab for treatment of mechanically ventilated patients with COVID-19.** *medRxiv* 2020; Somers EC, Eschenauer GA, Troost JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577684>
94. **Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).** *Microbes Infect* 2020; Lohse A, Klopfenstein T, Babblanc JC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574789>
95. **Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.** *Mult Scler Relat Disord* 2020; 44:102315Conte WL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32593144>
96. **Response to "Does amantadine have a protective effect against COVID-19?".** *Neurol. Neurochir. Pol.* 2020; Tipton PW, Wszolek ZK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583401>
97. **Nitric Oxide dosed in short bursts at high concentrations may protect against Covid 19.** *Nitric Oxide* 2020; Hedenstierna G, Chen L, Hedenstierna M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590117>

98. **Az also ket sikeres, convalescens friss fagyaszott plazmával torteno terapia hazai alkalmazasa intenziv osztalyon kezelt, kritikus állapotu, COVID-19-fertozesben szenvedo betegekben.** *Orv. Hetil.* 2020; 161:1111-1121Bobek I, Gopcsa L, Reti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564002>
99. **Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases.** *Orv. Hetil.* 2020; 161:1111-1121Bobek I, Gopcsa L, Reti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564002>
100. **A potential role for Galectin-3 inhibitors in the treatment of COVID-19.** *PeerJ* 2020; 8:e9392Caniglia JL, Guda MR, Asuthkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32587806>
101. **Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.** *PeerJ* 2020; 8:e9357Loganathan T, Ramachandran S, Shankaran P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566414>
102. **Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients.** *Pharmacol. Res.* 2020:105043Pan HD, Yao XJ, Wang WY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569819>
103. **Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?** *Pharmacol. Ther.* 2020:107618Bailly C, Vergoten G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592716>
104. **Photobiomodulation: Shining Light on COVID-19.** *Photobiomodul Photomed Laser Surg* 2020; Fernandes AB, Lima CJ, Villaverde A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32579049>
105. **Does PDT have potential in the treatment of COVID 19 patients?** *Photodiagnosis Photodyn. Ther.* 2020:101889Moghissi K, Dixon K, Gibbins S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592911>
106. **Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells.** *Plants (Basel)* 2020; 9Senthil Kumar KJ, Gokila Vani M, Wang CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575476>
107. **Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.** *Stem Cell Rev Rep* 2020; Basiri A, Pazhouhnia Z, Beheshtizadeh N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564256>
108. **Preventing SARS-CoV-2 infection by blocking a tissue serine protease.** *Ther Adv Infect Dis* 2020; 7:2049936120933076Jankousky KC, Schultz J, Windham S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577236>
109. **Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:575Allahyari A, Rahimi H, Khadem-Rezaiyan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586363>
110. **Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:573Pantos C, Kostopanagioutou G, Armaganidis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586399>
111. **CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:577Stockmann H, Keller T, Buttner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586396>
112. **A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore(R)-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".** *Trials* 2020; 21:576Tornerio C, Vallejo R, Cedeno D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586395>
113. **SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.** *Vaccines (Basel)* 2020; 8Elshabrawy HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585913>
114. **Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.** *Vaccines (Basel)* 2020; 8Subramanian S, Iles T, Ikramuddin S, Steer CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575350>
115. **Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.** *Virus Res.* 2020:198073Li C, Wang L, Ren L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32592817>
116. **COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.** *Virus Res.* 2020:198070Magro G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569708>

Trials (22 articles)

1. **Appealing for efficient, well organized clinical trials on COVID-19.** *Ann Transl Med* 2020; 8:632Zhao Y, Wei Y, Shen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566569>
2. **Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.** *Drug Des. Devel. Ther.* 2020; 14:2159-2164Huang J, He Y, Su Q, Yang J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581514>
3. **Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.** *Ethics Hum Res* 2020; Iyer AA, Hendriks S, Rid A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32567239>
4. **Cohort study of chest CT and clinical changes in 29 patients with coronavirus disease 2019 (COVID-19).** *Eur Radiol* 2020; Zhou Y, Zheng Y, Yang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32591890>
5. **Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.** *Front. Pharmacol.* 2020; 11:857Giudice V, Pagliano P, Vatrella A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32581810>
6. **Core Outcome Set for Clinical Trials of COVID-19 Based on Traditional Chinese and Western Medicine.** *Front. Pharmacol.* 2020; 11:781Qiu R, Zhao C, Liang T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574235>
7. **Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?** *Front. Pharmacol.* 2020; 11:791Sisay M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574236>
8. **Radiologist Reporting and Operational Management for Patients With Suspected COVID-19.** *J Am Coll Radiol* 2020; Hammer MM, Zhao AH, Hunsaker AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590015>

9. **Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.** *J Clin Virol* 2020; 129:104444Quartuccio L, Sonaglia A, McGonagle D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570043>
10. **Isfahan Covid-19 Registry (I-CORE): Design and methodology.** *J. Res. Med. Sci.* 2020; 25:32Javanmard SH, Nasirian M, Ataei B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582338>
11. **Tocilizumab for treatment of mechanically ventilated patients with COVID-19.** *medRxiv* 2020; Somers EC, Eschenauer GA, Troost JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577684>
12. **A prospective clinical study of detailed neurological manifestations in patients with COVID-19.** *Neurol Sci* 2020; Karadas O, Ozturk B, Sonkaya AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588367>
13. **Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.** *Ther Innov Regul Sci* 2020; Chow SC, Zhang W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583289>
14. **Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:575Allahyari A, Rahimi H, Khadem-Rezaiyan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586363>
15. **Shenhua granule in the treatment of severe coronavirus disease 2019 (COVID-19): study protocol for an open-label randomized controlled clinical trial.** *Trials* 2020; 21:568Fang B, Zhang W, Wu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580752>
16. **Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.** *Trials* 2020; 21:574Marietta M, Vandelli P, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586394>
17. **Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:573Pantos C, Kostopanagioutou G, Armaganidis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586399>
18. **CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial.** *Trials* 2020; 21:577Stockmann H, Keller T, Buttner S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586396>
19. **A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore(R)-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".** *Trials* 2020; 21:576Tornerio C, Vallejo R, Cedeno D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32586395>
20. **HBO2 for COVID-19: Clinical trials at clinicaltrials.gov.** *Undersea Hyperb. Med.* 2020; 47:299-307. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574447>
21. **I-ACTSS-COVID-19-the Italian acute care and trauma surgery survey for COVID-19 pandemic outbreak.** *Updates Surg* 2020; Cozza V, Fransvea P, La Greca A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583216>
22. **Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.** *Vaccines (Basel)* 2020; 8Subramanian S, Iles T, Ikramuddin S, Steer CJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32575350>

Vaccines (7 articles)

1. **COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.** *Comput. Biol. Med.* 2020; 121:103749Robson B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32568687>
2. **COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies.** *Cureus* 2020; 12:e8206Khan K, Dimtri F, Vargas C, Surani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32577324>
3. **Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?** *Front. Immunol.* 2020; 11:970Covian C, Retamal-Diaz A, Bueno SM, Kalergis AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574258>
4. **Does Early Childhood Vaccination Protect Against COVID-19?** *Front Mol Biosci* 2020; 7:120Sidiq KR, Sabir DK, Ali SM, Kodzius R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582766>
5. **Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.** *Int Immunopharmacol* 2020; 86:106717Gupta T, Gupta SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585611>
6. **Herd Immunity and Vaccination of children for COVID19.** *Int J Infect Dis* 2020; Velavan TP, Pollard AJ, Kremsner PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32585285>
7. **A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer" on <https://doi.org/10.1111/jnc.15021>.** *J. Neurochem.* 2020; Steinman L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574379>

Women – pregnancy (24 articles)

1. **Promoting attachment between parents and neonates despite the COVID-19 pandemic.** *Acta Paediatr* 2020; Tscherning C, Sizun J, Kuhn P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32588911>
2. **Maternal and Neonatal Response to COVID-19.** *Am J Physiol Endocrinol Metab* 2020; Golden TN, Simmons RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574110>
3. **Breastfeeding of infants born to mothers with COVID-19: a rapid review.** *Ann Transl Med* 2020; 8:618Yang N, Che S, Zhang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32566555>
4. **Laboratory characteristics of pregnant compared to non-pregnant women infected with SARS-CoV-2.** *Arch. Gynecol. Obstet.* 2020; Mohr-Sasson A, Chayo J, Bart Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32572616>

5. **Laboratory Findings of COVID-19 Infection are Conflicting in Different Age Groups and Pregnant Women: A Literature Review.** *Arch Med Res* 2020; Vakili S, Savardashtaki A, Jamalnia S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32571605>
6. **Prenatal anxiety and obstetric decisions among pregnant women in Wuhan and Chongqing during the COVID-19 outbreak: a cross-sectional study.** *Bjog* 2020; Liu X, Chen M, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32583536>
7. **Rapid systematic review of neonatal COVID-19 including a case of presumed vertical transmission.** *BMJ Paediatr Open* 2020; 4:e000718 Gordon M, Kagalwala T, Rezk K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574345>
8. **Management of cervical cancer patients during the COVID-19 pandemic: a challenge for developing countries.** *Ecanmedicalscience* 2020; 14:1060 Del Pilar Estevez-Diz M, Bonadio RC, Miranda VC, Carvalho JP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582375>
9. **A practical approach to the management of breast cancer in the COVID-19 era and beyond.** *Ecanmedicalscience* 2020; 14:1059 Luther A, Agrawal A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582374>
10. **Could Sex/Gender Differences in ACE2 Expression in the Lungs Contribute to the Large Gender Disparity in the Morbidity and Mortality of Patients Infected With the SARS-CoV-2 Virus?** *Front Cell Infect Microbiol* 2020; 10:327 Majdic G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32582576>
11. **Obstetric Management of COVID-19 in Pregnant Women.** *Front. Microbiol.* 2020; 11:1186 Mei Y, Luo D, Wei S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574255>
12. **SARS-CoV-2 Infection and the Newborn.** *Front Pediatr* 2020; 8:294 Ovali F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574287>
13. **Is SARS-CoV-2 Vertically Transmitted?** *Front Pediatr* 2020; 8:276 Simoes ESAC, Leal CRV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574285>
14. **Coronavirus Disease 2019 (COVID-19) in Neonates and Children From China: A Review.** *Front Pediatr* 2020; 8:287 Yu Y, Chen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32574286>
15. **Reshaping of Neonatal Intensive Care Units to avoid the spread of COVID-19 to high-risk infants.** *Infect Control Hosp Epidemiol* 2020; 1-8 De Rose DU, Auriti C, Landolfo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576333>
16. **Surgical prioritization of obstetrics and gynecology procedures in the UK during the COVID-19 pandemic.** *Int J Gynaecol Obstet* 2020; Memon SF, Khattab N, Abbas A, Abbas AR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564356>
17. **SARS-CoV-2 infection of the placenta.** *J. Clin. Invest.* 2020; Hosier H, Farhadian SF, Morotti RA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573498>
18. **Impact of the outbreak of SARS-CoV-2 infection on urgent gynecological care.** *J Gynecol Obstet Hum Reprod* 2020; 101841 Athiel Y, Civadier MS, Luton D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32590109>
19. **Characteristics of pregnant COVID-19 patients with liver injury.** *J Hepatol* 2020; Deng G, Zeng F, Zhang L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32569609>
20. **Care of newborns born to mothers with COVID-19 infection; a review of existing evidence.** *J Matern Fetal Neonatal Med* 2020; 1-13 Shahbazi Sighaldehy S, Ebrahimi Kalan M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32576055>
21. **Distress and anxiety associated with COVID-19 among Jewish and Arab pregnant women in Israel.** *J. Reprod. Infant Psychol.* 2020; 1-9 Taubman-Ben-Ari O, Chasson M, Abu Sharkia S, Weiss E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32573258>
22. **Implementation of Obstetric Telehealth During COVID-19 and Beyond.** *Matern Child Health J* 2020; Fryer K, Delgado A, Foti T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32564248>
23. **Report of Positive Placental Swabs for SARS-CoV-2 in an Asymptomatic Pregnant Woman with COVID-19.** *Medicina (Kaunas)* 2020; 56 Ferraiolo A, Barra F, Kratochwila C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32580461>
24. **COVID-19 in Pregnant Women and Neonates: A Systematic Review of the Literature with Quality Assessment of the Studies.** *Pathogens* 2020; 9 Trippella G, Ciarcia M, Ferrari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32570959>

to subscribe click [here](#)
